var title_f28_60_29632="Electroanatomic mapping VT";
var content_f28_60_29632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic mapping of ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electroanatomic mapping of the left ventricle in the left anterior oblique projection localizes the tachycardia focus to the mid-septal portion (orange area). The pink area is the location where the catheter mechanically terminated the arrhythmia, while the red area is the region where ablation resulted in termination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Nademanee K, Kosar EM, Pacing Clin Electrophysiol 1998; 21:1442.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29632=[""].join("\n");
var outline_f28_60_29632=null;
var title_f28_60_29633="Gram positive cocci clusters 2";
var content_f28_60_29633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram positive cocci clusters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram-positive cocci (Staphylococcus aureus) in pus (large, dark-red globules are white cell nuclei).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29633=[""].join("\n");
var outline_f28_60_29633=null;
var title_f28_60_29634="Virilization external view";
var content_f28_60_29634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Virilization (external view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal and abnormal differentiation of the external genitalia. Diagrams of normal female and male anatomy flank a series of schematic representations of different degrees of virilization, graded using the scale developed by Prader.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245. file://edrv.endojournals.org/. Copyright &copy; 2000 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29634=[""].join("\n");
var outline_f28_60_29634=null;
var title_f28_60_29635="Gonioscopy";
var content_f28_60_29635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Gonioscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: Patient undergoing gonioscopy. Right: Anterior chamber angle as viewed on gonioscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Alward, WLM. Color Atlas of Gonioscopy. Foundation of the American Academy of Ophthalmology 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29635=[""].join("\n");
var outline_f28_60_29635=null;
var title_f28_60_29636="Cavovarus";
var content_f28_60_29636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavovarus deformity in an adolescent patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 700px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAK8ATgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRSzBVGSe1W4tOnkbACg+hNO0eLzrtlzgBCSfyroLO03TkLvIPYjBrnrVnDRFKN0Yseh3cnaNR6s2BUq+HbxmAV4D6/MeP0rrraBpF2EYXqAR1qxBZDeGY/L3wOK5/rNR7IfKjjT4YveMSW7EjPDH/Cuh0f4Wa5q1qlxaXOneW3PzSOCPr8ldQtmColWI8jqPSuz8BSvaO9u4IDcpz271ft5rc1o04ydmebj4JeJTjF3pJ/7bScf+OU5fgf4mI4u9I+nnSf/ABFfRUXK8d+lWkwcE8EVP1iZ0/VYHzevwJ8UtjF3pHPH+uk/+N1IvwE8VN0vNG/7/wAn/wAbr6PjJBwCcAYq/GDl+ByuRTWImJ4aCPmcfs9+LSCReaL/AN/5P/jdA/Z88WkkfbdF4/6byf8AxuvqWJ8pk9CAanCZLcehq1WkyfYQPlZP2ePF7j5bzROp/wCW8n/xulX9nbxeWYC80T5ev7+T/wCN19W2rDIHrzxU0hwwUcbuuaaqyE6ED5Jk/Z58XICTeaKcDPE8n/xuopPgD4rjGWvNG/CeT/43X1rN99sde1Zd6ATs3YIIPvQ6skNYeB8pXPwS8TW4O+60onGcLNJ/8RXBeI9FudA1NrG9aJplUNmIkrg/UCvsy/3CRi4Gdv6V81fGvT2g1WzvVHyyKULD1ByP5mqp1XJ2ZFahGMbo4zRvD15q6hrZoVGcfvGI/kDW9F8NtZlUlJrHA/22/wDiat/D1kjAVW3SHPPYCvYdIiV4R5YO3HC1PtZXZzWPGV+Fuuk486wHGeZH/wDiae3wq15SB5+nnPpK/wD8TXuxtwEyDz0wKYE/eKrAgDvTdSQWPDX+FGvL1uNO/wC/r/8AxNMPwr10Z/f6ecekj/8AxNe7SKHm5XAXgClSLy1bzMDPzE0vazCx4PJ8LtdQjMtgc+kjf/E03/hWGt5A8+wz/wBdG/8Aia96mXco8octwKrzQ5kSJCCF+96mk6swsjwuf4Za5CPmlsTxnCyNz/47SwfDLW5kDJNYYPrI3/xNe6GEmQnepUe1QQQnJVQAMZ6YyaPbTCyPEH+GmtJnM1jgf9NG/wDiaY3w31pRnzLIj2kb/wCJr3T7PGzguckgnk8VXkQcxhBt9TUutMdkeJy/DjWY/vS2WcZwJG/+JqP/AIV9rGzd5ln643tn/wBBr28wMWOQMdqiEYO4FTjHX3pe3qBZHiA8C6oek1nn03t/8TTX8D6qp+/bH6O3/wATXsL2SNvYgZ9qjeAMmE4NT9YqBZHjR8I6kG2kwA9/mPH6UyXwrqMWAfJb/dY/4V6rd2qo0h2454PrWbNayZJU/Kex71m8ZUiNRR5rLoF5Gm5mhPsGOf5VBNpF1Cu5wm3sc8GvQrq3III+YjAIqlf20jwOrDA7cZqo4ub3BwXQ8+nhaF9r4zjPFFW9ZBW82lSpC45+por0IPmimZvQseF08zUWAGSIyQPXkV3ttERGv7vY7AcHqPrXIfD+NpdcZUGT5LfzFem2NqVl2sgbb3J/rXLXinK7LT0K0NjKnzHbitO0sMWxLKoyPlVR1q/bQsz72QDsoHODV5LVy4wCznqT2qF5BcxbKwnMbCdt0mc5/hUelaVin2TUbUjLc4Y57Hv+daZt8DC4CAc46ZqN44/IIBUE8DHehxuVCXLJSO7iZvs7mFQz4yqscAn0qa3ZmjR5EKOcEoTnB7iqOjTG4sFbHJHJq+CcD3GKxserfQkHD9eOKv2rnaD+BrPKENg55GKnglDEr/eH60J2ZLNe3OVIPrgCr8eFOSeKy7KQvjpnrV2OTHBxhT+laJmbRaXargqfvZ4pww591/WmMv3SvQc1I4xGW/iHNaIRXkAA5HIOazp4y2Sp+Y8E1ry4dQU4as6RCGOBtJPQ9DQ0VExdQjG5VP3n+XPr614X8fLMf2NbTRrgRSjPHXII/qK96u1PnEupKoMY7ZNeU/FrTTe+FtU4JMKmVDjsBn+lOGjJqxvBo81+FtrbyxSKzI+HI3AEZHtnmva9OhjigAQDgY4FeG/CWRwzqQNof5Sa93sI2FuPLyWPJb+lWviaPOJAoEfPehYozhgMZHXFTJGcAyc0obHBHJ4GKOUCqIkQkKvBNRMoYFNpPqT0q4YsNjdjPWkeMFdvPsaXKBSkTzXUL8oHXA6VGLRVZptxBx37CrUwxhcFSerCo2j82Ag7mDHoaLAU2t1MryoH5UYOeCfpUu2Vyvyqu3rzViOIqgRTz3Y0bCoOCM+pqWgKtwFDxqoy3XFNkg3wPxhjwNvWp2h3j5CwkB5NRSxyvGUgnaFx1cKG/LNHKO5WSFliBLMWxgk01ImC/OMVchXbCwbcxHcjk059wbCquQMcmp5RmNLGS4TIEQzkd6akQGSSBxkLV+eEhAzDLZzUEv38KME+1ZuIGdcxJICdvA5PfmqMtmxYN8pi3ZPtW55e/wCR1wQeCP51TuonWB/KbDN1+lQ4gc/eWgMx8uNtvTI7/Sso2Ukm/wA0twMD0IrqAGcbMlj7elZrwymd4x8oHcjOay5LNMLnlHjODyNVjU94g36tRVj4hrs11AAAPIXAH1aivWpfAiHuT/DBPM8Qyrz/AMe7cDv8y16/ZwM2VMe1egOcZryn4RJv8TzjBP8AorHj/eSvcLW2CgFlGazq6sB0ECrGFKARr+tTxRsOFUndTobZRhpDjJyBmr3l4iyjY9KhIZAUIQRKFDHjjtSrbRQjOA0mOpqe3hIXfyR/OkWTzZGSIfd4Zz0HtTSAl0CYI00IJAD7lHsa3WUlAyjOO1YFrEIr+IovBBBJ7n1roYW/dk9CT0rCUdT0qUrwTF8zehPOcA4ojOx1I6dacg+c+hppH3R1G7FZtGlzWscJLJzx29quxqX5xycj61nw8kkdxWpAAUH54rWBDZYtpC0YBGSOCKlYfJgEnb1qKMYbcByeDU7AhlZeOcHjrVpEsYFBiDZHI61XZNg7H03elTMpDfIMx55psg3LyM1SBGFcjcH8pTzk4B6VyPiqwaeymh3feQjC9+O9d9cRsEfHAI6Dmua1RePLAy5B7dPegvc+Yfh1A1p4hubORyGgk27cdeetfQmn7jAgUfLjqa8X1WzfTPiNM8a4SYDLDjLev5fyr2zR491lGS4JxzVp3Z5s1Z2J4UkIO8Eknp6Us1oGBKEqfrVqMYG0A/WnbRwuck9aogoeWqqM4YfzoMaj5iRn09KmuiYnEcYG88k4qSWACMMo5+lOwFGaEk9agELBWA5AI/CtDy2Z97jCjjFKsWAdi9Tkn0qbAZ7ptKqPqaUwjPyfnV3yMsQe/Un0pgjEiny8FQcc0NAVSuwYPJPQ1AyYOc8Dt2zV65UAAAA55zSNCsygsOAc/jS5QM1FPmMpPbNEcX7xnzuPTmrbR5dcjHYk0hQhWGMgelHKMzplA3bsksOgqF4TuUjJduTV6SDqWBG327USIHAO0qMYzU8o7mRK2yYDgnP50zy8bmYbt3WrstsCVz94dx6U7ysoIycEd/Ws+UDLNvGYzKF2Fc521RkiUcjI3CteaHa52twTg81DJAOhbPaocQPDvikgj8RQjGCbZSf++moqx8XkMfieBCc4tV/9Ceiu+HwohknwZLf8JVOFGT9kf/0NK93gTBHQmvCvgsqt4ruA2f8AjzfGD/tpXuCLJI6GF2CjqetRNajNIRrkM/JHQVJseRiQQB6Go1RgQC4LD1FSsXJ2jafw61NgHMxjUZOfQClj2hBxjJztApyKQ4LqpwOmeRUuWJ5jOT6c07WAibIdH6bWH5Vr/Mu1k6kcisybb5UinIbHAIrTsGaS2jYgZxg1lOJ2YeWjROjBgOeRSsoLL9ar5KSFSvuPp6VYiYsR0IrJo6C/bhWVc1qW44wfrmse1cDjHFa9v93uRTiiWXoSC3IxxTpyQqrjqeKZGQozj8fSpiRKo9f5VoiSOVWAXDjaTg5FRPmNhtGfUelLcMVjbH8I5pCSQRnlT3plIqXTgkDOCelY9/EqN5jEAYIZq1r2MMpBXJbpiqFxb7QFCBh0yeTSZaR5D470IbjqKxl/LXcRnBPOeK63wmxu9PjeNiMj5gw5U1p6vaLInliMPGeG9vY1y9itxo16xtlL2zN8yk9vSnB3MK9K/vI7WWBwyqgJzTGTY+AMOeuau6feQXtsJoDlc4IPUexprxtLLuI5PT2FbHCVWiwmTy56nFOZSQoAxngVYZTkKPu55NPMbEEqMDoM0AUWQH5ccZpUjPKn7p5+lX0iQ42r04Gaj2feDc5OPwosBlOpLlVbAP8AFiq9kdqsqLwDnJ71ryRqA23CgHNQrEDkooG45JHelYCnIm9QCMEU8IPL+XGBVtlGCp696atsQp+b5W7UAZ8kf8RPFQ7CQMfSrvliPiQ/MeFB7VGy84GMdz3pNAU5I2fqfl9KikBOAB7VoSJgZxgZqs6jaWPaiwylNGFbBBweBVZ42LE5ww44rTlwyZYdf51C64TeeKnlC5QMG4ZBIyeQe1MeBGOducdTV2NGYMxH0NRMh8zjlB/OmkhHgvxuXb4ut8DGbND/AOPvRR8cP+Rvg9rNP/Q3orZbCD4Ipv8AFlyvrZP/AOhpXvkMXlRKigKo6AV4R8CTjxhckfe+xPj/AL7jr6AjR2Xgc+tTLcYRR7jVhYtjfLy38qZCpBCswA6E1fSNV5HA7e9TYCCK3/el2IIAx61KEI+VSck9R6U98IgzxnjaBzVmNCRlhj1oQiutrltzkkCptLyI2T+6xFTY3cAZAqGzV47+aMAY4br6ipkdFB6tFi4UdxUNucPtzxmrV0sgXOBWeGKyfdI9xzWL0Z1rY1ocq2SK17b5U/pWJaTBwFzk471r2j/KM/zoQi6gOfmPyjoBT8fMpUkHv9KYjDA5pwZsHbyT+gqgGzEvJswQowSw/lSySFWZyvyg8kU+JWCDaFxnPJqOXzHfGV47AUxoryZYqxGB1AqCUYjORyf0q2UaM7mIJIwo96qyqQr5JY45oZaMm7CtGdqt8y+nese8tE8nbxnuK6V4cKEx14/CqUihic4yemPSpsUcXHLdaVdGe05APzox4kHoff3rsdP1G31OATWxIOMPGeGQ+h/xrI1WySeMAg5ztyKwNlzZTi4ty0U0XG4D731HcGrjO25z1cPzaxPREQYGO/TNDxhhu5z+lZGja5BqLiOYeTdoOY88N6lfUVul0IAXJGOK2OBpp2ZAT8oUDB9RSRREDIHOanAUE7QD75pXjOYwnDD5sCgRUmh8xyuMYHelEYVgqrgAYq1EBljzuodckEinYClIi43Ee3TrUdzE7FfL6/WrkiA5DDg9qh2kRnJJOc5J6UgM+SLaSX5PTrUTR7QxI960Zog3BGQeaJIFY7+pxxU2GZEiEQhnJGRnGKromSpHKn1Fa06fKFwcg5IPao0gRGb+7jIxTsBV8sMvIGaozQFjtHrnpWuYgJNwbjHT3qB123Az0YYpMDKZWjU7RlDUDK3C8AVsPGHYjHyr/OqfljaQ33s0WGfPHx2jEfjC2HrZIf8Ax+Sin/HvH/CZWuMkfYU6/wC/JRWi2JF+AQ3eNLkYzmxf/wBDjr6KjjZRgYJHX0FfPf7PH/I73eBz9gk/9GR19I28Y6t+VJ7gV40CDLfWrMUYkbdgcfpUhiUyct2p23aQuCEP61IxkMYacs3OB8o/rVry2fjGB/OkUrGWLAnsPpVuHJGcYFAiBIgQCMj1zVaT93q6beN0Q/Q1pMPQf/XrI1KXZq8S4JYRDOO2TUy0RtR+M05vmjxxz1NZ5Tnp9atJNuQ5Bx9KbhWIOSKzZ2WI4Y+QQAe1atuMAAVTG3HB5q2km1QwBNSkFy8jbR0qVHBOPzqkspOQfxFTo2R1qgLinAwDz/KnhQGO3HHvVeM5A+Y1OGAAwAcUxMbhnXOR1yPpTWHmZIUZAIoMgSTcwJQntUzEYJIwevPagoypY5A3ylcAEkkYqgYZAASo3HgMK3pYQ3fOO9QSQBR8qcDpRa5opGCYRjdj5z0GMVl3tpySADnqK6UoORt6fdzVK5TjghWxUuJaZwGr6WxmWaAsJ4zuVlONp9frW/4M8Xx3pFhrLJBqO4iIjgTqO49/UVcu7QSRum05PLD/AOvXFa/o28GRY2UpysiHDKR6elCk4sxrUVNeZ69tzGSq/KP7w5pWgDfOBj6VwPgLxmbyWPS9clC3LHbBNniT/ZPv/OvRANgbHU8CuhO55kouLsyr5HlwlgSC3PWmgOSpZuT7Ve2ZG0gbRUTLjIwC3anYRUnjk8wHAI70x12HDLn6VauJY4kJmkSMKOSxArPTVNNb5fttsT1BL0h2bHgED94MNnp14pjMvb61cChot6kMG5DA5B+hqMRgn/GgRnTbSTzkEUqKBAcDr3qxNbgnGBnPFRpBtyrEkHpSAreWSMjiq11GwUdN+e3atBkdTgNgY6VD5LsNxIyeuaBlBov3ed3A/hqqUYSYI57Vfe3cP8o+Xr1qPYd2WU59qAPmz9oMEeNrXcMH7An/AKMkoqX9ov8A5Hm0z1/s+P8A9GSUVaEH7Ouf+E5utoyfsEn/AKMjr6Xt0ABJP1Jr5s/Zuz/wnl3jr/Z8n/oyOvpm3TzH5+6vak9wGmHe5Yrkr09zT1BBPUADg1ZDDkDj3pEj81jz8o60hlbbvAZs4/nVqMOeGGD6DtVgKqAKuM+tLgrgLyT1NABFHukAPIHX2rmUm+2anczdmfanso4FdTcq0dhOMjcI2JPfOK5LRMeWgHHFZzfQ68JFO7Z0lrGCnQVZWJcEYAFR2xyvFWCPTrQatFd4lKkelNWPHfIqxx259qUbsYAAz61LQiuAueKkG4fdFSeXnrnNLtA9Kmw0xUlbuce1WEboagAx7CpE+pqkhlofOFGMkHPWnOcIQxJHrioY22njFK7Eq2D1HSmBOzAxDdj6etMdCxzgKoHTvmoQwVAepA9elSeYSMBefU00OxUki4bsAe3JqpNEV6jPvitUIBuxkDP51Xmi6k8jHGOooZSkYciF2bIGcVj6pbpMjEjeQMYzXUSQYBIY+2BzWfdRFSBgEdKho1TueU+ItHaOM3EcIVhzheCp9aj0zxnrtmIw99KqjgLJhx+tei6lZxSKdw7fWvNvE2iSWrPLGSyHlgRx/wDWoUrGNWipanaaX4+1WSLEsNnNkZBIKH9KtnX9Vvf9ZKsKH+GFcH8zXlGl30tsQsuGgBCqw5ru9MnEsYaGTIx69DVczMo0orobsWn294MzMZHPXzGJP61dXRLTywnlxjHYAVivv2/OPxFMN7qVsC0S+bhCE3evbNI6Va1kaJsruxYnTbp4OfuDlD/wE1tafrsEiRx6iyWt2zbNrfdc+qn+hrmW8Suqos2n3AOPmYAEZ/Oql7q1rcwt5kcoQjnMRpqVtialCFRa6M9FmjDYx9ajddo9xVLwdcS3vhqwuZwQzx5Geu3tn3xWg4G7k++a0TurnlNWdiq5G/dkE0kw/dk4yO9ShM5wPlPUnrTXx5Y7UxFCEMzkEnGM4pJEIbIGT3FWYFxM5A+XFR3W5SeO9Az5k/aP/wCR7tDxk6fHnH/XSSik/aPOfHVn/wBg+P8A9GSUVSEP/ZsXf49ux/1D5P8A0ZHX1FFHtjwn618v/s0Lu8f3fPTT5D/5Ejr6iRt+7jCjv60mBEFyuxhy3U+1SwoFQAcL6VNEh549qsLGoOW7DmkBXXr0qVFJdeTjNOjiySc4BP5+1PKHzQFGPagZM8IeF0PJdSufqK4TTMxu0LZBjYr6dDXoKgjAPOBnNcdrVv5GqPKgHlz/ADDH97vWdRdTqwkrSafU0rWXAHBI9a0InVwMITn2rEtJMYz/ADrUgmbb8vFSmdsoXLmwk8LikRCOppscpHc/jU5IPTjFUYyjYaQemOabsJbLHH0p4fsfwqRVGCeMU7EpWIWjbbnoPWmAHogPrkmryruXDEYFJ5fODRYL2KRDDBYnNSKQAM/rUjL8pHWoyuGGDx6Uik7koYbeKUcAjGSaizgcj8acHBPHNOwx5zjrx6UAKR83IpD06Uq/dIFFgIymenbsaqzxDockd+OtXFJ/ChlVlJ6560WKvY5+e2VmICYA9axNU01ZImBHJ6ZPNdlJGCMDB98VmXMA6lcknA9ahxNFK54zrmjNZyZULgn0xzUOmTTWjN5BJ3HJU16dqVhHMCkqAqfWuN1HTJLWRiqboycYXsKh3JcTUsNZSUBZEYMfUVtwXkSoCoDA9vWuPsAhYHdu46ev+fStWCNC3zMBwMimKzNpruzl35wCoywPBFRxGyuAFRlDHoM1BBpFneybsDzMYznqPSqGo+EVdl8l5YmT7vlsVp3SNVJNWNBDeaBJLc2JaSDO+W1z8r+pHo38+9dta3cF9bW09sVeGVA4IPIBHevPotN1GCFUN67cYIf5qzhFcaL+/jhdjGxk327FST6MvQiqUrHNWoe01W56q/U4xzxUDqSp7Yp9rJFc2MdxA4aORQyspznND8JjqBySa1POIAAB9TUdxhuO9WYCsgLKfwqGeHbkr+QoA+XP2kBt8d2gPX+z4/8A0ZJRT/2lQV8fWgI5/s+P/wBGSUVSESfsxqH+IF4D0/s2T/0ZHX1IuAhC4Civl39l8Z+IV3xn/iWyf+jI6+rETBGFye2aGAkIKoTipBgnkZqVEOPnojQbi3GBwKkBqKc5bhfT0qSIbQXYZP8ASnMNwx+NLEDsy559BQMeeUwB1qtqVgl3ZPEAAw+ZD6NV5EAAbPFO2lsFuFz0oeo07O6OGgV0kKSqVdThlPatOB+crW1qmki+/ex4jnUYDdm9jXPus1o224jaM9ieh+h71g04no06ymrdS+rgkDvU6nOc4z61nJKDznmpkk5yGINVdGjVyZnINSxTDkZ/A1CcsMcA0wL6nBHcUuYVi+bjyzzSC6yDzgVmzPtIBfr0Hc/SrNrpF9eJlnNnCejMuZD9F7fj+VNSb2M5csVdj3uPQE/SoHukyNzAdsFhVv8A4QrTJmzeTahdMRyJbpwp/wCAqQP0q3/wh/h2KPC6Jp+AMZMCk/mRVWkZOtFbGeswIBzlalByQVon8H6aQDp8cumydQ9m+wfiv3T+IqrLp+r6ZzIq6hbjrLCu2VR/tJ0b6r+VKzW441YsuhuODn2o3cg4IBqpa3kVyu+Fww6cdj6H0NXMgjmmmajlIx2pyDA47dKiw2eKkG7jNMYjrkfdx9KrTRb13d8YNaEQ3Hb+tSmJTxgUWFzWOWvLQ4yoz6Vj3liGRhKpIYV209tnoazrq0BJ44+lZyiaKdzzTUNIMD+Zbg464HerWmRxzAbWXd6YwRXU3licnYPlPasK/wBKG/zot0Uw/iT/ADzU2DfYc+iu/wA6SOjdmQ4xUV2NXiQbLvJXu6ZzWnpGrfZ0WLUQpI6SIOD9R2rd82xuowVeNsjsRTSFez1R57/b+o2jbtSthJFnBkhB+X3IrUh1C3voWaB0YEZwO31rUv8ATreZSq7H5zXOyaF5UjNbkxOe6cU79zRSXQ0fBd8I9SvdODhYiBPECcfMSQwA/I4rsY8sWHZenvXkEkd1a3EzX8RkVeVliGGGPavVfDMjT6HZXE7F5JowxY9SO2feqpy6HBioWlzdyyuI2OB160jHgjNSzx4bOPl9aYFzGA3rxWhynyx+00CPH9nk5/4l0f8A6Mkopf2nRj4g2gP/AEDo/wD0ZJRVoQ79l7/kod3/ANg2T/0ZFX1bG2RtXhemfWvlH9mH/koN5/2DZP8A0ZFX1jDEfLBxhs1LGPOQgVeT0yamVcKMnpTY1IGSc1KihiBzSAjB5AyPepghyAeKEiUSlyMIP1p8ZLyFjwKAJQh2DBxSxr7k1IMHAxkVIFCjJOMUACjgL/nFI8KTHbIqsn90jIpwJC55yf0qZVCxE0bj2Mq40SxmDbIjE3qhxj8OlRDw9EdpW4mGfUA1tRjGc44p7fKOBS5V2LVSS2Zi/wDCPoq/8fMuP90VYj0O1BG5pX+rY/lWmScj0zTxw4+lHKhupPuU4LOCB/3MKJn+IDn86sHr7U8AFsEVIFA96diGyDGDyKWVQ67SafIcDjrTVyOc800AgXIAAwBSFQHzmnKO2c+9KwHWgRjaloltfytMN1vdHjz4uCf94dGH1rHuIrrTHxdqGizgTqPlP1/umuwAzSFA6skihlYYIIyDUuNzSFVxOUSYNytS7+MtUupaIYN8um525y0HXH+7/hVCKfeoDYH1qW7aM7ITU1oaCSAYx1q0rBsYJrKVgDg8j1q1bzYIBNNMcolxh1qGWEHmpQ2aVuh96bM9jMmtdxJxis65tFAO5c10DAABT+dQyopXkVNjRTscbc6epyUABPSsW80cOOCQ/wDeQ7SPxruJLZWkZf4fWs6eDCsPvDkk45+lQ0ap3OBnkv8ASxugkkmVTkxzPg/g39DWrpXiO3vmEdyPIuON0bkfoehFaV7p63NsDLECcdPSub/slLYzlYwyMeFx0Ht7VLbRXLc6O6ghlU4wQR+lc/olxfaJfXP2GYyWivve2k5Ug9dv90/pWJqd9e6PGsto++3yA8UhPyj2Pb6VO2qghHMMgkbjKd/Y0uZbicFJcsj1mxmivLdLiNj5cg3AHr9Kn48sAY61w/hrxHBY6Vb2lzBcGbe2SiZUAnI5+ldtHh0WaJgUcZX6VvCXMjyqlNwdmfLH7UP/ACUO0/7Bsf8A6Mlopv7Txz8QrTPX+zo//RklFaozH/suDPxEvPbTZD/5Eir6zTLjAzk/pXyd+ywu74jXeP8AoGyf+jIq+tUAQdalgKgOQOCelWeExg5J71VJPG3ueanhYk55IFAx5BOMD/61SoAowBz61GWABJNSR/d3njsBSuBKpCkZo/1jYPQdaMDBz+A9TUipx8xwB3oAfEMtzU+ARmoQDjJ4Hb6VN1FMBFGee1IE+YnmpOi0JwvNADQCQacPU0pz26Uh9KLWC4KRu9TUgI556U0phc96TPFIZGTubJ4NSBcKfWnIoXrSEbiewphchRW80Ht1qVh09TTgMUpHPPagQ1RwaQjsepqU46GmMPm3e2KAGkDPHbvWJrmm+YGuLZR5vV1H8Y/xrb5HNVp2JkwPSk1dWKhJxd0cjHlhwffFSbiMEHpWjq2mup+02y5OMyIO/uKyA4IyDWLutGelTmprQvJdfLgHnrUq3RbAPWsoyc8cGlLMAQ36VSkU4I1GnJYgnFBkBPvWSZSDyaBcFcc4p3FyGg4ABOcE96pPEmACOM5PvUctyQvXioPtORz+FLQcU0OmXK4x0/Wsia2HOQMVpGbIz1J61RuXzn0qWaROO8T2atayoBw6nmtrSdKSfQtOlKAs0Skn6CodRiMwIx1q5p8M8FpHDFcOsYGAvoKiMdXcucW7WHusFopMu2NQCGY44p3gq/KyXWktJ5iw4lhOc/I3b8DWfqVvAEYyje3XLc1nfD1nu/GWqSwq32a0tkhdsceYxJ2/UDB/EUo3jNJGGIpqNJyk+x5J+1Dj/hYdnj/oGx/+jJaKb+08c/EGz9f7Nj/9GS0V2o8gn/ZV4+I14f8AqGSf+jIq+r48sTuBHfFfJ/7K3/JR7zH/AEDZP/RkVfWaZwSfzqWA8ZYEfwgVNEpCAdiKiXge3rVnOI9x78CgZE6NJKi9EHJNWGI3bVPApsJJJLDHFOUFuQMHtSAnU8g9l4H1qZMbRzUUYAAB7VKTxgUABbJxxxUy8AVWHHP86lV/lx39aAFYkk46dqk5WP1YCo4x1OOlSM3b1pgPXkZHQ0bfmNIn3QKUsOaAHMcrio/4gPWm5wCT+dPABPHXFADjgk4py8KPWmCn7vlB/lQAjUu7vTCe9B96LgKTkjIpSe/akwRRnkDpQAh5J9Ki8oNIGPapT0NK3AAzQAxxyTWHq2i78y2e1ZT1jPAb6ehrexkDmmOMsKUlfcqE3F3RwEhaKTy5kaKQdVcYNOEoxgmu5ubWC5QLcRJIo7MM1k3HhzTnyRHLH7JIcVi6clsdscVFr3kctNKp461TuLtY1yzADvk11X/CMafvDSG5dfQykCrkGh6Xb/NFYw7h0aQbz+tLkmyniYdEefQXV5dzY06zuLwd9i4Uf8COB+tPnTVYy3naNqK7f7qK4/8AHSa9LWPACYAT0AxTm46GqjT7swlipX0R5WLqWIM19a3Vku7CtcR7A3406SUOnysDnuDXo1xh9yOAynghhkH61jXPhbRbrLGyWJz1MDmP+RxQ6b6M0hirfEjiGkUEkgH3qvLfxW8ZLuqKO7HFdVN4H0lm/wBZqG30FyaQeCdBtWSQ6fHcSA8PdMZiD/wLio5JmrxseiPNJbzUvEcxs/DELTknD3zqfs8I7kt/Gf8AZH44r0bwloFr4d0NLG13yDJklmkOXmkJyzsfUn/CuhjVfLVEVVUdFUAAfgKjJ+QgDtzWkIcurOOtXlV32Pk/9p//AJKFaf8AYOj/APRktFH7T3/JQbTn/mHR/wDoySit0c5J+y0cfES85/5hsn/oyKvrROQOmK+Sv2XP+SiXf/YNk/8ARkVfWSEEKTxmpY0S/wAQHarEuXxtGQPSoo1BGWzirUBDH5egFIBY1ONp79amQ89OOgpOvHr1+lN3BWZRQA8HBJzT13BDn8KbEoJJboKVnLHpxQA+Nc8mpdnB9RSDAUZ4A5qTOeBQAiDaD60hbnmkZhj3p0QB5YUASg4XmmHOKc2Txj3pRwMUwEKZTFEj7ULDr0FP4JxnmkI7YBFFgI0LFOeTipUUbfeomOHx2NSbtvQc0gHbT+NBGcZ60A+opMjqORTACdp55ppzzTj0yeppC2TQA0HFOJ3c96Z0xjqaeMkZP4UAFJn5yB2FLnHWokyST0z0oAkpHHy0E7QM00twc80ARsNx/wBkCoJG281Z9x3qCUcjNJjQobBpsp2gnvSDr/jTJuTx83b6UIBjKXjDAcnrTAhDZ6YFPfIUAHkCog/B6UARkkSnGKoXU7GRlcDb2FWmfaSRzVO5kjd1BJzSuMRZdsmO2Krvld2D97mlmcZOOlQO2UH5mkmJnyz+0sxbx/a57afGP/IklFM/aScSePrZh0+wIP8AyJJRWi2JZY/ZgJHxCu8DJ/s6T/0ZFX1fAzAgP90818ofsvnHxCu8df7Nk/8ARkdfVSE7l9aUho0IiScc1dRhGhPpWbb/ADvuJ+Venuato5d9vYcmpuMnjkITcw+ZucelSIoxluppiD5ufXipOSeaYh33UA4oQc564pnLufSpol6UASsgdcNyKXcQSozminAbuo6dKYEaDccelTHC4AFNiABOKAdzEY9s0AODg9ccd6cGB6VGEwuPT1p6YHyigBVz70Zz/Sg/dxmm98YoAUryM804DnPejsPpT0Hy0gAUhGV4pWOAPWkUjbTATORim4JfOOlPTGfSjGB7UAQnO/NSFsCjAA6c9qQKDkHpQAkjAA84pByBnqKc6jAzTWBBzQAOcoe1MONnenHkEGkXOWz92gBinoT3pknIOaV2YkBcDnn6VHIdx47UgQzPO2lkO0EioyxEgyaJiaQyK4fjjuKpljz6Ac1Yl5jJ9KqMSC2eKTYDGcsu4fdqlNgnzOeOMVdVvl5x1qjcDJ4zyeQKLARSvxVTzhllappOp7gDNUZWAGfU9qnVDPmf9o7/AJHy2/68E/8ARklFH7Rgx47tv+vCP/0ZJRW0diXuTfs0XENt4+u3uJY4k/s6QbpHCjPmR+tfUMWracWB+32g/wC2y/418K6JbTXV4Y7Z9j7c5xnjIroxoGpf8/ifl/8AWrGpVhB2kxq59prrGmqpxf2mR/03X/GrMGraYijOo2WepPnp1/OviaPw7qrlR9qG4noFHT16VI3hnVtpZLxSB1yMf0qFXpPXmHZn3AmsaXjJ1KyH/bdP8abLrWmLF8mpWZY8D9+v+NfAepQ6xp7kXAk2Do4UEH8cVnf2ld/89j+QreLUldMnVH6JR6xpUcYUalZH/tun+NTJrWlAf8hOxH/bwn+NfnnpMt9qV/FaRXIWSUkKWAAzj6VuRaTd2+V1q+k0592FaSAmNh67gCPzxTVr2B3tc+8v7c0rP/ITscf9fCf40o1zSgv/ACE7En/r4T/GvjPTPh7e6im628QWcmRlQuDk+nSr/wDwqbWi2BrEB4yOOfyxW3sJ9jL20O59errmkjP/ABM7Hn/p4T/Gnx63pI66pYf+BCf418gx/CbWNhMut2yNnGMdT+VQz/DDU4n2jXbcnuCvQ/lR7CfYPbQ7n2K+uaTkY1Ow/wDAhP8AGmjXNJ3capY/+BCf418YP8PdTMhWHWIXKnBO3Az+VIfh1rHzN/akflKM7ynGe46UfV59he3h3PtQa5pG3P8Aalh/4EJ/jQNb0jvqlh/4EJ/jXxHoXgDXvEGqfY9DvBeqrDzJ0TEca55YsRj8s1R8YeHx4a1NrK48R2ssicuI13FecdAOvtSlRlHcpVovY+7Rrej7s/2pYf8AgQn+NOOuaPj/AJCth/4EJ/jX5uPqV0HYJcMVycEqORTf7UvP+e5/If4VnYs/SL+3NI4/4mlh/wCBCf407+2tHwP+JrYf+BCf418PeF/AWu67aJP9ujgVhkbgD/St9fhDrjKCusQnnB+X/wCtWcakJbMppo+wRrejgn/iaWH/AIEJ/jTjrmkEYGq6f/4EJ/jXx8fhBrgzjWISew2//WoX4Q62VBbWYc+y/wD1qu6JPr9ta0jqNVsP/AhP8aYNc0gEZ1Owx/18J/jXyEfhBrmcf2vF/wB8/wD1qG+EOthgv9sQ5P8As/8A1qLoZ9etrmk5wNUsD/28J/jSSa5pOBjVLDP/AF8J/jXx+/wl1uMZfV4QPXb/APWpR8JNaZdw1eLH+5/9aldAfXo1zSsE/wBqWGf+vhP8aZ/bmlf9BSxz/wBfCf418f8A/CqtbHB1aEH/AHf/AK1Q3Xww1qBUY6rCQWweOn6UuePcaTZ9gy65pQ6alZZ9p0/xqGLW9LLP/wATKzH1nT/Gvk6P4S63JjGrw5/3f/rVYX4N60SANZg5/wBn/wCtU+0h3NPYz7H1K+s6ZuB/tKy/7/p/jUc+taZx/wATKy/7/r/jXzC3wZ1oA51mHj0T/wCtUT/B3WgMnWIP++f/AK1HtIdx+xqdj6dOsaYBkajZ89R56/41Um1jTgRjULPp/wA9l/xr5jn+FGsxEA6tCc9ML/8AWrK1D4f6tZqS2pRsQOgX/wCtS9pDa4exqLofVX9tacFIOoWmB/02X/Go5NX09gNuoWmO/wC+X/GvjLxDpd5o0TNLfK/zBQFHU/lVTQLTUdZnaOCbaFxlmAx/KruuW9zJ3TPs06ppw3f6fa8+sy/41nXOp2CISL61OD0Ey/418xTeEtSjzm/jOPb/AOtUT+FdSAGbxPy/+tWfNB7MevY0/wBoC5juvGlrJDLHKv2BBlGDAHfJxxRXC6/YzWF6sNxIJHKBsjsMnj9KK3jsQzQ8C4/tl8gn9yen1WvSY7UEBlHJ6D0rz74bxGbxA6qcEQMRxn+Ja9Y+zyGPlWVF/u9Wry8Yr1Gaw2K9taLGDkHJ4PHWtSzsg8ZLAKgHC0WVpIWIlQIh5VSefx9q2EgjjlAOW4wcVyRXU0Zm/wBkRSrtIHlH8SfWsPUvh7pV60jeUI3xkshxz/Ku9MSYKW5JP8THtSi2ZWCSc57f41om4bE7njzfC+4hljuNMv8A95G4dVkHOQc9RivVNIUTWojuI1fAwysM89xWtHEI4QEiAYHGOtUFia3vHLB9j4Y4GB9a3jUlPSTua0rJlGb4f+HNTl+0R28llcHkPauYyfwHFRRfDScSM1t4q1eJjjO5w+B2HNdhacACNs+nFa1uxU7cACj2s4bM7HThLdHn3/CCa9GTjxMblt+czw4yPwNU5PCnie23FDp1wudwDMwJPqeK9WUq2Mkn2xTHAUDAOOmccitI4usvtGUsHRe8UeZafptx5DR+JL6DR2ziOUwNNEfXLgjb9TU+sR6F4S0261jxRrFrrsSny7LT7Rm8h325/ecneSMcHgdfp199GrIVIXZzkHkfjXgPxlggtLOyS2TylmmeQxqcLkDGcevNd1HMKkvdkcFfAU4e/HQXxn8aNZ8QaMtjp0f9hIJTlNPby18rACpkYPXOfWvLHdndndizMSSSckmpLS1nvJhFawvLIeioMmu68O/CvX9V8uSeEWsDEZ3/AHsfSirWjHWbM4U+kUcJbQS3MyRW8bSSOcBVGSa9i8BfCCS7VLzXSRHwRCMj869P8D/DjTvDsayC3jluQOZGGc/jXdxxfKvyqB6DoK4XiJV3y09DbkUdWZOm6NDYWYitkKwgYAHGavrCwVQxxngYFXljUYXIyT3p4iaMMeMDpmuiFNQVkZt3KJgUKDs5FIYR5Yxy2cACrrRGSPI4680xIwqFhj/GqYFNRhcBeveomRlfCnr3rQcjYgK7e+0jnNRMm9hkkA9v60rNgVJIGaT5sEdvem+Rt4U5YnJb/CrjKo/dMx8zrjHakaIAeuaTTAyprViW2kZHAPvWdrECfZoimN28ZNdFtVYyeTz37GsrXIT9h3HG3cOnWk1oVB+8hdOwYR1LZwT61qKuJFIXpxWNp5PkKFzjua20OQp7g/pXG3Znqx2Jdg4PQ45/wqtNGSCx6CrLkbc9RVeYhVYFuOpzQ7lJGVe5QEjB5xk1xPiEHzCM8YyT9K6/UizqFTIU8lvSuJ8STKhYbzwM59acETU0ieNfEm5L6jDbKMBV3kD1PFdv4B0IWeiCV0XzGG5+OSa89tYX8S+MiYgXRpQx/wB0V77p1kkFssSk/L8pB6GuipsonlNXbZgzWYe5BkwqhdxI7VXkttqfL8ynuOv1rpZrcO8hUhSec4z0qjcxpDGxx7n2rG2oXPEviIoXXIsAj9wOv+81FWfimqp4jhC9Psyn/wAeaivQpfAiGP8AhMgfxPLuzxbMR/30teyyK29Ryq54C9BXkHweQv4onA4xaMc4/wBpK91s7dwELAHPTNefi7upyo0hsMtrYJh34LDuOasIm+TYinAHJ7VPNGPPCwj58fO5P8qsQwooO1SSOAe1czVtClrqMghLscjjsP61cSFYlZVG5B37k1JEEEHyEZPBfrVmGFUXru9z3p2HtuUzEygOQoIPyCqGqR7USQvlg2GJPTNbzQF35wF9f6VXu7ZZopQ67EKnGew9alXjJMtMjsBlUfAPHP1rVSPjIyCevNc/pUu0tGzc46d63raZcjB5PY10ySZ2wbaLUDbo8tnjg0rEbSozn1Ap6RqeRw3cdKjlDIMcD0x1pcpW5h6k7IHBIIbjr3r5++M0Rm1nSLZDmVwwx9WAH8q+gNYwYyTjd7V4f4xgF58VNFt2+ZfLVip/3mNa0vdfMc+JV42PX/AXgrSdH0m2kgtI0nKgySYyznHrXYpEuRgY2ngAUllFJFaxx8gKoHI9qniSRAiMep4PoK43+9lornNew8R7sLnCqcn39qkGZBjOMdeOKkVAAMEE+1OEbFsALtA/WvUp0lBeZjKVyM4HIGSOB7UrBnVVbPrxU6oqKFfFRja5GM8mrZI0RhVC4O70FNdAoLEnA7etWlRgfkwB61DsLycnIzxTsBXK/vVaTPP6VIdpYtg7V7epqWXAOTk46D0pFj3KSTznjHpQkBUeMPN5mP3hGCfQUx9oKhBuYcVc8sDe5HPTFROnlMoYEZ6mgCJo+DgZyc81ieJWzprKF/iB/Wt92JQFOn0rE8TqV0iSTA5ZR79aTHHdGfpLF4Bk5GcDitqPLDOcKB+dYmmSqY8g4Hp6VtIAbcMASf6V58lqetHYlYkBtq4xwKqTDMfzH2OKmuZD5ICd+vtVG5kAjIIOepGOtI0RS1FiIJGUdv1ryb4h3ostJvpi+HZfKjHck8Zr03V7jbCpwMt1zXhXxUne9vbPTYDumaQNs65LcD6f/XrenHVHNiJWianwQ0EyQXGpSggOdqEe3/169cktSkCKxy56moPCGhx6PoNpbou0ogBHvjmtaSMOB1+U/rVy1d2eejHngiDMEBHbOeKpXFt5rBXB2Yyfc10E8IHUAke1VJE3Sg7eSMfSp5dRHz58YU8vxTCvYWqgf99PRU/xux/wl0GBj/RE/wDQ3orsgrRRIfBPP/CWXOOps3HH++le9QRbYwucZyQGPNeFfAlS3jKcAZP2Nz/4+lfQkdocMzMd56sOv0FcGKXv3NYbEECcrxgtx7mruwKm0DHrjvT40jCAqORxmn7fMcDHPauGeisaIbDAHA35CDkDpmp40kaQ4G0fzqxDHggAbmHr2qcJwOg9TVKKsLUgjBU89egpzRA7y67geSDUpVxuIzk8ZPb6UG38xkVWwvf3pO62RVjnL1TbakHcALLkqR2PStK0IZlOOAPzqTxFZqdMaTGZoTuHuO9UdFnSUmMk7kAI+hrqSbjqdVCV1Y6GB28sFj+dNmct/Fj8MjNMhG7cG5GOtSHG3AIHGRin0NzD1QblYsRjvivJEg+0/G/Tg65VLYP/AOPGvZdQj/cuO5rzCwhWL4t6TNIuS9vLEM8cggj+Zpx0iznxKuke4LvDkA8EgAH+lWFiIHPzN3IqKG3PyyucIv3VFXUBwvG3PrW9Ck4rme5585XehW8rAyy89KmUGMYU5bqQamdd2FA9zUSxuJiWxsAwPeugggKMVLsOT27VPbpiLd8u/vjtUhjyWA6GlMI2Ko+93PTFOwESqSpycDvSYVMjoKmK7E+VsgHvUQzId7qV7D3pWAYwBHBJJNByqg4zzU64CcAEdz6UAZAJzj0oArlC2CTg0wqsjYP3F/WrgBwxb7vaoY4wNxGB6UAQO2TtGAPasLxjhNIl2kA7l/Hmt5f3xYsuI0OMeprnvHbeVooAXDyToAPxqZbMqGskZumqvl5wAW5PvWyikhWyQuKx9M5TngA4+tb0agoOTz6+lcL3PXWiK8qgoARx65rPunKR/KCRjoO9aLkBsBfr2rLutjFlbOPryKVtS+hz3iGZREd+eBnANeTeALE+JPHt5qM4UwQyfu2ZcjI4GPwrsfiZqx0zQ7l42CySgxJk85PHFavwg8OPpfhe3M0QWWUeYxPXnmuhLQ87ES1sju/LjWIL1OM8VE0BZFYHAySRV2SAB9nAHHtwKjcFoWCgAk9e1apdzmKc0fO31FZ8sRXccHketa0pyxVVJOPvetQvEwjJJ5HWiwHzf8c12eL7Yf8ATkh/8feipvj6MeM7X/rxT/0OSito7Ejv2fv+R2uf+vF//Q46+jU24I4J+tfOn7PShvG91kZ/0CQ/+Px19GPF5UW1Dgk8sP6V5+KlyybNYK6G7GMqRovGDk9hVuG3Cvxy1RxIgIA+YjqTxirkCMSWzk461wxactjRjkTa2fUdfSn8sPlAz2pwjIjJcjHXAqWJVwWb72OBWrvewhiIGUKW56ZqUIF6evrTliOxTn5znJpyR8sCeMYp7dAIZkV4nBAOVKgGuG0KbyLia1floHMYPrg16B5e1WxXmUU4/t+9lwVVrhsfTpWlJNmtF2kdtbydWH8Q5Gal+5woBDcVmWEhdMEg+/rWqn8BfGVrSx3lO9BZTg8gVwep23k+J9Gv2UbYbjDH2b5T+pFeh3KZBx1PJFc1q9lut3BxkHp6GqjozOrHmg0emW5O35ugHFOZQ3LHP0rO8M3Y1XR7eRT86Dy5SezDg1rFQvTtwBXaeQ1YiUjoepp7JtTnv3pAgPBPJNTlOhPNCEMRQoye/rSNgYLfgBUjg5+bj0pn8I45NMBrL8uO57UgAA5PJ4FSY2ggg56ULEVAY0gIPK2kA9SOTSSExj5Dux2PU1aC7iBTGhAlU45HanYCE/NgsCq0jqoJ2jnrU7dRxTGiG5iwx7jjNICBeFy6nJ6D1rj/AB4/mNYWq8uX81vYDgfrXU6rqdtplsst1L8rfKiAZZ/oK4iWZ9U1KW8kXapwEU/wqO1Z1XZHRh4NyTexa0+PZGPlHU1qgE8E5PpVOGM+RgDnP5VbClVUbuWP41x6nqEVxtIwf/rVz2qXCwhsuRnovvXQ3ByG+X5QMc1xHiFki3yl2wmWA64qop3Jk7RPO9bg/wCEt+IekaGSfLh/fzgdP8/4175b2q2dvFAMHaMDivOPgToxu4tR8RXSq019O3ksw5WMHAH0r1i5QZyBgg8mumKW55M3eRnFCZGY8qPWnNGGOT0Aq7tURbe5PeoLkMiDYMn29KsgozOu5VUHBOM1UnGyT5vuH0rTZDxvC4qKVR5ZG3gdPrQB8y/tCADxvbYGP9BT/wBDkoqT9ooY8c2vGP8AQI//AEOSirWwh37OQz46u88j+z5P/RkdfSsQJGcYAr5t/ZvyfHd2FGf+JfJ/6Mjr6aQFW4wfbFcGKV5msNiPyRHFlhljzg1JBvbOBx61PHFx84yTyc96kRd5Kj61yW5XZFjMqcZ6D9alRNylsEE/rTjGADnH5VLGpOBjgHmnFNvUPQjRfmzkYHGKeiFmB4+lSGNWc4wvrUyDaMdaqMX12EyFBuLA9a85urEtK7JgPuI/EGvTfvMDjB9a4jVFMOqXKAcCQ/kea3ovoXT1ZWsX2sDjK45x+tbaSoYW3DjrmsuKHAV14/vD+tWW3pskUKwHbOM1o42PQg7o0SQyBlAJ+vQVm30fmxuMKDjsOtWopFeMMVZCRkk8VBL/AKv5tyEg5B9KnqXbQX4f3rR61qmnjOPKjuQOwJJU/wAhXdhCSCpJOO9cH8Prff4m1y57LDBAv5sx/mK9ERAEOMf411w2PGq/G7EPlqo6Av1zTlBHJHOKeEO7p+NK/CnHXOKozIQMyc80BCuCV56D0qdEAXJBIPWlx0AIC+h707ARRqwwDj15p2wY5AIHSpFXnJPNIeGwR1OKAIljG9jyCe9NlKj7p+bpj1qw3AAB570wRBSTjLnpQBXYH72OKJCFiMspCxqCT7AVZKkLg/jWL4qk8rR3iU4aZgn4dTSbsrlQjzSUe5xmozHULiW7mGA2REp/hXsKSwRY0AK5GKS7ULBHjgVPAqqobb174rmqSuj1YxSdl0NWBB5Y243Hn6UsmUJbIz646VHG3C7OABzk065baGZiwH90DrWfQ0sZ1622F1LbievvXmPjZ5jo9xbplbi4It0cnkl2Cj+degzTtMG8tTuyRuPTFYU2nG91jR4ZXyv2tJXYjrtyQPzxVRMsQ+WJ3vhHSE0PQbTTogAsESrnGM4FXpYt0qDBBzuJq4yswOBn3FRxruPmHn0BrpPKIJoVMQTjd1phRTIQxBwoFTumJQ69ejVWnQ+egHLHk/SmBVeBstn5l6iq7ZO1jxGO1ajKEGW+70HvVS9Cl0CgfL/nFAHy7+0aCPHluW/isEI+nmSUVL+0p/yPtp6/2dH/AOjJKKpCD9mwE+PLsKOTp8n/AKMjr6cjUqCcZA7npXzL+zSSPH12R0/s6TP/AH8jr6fhUyybR93ucV52K/iWW5rDYcCeMcqe/eplAA4yCf1ppwquI13P0UE8VJEmzbvPzkcAdBXI37xY4syY6AdzU0XKAnPPODQqeYAuPlHr3pwXJVQa0ine4tNhU+6ScYzwfWpY1B+Zjxjp60MuSASAPSnYyfkBINaJNPUQDAYA9DyfauEkkF7qlxMPuu52/QcCu1v3WKwuWU8iJsflXB6W+yNM9AK0pO97nRQjd3NiCABMipVtsqxA4POKW1cNgY5rQjXC9c1ozq2KUsO0DavuM9BVG6c7CHG4HjPoa2bjG0bTgntWFOCpIycHPJpW1LT0NH4aWx8nWLsDPn3m0H/ZVFH8812pUFD1FYXw+RU8PucDH2iTgeua35MgjClm64rsirI8eo7yYkY5BPAprIS+4fdFTE5GaY5yfl6UyBpBJC9utBjVmIcZX0xTkQgKcH60O+1GABJ7UABHzLg89SKUp83XJ71IFCD/AGsc04KAuR940AN2ncABgetK2AwIGW6Uc46ZxwKMfMFHfqaYEYA3ZPU9qwfGMObKNxn5ZBn8a6NgM5HFQX1ot7bSRNwrggex7GpkrqxdOXLNSPM7sZhZR/DUlixaMDGPU1Nc2zxfaI5VxIrHIpLUAIoQcgZJrnauj1YvUtQkhyoH8ulPnJZTjJHuKhQMJPmPyn17VJOwCn5jn+dZNaGttTKeAK7nDdeh6Vj6nJ9mniuOR5Lq5x2ANdBcOdufxNcprrj7HcZ7qfwpwM6seZanrLZMaSRthGAPTrmlkToMYAptria1sgCdqxq314qaQF2O3tXWtUeMU9rM52ng9AajKeWdxH1PtVvIzxzmmyrtj4oGVLgIyBeMnpVKVCsak+vWtGZMrnHIPHtVWZSu5Sd5xnB7fShgfK/7Sgx49tB/1D4//RklFP8A2mf+Sg2vBH/Euj6/9dJKKpbCD9mcbvH92AM506T/ANGR19TRLsDKvy+pr5b/AGZCR4+vCo5/s2T/ANGRV9SJEQeePavPxLtUujWGxNFhV24/GnEASZ4zjkU1cICGJJPTFShfMYDGB1Jrmeqt1K8xV3sGwMKafFkvhMBR1OKVRn5QflHWnqoC4GAO9NJt3uBIY9ylgOB1NPUFU3OMt6UiMfLXHQdBTkBLBTy3fjpWySb93diOY8a6vFY2S2EQL3d0uD/0zTuT7noK5a0yoUA9qZr032zXbyfOV3lF+i8f0p0DEP04PpWiiorQ76EOVG7p5IYcVqebhcgEjPOO1Y9m4DA5xgVpwzbu5bPTFOOp0SV3cSSYFsD61n3sm8kenNWZlZXLAnB7elULsgEH8aa3E0rHaeCohH4bgI6tJI5/FzW2rgFgOeOtZPh2Mx+HdPjOQDEHPuWOf61qxny1AUZJPJrrR4stW2LxnpgfzoCAZODz3p2wuwyOnc09m2jA60ySPnC9QPSkC8jaOlSbSTlqYBl8L+NAC5ZWHfNOI24weTSLy/sPSkI5GAeKAHDIUnvSMCoBz8x60uC3A4phjLuCfurxQApDE59aVspGADzSyAsMdBmkJyCvYd6QzF1vTFv1aSPCXCrgHs49DXG23yZzkY649a9JWPJ44NeduCl5OMfdlcfqazqKyud2Ek27FiP73zc+lJc4OP7vtQhIxnBz6026YLHnjisWdy3M+4YbWAPQcmuX1vBtpsc5UjFbWoy9QSuD/eHFYd42YyM4bkjHOD2NTBE1b8p63ZIUsbUDPESg5+gqz2I6Zqj4YvF1bQbO6OPMZQr47MOCK05lG4Z6YrrWx4rVnYhlTaDgZIFVxFul3tnIHTPWrbc46gdTUWQxOMg0xFdsqzAnIJ49qrSAl8gdO1WWBVcMd3PWocKeec9Pakxnyp+0+SfiDZkjB/s2P/0ZLRTf2m3L/EK2Ppp8YH/fySiqQh37MR2/EC8IIH/Euk/9GR19ToCx3NnHYetfLH7MIDfEK6zz/wAS6Q/+RI6+p5d2whMbye/avPxd1Js1hsPRS7bjn0UVYj2rnOeKZApRQobnHJqRvmUgcYPSuW3Kr9S3qPDr1UYUUvKtk0iR8LngDqKfEpfO79Kq7bQtCRIxsHBBI7Ul7Itnp91cA4McbN9TirEaMcsx69KwfHd2tvo6Wif6y5fbjuFHJ/pXfTpqEeZrUle/JRRwEUeY9xyWPJ+tWIUZj0PHtVlIdsQyO1PhjAbnODWLZ68SzbRtjccYHpV+2OGBAGD0FV0T5SNx464qaNSJByT2pxKY+6QlhySpHUdqzNQBCEeinn8K3ZE/d5HP9ax75c8Y9jV21JvdHo2lxqNLsuM4hTHv8oq3t9etZ2iSGXRrBs8iFf5VojJXk11HitajdwJOTj0pWG0UqrwSFyRSDLNyMAc0yRobeeuF6AetLgjPp0wKGAQ5A57AVIVYDsKAI1XAz+FKc/jil/g6c/yoTIHPJNACLkZ796V8kegp7D5cdDTD1wO3WgBeMALjNIQei4wODQOp9KAwHU8etK4xDlV57da81DeZdTEdGkY/qa9D1K4Ftp9zNjASMkfXFed2cZwvrUVDtwcd2W1AwDxjPeqN+2wnLEj6VqmNdhJxzWHfsxbA4xxmueWx6EdTPmIdScBh0FYV7GHlO0MMnpW7McIV/izggVX8jewOefcVnF2FNXR0XwuutiX1gzcKwmQex4P6iu3cZk9ea8p0S4fRtdS7PMY+Vx6oev5da9YDoNrKdysMgjvXVTd1Y8nEQ5ZXGTjgj1qBeE4IJ71LJ8zZOc5xUYQISR/F1rQxIZFLDjt1qq3LqMdauO2xSO/SoQMnj0oA+T/2n1C/EK0xjnToz/5Elop37UYI+Ilnn/oGx/8AoyWirQg/ZcXd8RboEZ/4l0n4fvI6+qxCCS4OBngHvXyr+y3/AMlEvMf9A2T/ANGRV9WkYGG6/wAqicIzVpIabWw4qSMfdY05QsRB60KTwrA/SrIhyCVI3d81x1cM/iiXGfcjUluDjJ6D2qeJS7YH3R+tQxAeaUX72MknqBVlQyFQo4608PTb1kEn2J+QfXFee+IHbUvE8rbv3FqBEvuep/Wu01e9GnabLcHlwNsY/vOegrirJGjVpJycscsx/iJroqO+h04Ok5Pn7EssYbA79qYsGGGevpUsMolmJA4U4q15W7LEHOegrBo7r20IokIXqamjjw4bp7VJboBkHr70+RMEegoSJbJwgMZUCsq9tyN2O1bUBXZ6mq9yoMbZrS1yVJo2PCMwfQ4lPWN2Qj8cj+dboB2A1y3giUiS/tT2KyD+Rrrug56VtHVHm1lyzaGBePmpCM9BinjmggAk5P0qjIYygyKe6ikbOcLT1OBjHNAXFICI5AIBx60o+UAj8KeUy4/ujn60rD0pgMAyoJpCvJ9PWpAOhPGO1NznjsaQAqgYzUcgG0461I5xhRSEHHHWgZznjOfy9PitlPz3DAEf7I5P9KyIbYCFTj5qTXrj7Tr8gJ+SEeWv17/rVsOBFjsBWLd2enSg4QXmVLjhcHIHOKxblSzHArYuJASe/FUQhbPv3rKaudEXYyZI+QMZ/CrCQ/IDt9uammh49cVYjXMBIU8dKhRBsxdQtWKhkG1hz0rrvAt6bzRTDKcSWshiYf7PVf0NYUsyhMMcgdQajjM+l3y31k2Y2GJIs8SL6fX0NaxdmZVqPtIabnoAAALEdaicMQCcYBosbiPULOG5tzmGRcqf6H3pZeU2Z5z2roPJ9Stw+7J4prYGCBx0qZwAvAGGPSod25/YcUAfKH7U3/JRbP8A7Bsf/oyWil/an4+I1mPTTY//AEZLRViD9ln/AJKLd4/6Bsn/AKMir6yjjDnPpXyZ+y1j/hYt5u4H9myf+jIq+trcgoAvegCZUUAAcn1odhhsfjjuaOF+voKjVN/zdqzqT5UOKuxFBD7j1z2qyJ26SDj9aiUA5IICj9alRMyb26dhXBGc4v3Wa2XU5XxZcG41y1tuRHDEX2n+8TjP5CsLxBNO5tVtWVQsm5ge4ANdB40tP9KtL6MsGUGN2HQjqAa5q1l+2XrsMMqnaMVsp8177nrYZR9krGpo0PlqHmPUZ9M1oCcXEoWI9D2rntSvJEuUt4Ry5IyP4QByf5VqaSrW6BzwoGB71Vypw6m2ke3BNPkjyvrnmsqTUC82yPqOpzVu5uzHbxk9yBTujDkkOtsh29aLiQL15FV45xkgVDdyFyEGc+1F9ClFvc2PByZ1u7denkAfrXXnJJHaub8GIB9tkI5yqZro8hjgE5raHwnm4h3qMcByPQUE/lTWLYITGfegHPXr3qjAco9elHXNGfTtSA87R+JoAEyyEn8KSMNgbupp4IwcHIpudpwQcfzpgMfcWGCQP5049uKUDqD1pw4HFICJ+2aUsETcxwBQfmOaWVBIoB6d6BnnVxHt1O5JHWVj+tXpHCoAT17Va8T2RtrxLmNf3UmAfZvf61nykMqkDP0Fc+10etCSnFNFW5IXcAe1PsgstlvbFUr6QpIcHnHSk0W4EunyovUMw/Woe5q46E0e2VnjH3h0qpHfiGXyG4YHI9xVGS5lstRikPKk7XH1o1u1M6LPA2BnIPoaEi+TUZ4ltpjC72jhXYcHPGan0yR5tIgV2y4TB+vem2ExubBiw74x7jrUeh2t7cy3i2cLSpE4JwwGMins9DT3Yq8jqfh3KR4fmV84S5k25785/nW7gtuLfWs/w5Y3FjYPHdYVnkLhBzsB7fXvWsylsJ90dePSt4X5Vc8Ks06kmu5VVg6NxjBxUbcANVlhgMoqGRQFIH3hyKoyPk39qb/kotnzn/iWxf8AoyWik/am/wCSi2eP+gbH/wCjJaKtCGfsv/8AJQ7sf9Q6T/0ZHX1xEdqKB94818k/suf8lEvCf+gbJ/6Mir6uZ8Jkn5ie3pUykoq7GlcsO4PyKevU+tTcnCg4UdapxHJz+ABqeIksOeBXnurzu76mtrEwI7DCj24qZMluc1Ep3Y3cYp5AIIzj1NT6AKqxyhoyoYHqrDINcJfWklv4pvRAI0jPzBcYAGK7pcR9Dk9CapajpMV86vI7RS9C6ddvpQpcrV0dOHqKnK72OBkdZNQUKOVHNaGoNOVtLeyCm4mcIgY4HPrT7rT4rTxA9rp6GQKo3tIxJZu5/wA+lJLcpb39lcNhfKmU89ucf1rdbXPRlLnXNHsVbRHiuGjkIMmSGPbI4q7fW95ql3BY6eU80IZWLtgKB6/nUNqN0zu/8blj7ZOa1NGlFro+uaxwZGP2eMn+FRx/Mk0Rt1IqtxjdblC0Mn2dP7wHJ7Gpx1JZBge/SlgDlY4o1ThRkscUTNtLIxAbvg00XGz0Op8GKTpcz5+9Mf5Ct8DB6Vz3gck6XKMYAmOPyFdEwyMDrXRDZHi19KkkA9hxSg9R+dA4AGaQn5wM1RiKBzSEELgd6dSHnrQAICvXpTiSR9Kb3xRuAHB9qYCEkYHekJwvuaccZz3pCvTNIBUHT9accZpucUo6c0AVtRt1ubOWFh99cfQ9jXAo0gZo8fvFyCD7V6N39+tcBq0Elvq10oGMvuHuDWdTozvwTu3Expl3XJMnUVT0qY22rTWzI6pKdytjgnHIz61pvbXMyyPH5ahepY8n6Cs+OXZa3m51MiBJMDsyt2+qlhXOviPRk1bQbrkAVZSeTg4p+mM0umbZQVIGcHrUmpSxyRh1BbK54GcVFpsRu7YrvKFFI44PHSnctaR1KukhnF1ArbSH4PpkZrq/h9ZyWum3ksjFpJZyORjhRj/GneFPDtpJoqTXkJMzuzF8lWYZ4ziuohihgiWOBVSNBhVXoK0hFu0jzsXiVNezRCUIPPA6g+lNR1Gecgjj3qeUhgc9OlU0wjkYGF6ZrY88RzzkVAzHdkn8asvtK5HT0qtLnkDpigR8n/tS8/ESz/7Bsf8A6MlopP2ojn4iWn/YNj/9GSUVSEM/ZhfZ8Qbw+umyD/yJFX1UE3KCT09a+VP2Y8f8LBu8n/mHSf8AoyOvqzBcAZAA7etcWKk37prDTUmhUsc9TUmSrHJ6dPrUcRIzg8+1SquBluvpXJZtaFksDs3XHA61ZT7wz+FU0Vgh69aljf5hvJ9zVwla3MJosAEt3IznnuaV+FVQOfek3b3BH3B096ccHHGaprR2Ay7zS5PtzXVl5bSOux1kz+YNYPiHR/skEE9wys5fCoPuqcdz3Ndqmc8Gi6ghu4Gt7hA6N69jTSe6OiniJQavscFPHHZWyyRncxXLYOa1ZbFrT4eFZFbzHInZfq2a1Lbw5ZrKGZ5JVU5EbYxn39a3JFEkbRyKrqRtKkcEVV+ZbWNauKi+Xl6O55vpRQR5Y75mGST8oH+NMlj8uSSWQrub07AV09z4VXzC1nc+Wp/gdcgfjVnT/DkNtIs13J9oZDlV24UH39aTvbRHR9bpL3luafhu1Nno8KPxI37xh6E+v4YrQdhvUfxdeO1MDHAyPmNNR1Dsz11Qqx0R487ybkywmAuSaUEYzTVZWT5CDmgnBA7VsZjtxI4oRt2cA4BpoIJwaeGBOB2oAd9aicDcCeueKc3bnp2pgO40MCT69qQtkjHamk54FOAwPemAuOKacl+OgpTlmwOgoHf1pALnjPasHxHYtPGtzCpM0Y+Yeq//AFq23bkD0pJGGzoOaUldWNKc3CSkjzhW8uYSrhkJ+dfb1FUr20iv9VgiskkQzOI2Uc/KfvH8Otd/e6JYXsm5o2jc8kxnb+lP03S7DTJCbeM+awwXY5bHpnt+Fc/sm3qehLGwauk7nHvpOoWiS2i2rThwFDqOCB3z2rf0LQreysY47qCKW5++7EZwfT3ArcyN+AaZnDfpWigrnLUxU6isRk/KAOBntUUgVGBxyKnkwq1XJDg5OSa0OYZKflGMf41CcHAHepdu5KYMKCWAB6UARyHGAaqSn5SB1FPk+dhyeKhOQSDk570AfKf7UX/JRLT/ALBsf/oySik/agyfiHaZ/wCgdH/6MloqkIj/AGZs/wDCwLsjtp0n/oyOvqZWL4x3Pevlf9mk48fXfOP+JfJ/6Mjr6hjcliFPT0rz8V8RtDY0o2XeqqenX3qcSEseOOmfSqMTnA2j6n3qfexQKoyT0Fc6nZFNFzzASFXGKadq8M2QO9MXCqOPxp4I5JGR6UN824bFiFtzkEjA9KmByGycVBChCBgAoPQVNt3IQSQTzW176xRI8EDGM4AoVizdcZHJ9KUL8uBwB3pYsc44FNpsBYD8xPYU/dtH+0acmNmB0ppIMny9uKPhVhisxABXuaezDADdu1DtyFUZ96GQKBk5JofkAuciopCc7RzVhBtGTyajVAJNzdKmSBDl+VCTnI9KPMbgEZp/HAx70xs981reUdmTuSpt45B9akXAyB61VlUmMleuafhmRQG4H51tCvd2aJcexYc9PWmD5R7U7huefoaTB3Y61t5kguQMnp1pVJIye9NkbPApcEADJpgNViHCgcd6cRmU5PHakf5eR1JpBkncaQCSbskDv3prHj2od8Z9aiL5KgdOlAEhOASKadhYEqN4HX3pjOQxYdBTLVjtZ36sc0gHRAqGP8Rpv3c46nvTmbGM0wHJFMBJRmM47+tVgPLXaevep5W29e1VpG3jIpNjASCT7o4FRSEFT2ozsXAPJ9KhclYzn86L2CwjuFUgcetU2fAPPenyEbQM8k1TupcMcY4GalsD5g/agOfiHaH/AKh0f/oySioP2lG3+PrU+unx/wDoySitYu6JZH+zk23x3dHOP+JfJ/6Mjr6gtm3qByPWvlb4BXkFj4zuZbmWOJDYuoZ2AGd8frX0VD4g0wLubUbTn/pqv+NefidJ3NobHVo4ZlUEAD0qxE+GBA5xXK23iLSy/OpWYGOP3y/41ej8Q6SGP/Eys8nj/XL/AI1zLXWxo0dGp4yetPDFlxjvzWKniLRyAG1SywP+my/41L/wkekZB/tOxAHT98v+NNwbRJ0EbAMATx61LkdSea5weJNHP/MUss/9d1/xqceJNHK4Gq2QHf8Afr/jWybYrG+XHljHQ/rUiDC4JHvWFH4i0UDLatZYH/Tdf8akHiTRjz/a1jj089f8apXerQjbP8OBj0pyKEbgdeTWSniXRM5OrWP/AH/Xj9aeviTQ/l/4m9iO/wDr1/xo5eoXNoADPAoIHAGM9/YVjnxNoh4Gr2P/AH/Xp+dPTxLoQBH9r2JP/Xdf8aqzelhGq5xSlc4AHHesk+JNCzn+17DP/Xdf8acvibQ8f8hew5/6br/jRytvULmq3rg0j5J6Gs1fE+h4/wCQvYZH/Tdf8aRvE+h5/wCQvYf9/wBf8apwdhXNIDaSW57UbiW46elZZ8SaFt/5C9h/3/X/ABpU8S6EvP8Aa9h/3/X/ABqORp2Q7msQST6YpwYqo5ye9Y3/AAk+h7s/2vY/9/1/xpR4n0Pr/a9j/wB/1/xrSLa1EzWU85PXrT0JJOaxG8S6HgD+17DH/Xdf8aE8T6KoJGr2GB2M6/41oqnRoVjYnfaVwBjvSBvkOaxW8TaGz5OrWP089f8AGmSeJdE3jGq2OB/03X/GtU7kmwRk59BUBLecAgAGOSaof8JNogGBq1jnqf36/wCNNPibQxwuqWPr/r1/xosBqgAcD8TSM2Dg4xWQfEmijP8AxNrEk/8ATdf8ai/4STRmxu1ax4/6brz+tAGwSdgJo4+hrIfxPouP+QrY47fvl/xqF/E2jdf7Vsj/ANtl/wAaANa55xVYng4PArLm8T6QWH/E0s+n/PZf8aY3iPRhHn+07L/v8v8AjU6jNRm2rkmq8km8kE1jt4i0g5J1Oz/7/L/jVSTxJpKgkalaf9/V/wAam7GkacrnzSV6isyacs4985qpJ4j0sddStMnpiVf8aptrulgyZ1C04OR+9X/GpaYz59/aIbd44tTn/lwT/wBGSUVT+Ol1BeeMLeS1mSZBZIpZGyM73OP1orohsiHuc54G0B/EesvZR3CwMITJubPOCoxx9a9NtvgveS4/4m8I/wC+/wDGuD+E84t/FYcnGYWXP/Alr6e0ecPGuO9c9acovQ6aEITWp5bF8B71+mswf+RP8asJ+z/fHrrcGf8Atp/jXuFq42gDrWpDnvyawVad9TZ0IdjwFf2er9hka3B/5E/xpx/Z5vgPm1yD/wAif419DLlep/KnYGM5Gav20hewgfOx/Z6v+2uQf+RP8aQ/s+X46a5B/wCRP8a+iue3AprtjqMj1o9rIfsIHzi/wCv0661D/wCRP8aq3HwMvoQP+J1Eev8Az0/xr6MmbIIHIrIvpOoPUZP4VPtp9wVCHY+XPGHw7vPD2jz3z6osixKCVUuCecY5rz2wNzd3ccCzyAucZ3mvob41uP8AhCr4gjgpjPuwFeCeEYfO123XOMHNbwnJwbZy1YqM7I9A0r4Y399Ej/2mq7hkZL/41o/8Kg1DB/4m0efTL/416h4ZhaOxBbn5RW8sZ2K2MZ6inzSMjxFfhDfEcaumfTL/AONPPwev9mf7Wjz9X/xr2x7dUQsCST3pfLJQEggDoPWjmkFjxEfB6/yR/aqdM9X/AMaUfB6/wD/ayfm/+Ne4GMKAM/UGh7f5gCflPajnkFjw7/hT1+c41ePOcdX/AMad/wAKcv8AkDVk/N/8a9vFvhhnOexpEDurKAAR3FPma3A8OPwe1DnGrRkjqMv/AI04/B2/Cg/2tHjvy/H617cqeXlyDyQPrSlMFxjIP3QfWjnYHh5+D2oD/mLR/m/+NN/4VBfgHOrR5+r/AONe5eScFnHz+lRNGjsxXjHanzMDw4/CW+2kjVoz6cvz+tIfhLqABZtVjCjqcv8A417g0K4AHPpx1qpNGQ5Dj5G468VPPIDxU/CrUOo1NcepL/402X4WX8ZUf2ohz15f/GvaRCqqF/hAqvcx5jYsMe5FQ6kiopN6nm1l8Fb+5QN/a8Yz6+Z/jV9fgLfFQf7bhz/20/xr2HRgRCm7pjqK2oCCcbs/UVy/WKnc9F4an2PB1+AV+3TW4f8AyJ/jTh+z/fn/AJjcH/kT/Gvf4xjpwfQ1KrZ+8RVfWKncn6vDsfPf/CgL7vrcOf8Atp/jQf2f78f8xuD/AMif419DFlwDzj2pkhyM54o+sT7h9Xh2PnZvgLfDI/tqE/hJ/jVaT4GXyjP9sQfm/wDjX0PO3XGcetZ054OQfyqXiKncaw9PsfPV38G72A86tCeM/wAf+NYmofDi5tFJOpIcem+vftYdSGJGV9a838Y6l9nhZFGSBTjiKnVlTw9NK9jwnXLJrC/aB5BIQAdwzRUGpTm5vZpjxub60V6Mb2VzzJWvodD8OMjXZSDjFu3P/Alr6H8Iah50CjOJF4YH1r56+GkYk1+VCu7MBAH/AAJa9u0hTZ3cYUnYR8w9D7VzVE3Ua6GtKXLY9WspSxAPGR0rXhfOOtcvpc+dv889a6G3JOOa53ozvNBc/X3qXO0AAcepqGEgjIznpUyjJznj0NNCFJLDjGfeo5Mgc1IRtHbFRSsEyDgg0wRTlJGcgcDFZN9wDnlcVrSn9elY+pElT1K9sispFJHjvxudR4GuhxzPGo+u7P8ASvHvhxa/afEcYOMKO9epfHxgvhqBA2A10GII5PB/KuG+Dtn5+rvKTwpA+ldtP+GefX+M+kNCtfLsRjpjvWgqgIN5BI603TYsWY5O0/d4q4IAX2qMcVTRiVIyzYUgY6ipXXZIilePSrggUkBf4e9NuLUu6k52kY4PShAVY4fNZyQBt6VK8YByeQOKsRIscUmOnTPekVAVXByp71QEDIGRgCC2MY9KghjMCrjgVdW1VpGAUqAchs9aluLYMgbJBGaLXAzEQ734BA5qYIASxXjrVm2TaTkZJ604ICki7TuA6HvQBnlSzK24e49aV7ZCwJHzjnIq4bYxxfu13Dr71G0boqgZy/eiwFJlAK7sc/dB9agnjHAdRuzggVoSQrK6qeDH396WSPcVJU7umaVgMh4NsZAHJ4wKrXURELZ64wtbXl5JwvBqhewMWbGSEOR70mhouaGP9GTLZJ7VuxpgHBxWLo4HkrsPIHX1rbgYlSeAfevM62PYZYQ4OCKkXGckYpqNubLAA08/54qhCMQBnpUT/NjqKkf3P4VC55xke1AEMnJO3ms67YAHOc/Wr7gnJJ9hWVeuvcjjpSBbnO6y2FOfvY4rxL4mXjQ2TOHxI7bF7cev869f8QyZjba2M9WPSvnP4i6ibvWTbo7NFB27bj1rehDmkY4mdo2RyVFFFekeYd38HF3eKpsDJFq5H/fSV7Z9nyjNt5x8v19a8Y+CmT4suAOps3x/32le6xRvwAxy3tUSV2NGlodwHVcgblG0j3rr7GYYHOCeMV5/bP8AZdRcZ+R8c9s11unT7lBBrjqKzPSoy54nTROfXrVhW46tis+B9wVl79atxHnrWaNCxvB6H5vQdKhlJGR1H8qkIH3gKZMegHX3pgilPnBwcDr0rI1AkRHc3y9c1rv3ycGsbUm3Iw71kykeGfH91bQbPdnd9qOPf5TWb8B7IyPM7x/KzcnuRWr8dMDw1FkDJuBg/h/hVj4CW7mwR8LgnGe/Wu6D92x5tZe+z3KxVEto1UEKgwB6mrMa8c9c5p0eVxECvrnFO2sAWJHX0rSxiDKpQgcdzSqCWB/hApkYfZIcDHUVJExEQcYy3H0pgAgUpnH3utIkQBPp2qZ9xUKMDHXFOYEIMhcDvTERhCzDAwMZ/Gh13oMjgHmpckRgYBx3zTWVm4AGfY0AQQxBZX475+lLuBmIZSrdie4qeKJlDswwQfXrSyY+TKkikBRO9ZURs4boMdKnI2DLc88VKYmLh9pyAdtPJyjALziiwGdIm6VpM/L0OKYsZOcnjOc4q8EAyNhJPUelRum35VJJyOSOtAyoUUxsrdAMY6Gqk0ReNmIHQ8VozKjccnnBqCdSsTFfk9j0oAo6OoEa8nrmtxCN/P3aw9OBEQVhjnqO1bNv8q4Yce1eZJe8z2VqkWuMcZpxbgHBpqZ44+X0p5UZ680CI1UKAACB6VE52ZOMmpnJHODmq8jZOP5mhgVJ5Cw4yB6etZF/KNzbugFaV04DnaOgrCv5RHE5bqfwpJXY/M8/+IerLY6ZPKZOdv3OlfN9xM9xM8shy7nJr1f4v6i/2VYMY3vzivNdCsH1HUooEBIyCcDPFd9FKMXJnm15uUrFKaIxLET/ABpu/Uj+lFdR8SbNbHWbSJYxHm0RiB/vNRXRF3V2c5t/AdQ3jK5BGf8AQn4/4HHXv7QqdoUc14F8AwzeM7nacH7C/wD6HHX0Mg25J7cVL3Ay7+zkYF0PzRDIA7mtHRLkGIMo4YZ69KsRIrgk8cc1k2rfZL2SHHy5yCeMisa0dLnVhp2djtbWQlVJH1rTic9SCK5/TpfkXDHpmtuBzgHiuNaHc0Xkb5cnH4mmPuOBxx6UgYZHGM9/SgnHerEirMrNn7uPpWLqR2o/fjIrblPBIIIrD1I5Vg3BxxisykeLfGyPd4Tds5ImV+frjj861vgC8MOgRSO42rlmLdqr/E62N94P1JSwyg8wE9tpz/SsjwZeLa/DBGD7WeQRkj07/wAq7Yu0dDz6kbzt3PcJfEcEcJmS3eWMHdkEAkeoFamn6na6pbrPbsShx8pGGB9xXiK6trc9qfJjaJCBgHC7h64wcVv+Cdaey1iGO8kk242SI4GQD0II64NOEpX1NZ4eHK3Hc9dLDZ7Gmxqd3PQcgU4puxnpS4K845rU4QV+TuHU012DMc9gD9acdpU8c9aRUzt9MdaYDofvEnOMU9FDAqcgn0pqk5x+tOQkyDjOeRQA63A3Sx8nae9SFQTgr070xH2s2e5qRCNrLng0AC7SwAJ4phKNMUU/NjkVMy/LlTgkdaYow2714oAau1skHnpUCrtZti5Hp6VMSfMOVI9D60zjcMjp3pARH7xyAM8nFRTICQccDt60To5uAykhcYOKYxY4POfT3oAx7X/WuEPRzWzCfl4OPSsSzx5r7f7xrat+evX1FebNe8z2Y/Ci1gjvTXOTn+dOBOB0PvTG+n/1qkYyQk9yfY1Xnby0Jx0qUnbnkk1TuZBj0FIClPKAcnniuS8S36xRyLLwmOo9a3r+Yhc7hweM15j4+1QW1pcTFz+7jPvzWsImdR2R4z431eXUdducNmJB5QHbjnNdz8I9CjaJbySMiV+59O1ec+H9Nm13WY4RyXbdI2K+mPDWlR2FnFCq4KqBn1rqnZWgjzG7u54p8c08vxfbL0xZJ/6G9FTfH0AeM7bB4Nih/wDH5KK6I7ED/wBn0Z8a3QHX7A//AKMjr6IaPLBew5NfPX7O4J8cXQGM/YJP/RkdfR8cTE7ePc0mBHbqpfA/P1rL1+PybiC4A4+4eO/Wt7byEUdO9Q6lY/atPljXkgbl+oqJK6KhLlaZU0yfKDHp0ro7OQMoYZ9CDXGabcDyY2HfAIrpNNlBO33rilHU9WLujfQnADDgdKewA6c4/WoIXzxnFPJ2Dnp6+lO3YCG4JJ9iCK5/WHzHu74/WuhuRlSR19a53WgVgJxxis2tS0cPqdqLzS5oJRxKGVvcHrXkHhG6fThe6Feq7iC68xFHbt+R4Ne3rHvjZRnHWuE17RRZ+K4b6NVEd6nlycdXXp+n8q6YS3RzThszY066jnKjYwHQZ5xV66sdjRz85Vgc1HpVsh2tHzz81dDewgW4GODWhqveVj0GGXzYIZIySjqrD3BFTht2ABx/OsrwZItxotuHb5oQUP4Vv4XdkDjHFarueVJWdiKJBtYHjB5pqtvG3GPXFTRr95eSc5o8oqpC9c0xEW0swx2FOB2oCD261KqFctySain3IxKoSowWHqPUUwGqGbknIJ/KrCIfLIxzTIdrqWByhJII71OCM+goAiU5G0dhTZSflxwPapIwQ+P1pJuG4HTvQAjkDA5HvURXgkHilQONxYlgT+VIxIXA9OKAIgGww69xUMhOOOPerCEjnHTrTLjBjJAyR0pWAwLVf3zn1c8mta3UZY8cnHNZFuxMjlwAC5rWibb93JJrzZ/EexD4UWSRt4NRl8ZwCaevHBIJqKfgcHn0qWUQzPgcgfSsu5kAGMc+tXJvlBLEjPoayLuT5TzgjOB60JAjF1ac8YJyOa8O+LmphXTT0yC/zvg+nQfn/KvYdUlEUYLjJYEnNfO+uMPEPjdooHDRPII1Y8DaOv8AWuqkle76HLiJ2Vj0P4I+Gx9mbUZhlpcbeOgr2doTGcjGBVHwto8enaXDFAqqqqMAdOlbbBZIQR9K1ir6nAfNv7QgA8bWmO9hGf8AyJJRS/tDADxvagdPsEf/AKMkorZbCHfs6ru8c3Q/6cJP/RkdfTUKAg569zXzV+zcM+PLvPbT5D/5Ejr6ajAyMg88mhgM2Yx8wx3qVlkKjy8YHU0scWXIQDGcmpwCBtwAKVgOGa3a2vJoWyAJNy/Q81pWdw0ZUN94frip/EUBS6iuB3Oz26cVnzKVjDryVwDj0rjqqzPSw8uaJ1dnPuwCe2avmQtkDkelcppd5umCk4xx9a6KKUMVJ+lZpm/KPDYcAjgnvWPrx/0aQfeIyPwraIBzwevQ1j6wmbWQ9CQcUMZzVhCWj3ryD/KqXifSRe6W8YGJkIkjOcYYcitrSEP2eMnrV27gDLjHJ6U4uzIkrqxw/h91cIcENj5lYcg966W4jMiqq9T0rNgtFhu5MDkNgCup0fTpdSl2wgBFOGkPRf8AE+1dD1WhNOSim2angu1MemSKwwPNOMfQV0TQkIGz+FPtLVLaKOGBcJGMc9/erDrnsDitoqysebUlzScintKjcOvWpBGWQe4qQIChY9SOlMVieBkY/WqIIo1YKMg051wwweamYDZxyTSBAzAdQP1pgUzG0C5QARluR2X/AOtUzLgrxxUuw4RTyCTwaaUIlCYygGB/hSAjYfKNvU0xlJbJPsatyL8qnsOpFRSLwMdAeRQBEw24C85OCKglQoAo5P8AMVbEZY8D8ajkADDI5Hf0oAhHO3JHTmqt3OlrazTyDIRSf8Kv43DAABFcv4xuBDbJbqfnkO889h/9ek3ZXKhHmdiHTmLxpJL95/mIHqa2I+xbpnjFYmjKRaxEk9B3raBB4C4FcE1qetDZEpZsHAH1qvdDYpOcZ6GpWBVSe1Zt5OpyAevTPWpaKRBdShBgHP49axbuQkvzg5GPpUlzcKgDlhnOBnv9Ko3RbytwGT0Jz1oQ2zi/HWqf2do1zcO5UqmxNvXcTxXjPg2wknv/ALfIAIY2zyMAk12Pxmu/MbTrCMESyP5hTOenAz9ST+VP0HwfNPp8MLXTJDkOY9vXvg+2a6VpG3c4rc9S76Hsfw6vJL/Q5Y8fLBJsUg5GMdM10E6bPUZryn7PqdlYJbJdvbxwnKRxHajH1Pqa9B8F6q+ueHkmuRi4jdopD1yVPX8RTg7e6zKtTcfePB/2iVC+OLTBznT4z/5Ekopf2ikKeObVT2sE/wDRklFdC2OYn/ZoGfH90Ov/ABL5P/RkdfULoBgDr3r5g/ZkOPiDdnGf+JdJ/wCjI6+pCCRnHJpgQpG+8mMBYx696l2nHv0FORjv2rgrjrTypzyecUgMnXISNPkcnIVl4/GshIVZHyO3Suj1KMy6Rchh0XOfxrFsTnKsOf51y10dmFejMdkeC5MpGCvQV1WmTJcW6srZrMv7fMYZRnHGPUVX8PytbXUluTlSdymueNrndudYU+XIyT2rI1cEW7jBPy81tA5X271narEXiLAYODWkkK5j6SuYwe2a0ZYtyH86qaKCYskc5PFac7jbtAwaSRm3qcbqCyNqNtbQELcXcywofQnJJ/AAn8K9Y0y0hsLRLa3XEcQwM9T6knuT615xp0In8faSCMrEJpR9QoH/ALNXpyg5PFdVPY4671sOXgAH86UMMHb0oZApBJ4psahSyt0rTY5xACU5qLafMCkHB4BqxjAxg4p5Awvc9RTEVowDlTzinomCTxShApY+tKQSoA70AMjyxTH3aUoVdu6nmnRqVUEdh+ZqTrw3Uc0wKsgYsRzim4PfOMdfWrchUMMmkKgtt70gKyPtUqQTUToXmOBwelWxGFDb+RVcABuTkHPSgCFov3+4A5HpXF6/GLrUbl2XKqdij2Fd7FjnHGa43UY/39ztPzbzn86yq/CdOG+Ig0UF7fbjofxraQYUEntkj2rM0ZSLfjnk1qeUUUbjnPv1rn8zuT6FeeZPLJxj0rA1K7SNXbI4HPFaOpXIiV9xHHYVx07fb7kqoO1W5A7+1ZstE1sHu1Vn/hOcCk1Bf3IUDA6nt+dattCiQIF5OOfc1nazuW3YgHOCCO+KUdWEtEeD62sviD4gXEZJNrYsFX2OBn9RXomnystuqKCsiDAbFc/4a0kJe6hM+TJPOzgt1xkj+ldfY24SQB15966JPU5aa3Mi+t9U1K4H+kLHAFxsQfMT35rU0e6vPC4iMUpl04yZngccjJ5YHrnvWr+5iDlcD2HaqltZS69efZIFJhyDM/ZFzz+JHalu9Dapbk948x/aRIbx1ZMvKnToyD/20kopP2kF2eOrNR90adGB9PMkorrWx5JP+zGM/EG7H/UOk/8ARkdfUcpJiCDqeMivlr9mYFvH92FOD/Z0nP8A20jr6nijwgDH8aGA23UIpK8++OlTxRFlIY89akiiCbVByAMknvUhwFOe9LYCveIX06dFHBQjH4VzMABCOBg45rrkTcPmbCd1rm/IMUskWMFCQM9x2/SsaqudWGerQ6UB09x0rHf9xeJIB3ArYXuaqXEec5HBrk2kd0XodFb/ADRgnjimX65gf6c03Rn32i9OOKmuV3xsB3FdDWgmzE0tNtsCOuc1ZnyqsW+9SaYvzuh4C1JedNv41NjO5m+GI/8AirLeRuCYpo1PuSp/oa9FThiAK8705vI1Cwn6H7UFz7Nlf616KgKnmumGxx11aQ1uuOtG0swx09KCPmyO5p8YJHHAFUYgwCoKiKkNwT6/SlhlErMpUcdDUpA4NMRDOhKNt60p+UoevFS9VYd8UiqSq5BwD3oAI8nA4ximPlXyKkPAyOPWmMP3YJPXpQAxyGKnkY605zyp9KfgADPQ9KZL2HegAk5XjoagERK57dCKskAKARjim7uoU0AU5A4dy3CjoRXM60uzU59owGAYY+ldfKM9e4rlvEabb0be8YxWdT4TfDv3ytoyAwbuuTWlIPlI645+lVdHTFqo9DxVy6G1Cc9utYpaHcmcP40uvKULHkyseAKZoFiUtFaXBkIzn0qK+tzf6wzybtsZwMd+a6K0TYg+U7QOBisJI1uVxEVyHXDY61lahC0iEEE54ro2AbJfgVRvI8gt6VrTj1MpSuedTW6292m0HiRh+uf61qTREIGHBFRzp5t9Oq84lb8OFqzeYjtssefT1rSSuyKOzMq6Zm83byQvA9TXpWgaYml6PbW8aAPtDSHuzHkk1zXg7RGvHjvbhcW0Z3KD/wAtGH9BXeMhPX9KdOOtzDE1L2iuh8s/tMbT4/tNvA/s6P8A9GSUU79pxQvxBtAP+gdH/wCjJKK6Ecgv7MAz8Qrsf9Q6T/0ZFX1aSFG4Acdq+Vf2XP8Akol57abJ/wCjIq+qmBYZxwaAGZJclc881YiXI9O/NNUADp8vc1Jb/PnPA6ipAfGuD3J9Kp6vp7XEYlgIFyo49HHoa0QgUknp2qaNRwT+FDjdWY4txd0cOkpJZZFKOpwVPY0svzLWl4st47dre8QYMjeW/vxwazUAKBhzmuOcbOzPSpy543JNHlMc8i44PNbAO8HPSsezXbdggcEVtIvFXE26FC3TZdSHHB5FJd/ckY9xxVuaP5gw6k4qK+QCIj0qjFmNbpvv9KRjhTdKx98ZI/XFekgb2xXmcxZBG6cPEQ6/UHNel2sqTwRzx/ckUMPxFaU30ObExs0wkXA4pYeuMZpzqMipIxhz7VZykSR7ARxyc0bSOtWCPm4HSkYZ+XFMCBVHJ9KkXOxt34YpWXA47U3BCMc0ANI3lMDHFNkHyCplX5RTXjJYAY4OfwoAbGPlwR0pGjBz2qUDDc9KYV+cE9KAI3+YLkcd6a6ben51OE5J7VFI21+Tk9PpQBEfnHvXM+JsC9VT2j/rXV7fmBPFcTqtwLy/klT7hfYp9hxWdTY3oL3rl3TlxCmOuKdqLbIGzwcdqLdMADNR6oGMDnPAHFQdpz1lDlmb1Oa1gPkxjmqdqhUD0FWpHKrx1rB7lEMgJJ9qoajcR2tlNNK2ERSzZ7AValkIySeK5jWzJqUoiJ22MbBpB3lYdF/3fX1rWHkRJ9DO0OJ5G82YYZwZWHoWJOP5Vd06x/trX7ezfP2WHMk2O4H8P4mo45hHDNIpyzHA/lXZeDdEfTtPaa5H+lXTB3z1Rf4R/WhLmlYVR+zpebNjYIlCqoVRwoHQCggnBGMYp8gIbk5IPWmtkHAxg1uecfLH7Txz8QbT/sHR/wDoySij9p0Y+IVpn/oHR/8AoySirEP/AGXWC/EO8J/6Bsg/8iRV9XsuQvYYzXyf+y8M/EO8B/6Bsn/oyKvrAnK8dxgUgHQ4YkY4FTRqQ57CmxKFWrCLuQjgdwaAGEYGM/jUqAgKBjJ70m35yWPHapIyPfHXNIDG8aRGTRSQOY5FfPpXLWsuYefvCu51KFryyuINuFeM4Pv2rgoFIBBGGHUVz1VqduG1TRr6eAWDHmtfgqPX2rF0xsDHNbEWJD7fzpR2Ou2g8LudePu8/jVW/wD9Ww6mtAYwcYFZl8+c1Q4QMiSPIrtPDDGTRbYf3dyfkxFcltyRnp/Su18PQ+TotqWUglS5/wCBEn+tOlucuL2RdIyVwOO9Srw2acF+X0NCc4rY4RFxk5pVIY5FLsAz78U2NcZP4UAK4xGabwOAOMZNSN90ZpBjBwO1MQgX92B3oHAyeKYC23aac+CAGJwaLgMl2hSwIxSMPkUgckUpiXYVTPXvT9vyrnrQBGMAAA9etJNFuxzTyvNOYYFAGL4huPsWlzOrYcjYn1PFcvaQAJFnkLxWn4ukMt1a2+flXMh+vQf1qK1TMeMdaxk7ux3UYWhcmiAx7jvUOpcxFSDg1NG36UlwN64J4FCNrGSi4Xihx8tSNhQRnioZG6jtWfKK5maixK+WnU8cVkakVt7UjOAK2/LDSMzDoM81RsLL+2fEEFswzawnzpvoDwv4n9Aae2iE9E5M1fCHhpIreHUNQXdM+JI4SOIx2J/2v5V1TgIRnvwSKsuBwRjjoKilXo1bKKitDglNzd2QSxBnJ5+tVwo3svTHNXGbCgHoe9VG+WQk8g0yT5V/aeQp8Q7UE5zp8ZH/AH8kop/7UR3fEOzP/UNj/wDRktFWIX9lpd3xGuh/1DpP/RkVfWCqByxJH9a+Uf2V/wDko13/ANg2T/0ZFX1eVYurH/Vrzx3pMB6EB23HgYFXIhgH86pRAtKGx8o5q2zjlQfm70gEZ8Z2jJ96mA3RcDDGowuMHr/SpBwhNIY8EDjAOB+tcj4i082t39oiUiKU/N/stXYRDKbupNF1DHPDIkqhkYYIqZx5kaUqnJK5wlqQpzWnDKAAQaiv9HntGZ4g0kHUEDkfWq8T443Vzp8rsz1Kc4yV0aplG3+dZ9wCw3Z4p4YAdcD3qa1sbi+bbbodveRuFFO7exTnGGtypZWb390tumQD99v7q9/8K72IBUAUYVRgfSqmmafFYW2yM7nY5dyOWP8AhV1OM46VvCPKtTzK9T2krrYc+QMDvQgxg0mNxqQ4GKswGsCXAB96U8Zz0zSMSvPWgfvIvmGDQIG5UHHFMySz+mO1SKRjb6UjHIYUAIfXNGRnBpjvke4pW5f3xQMZbsTLID0B4qU8j0pEUAkgClPUeuaAEAJPWnYyOeRSleRjtSdDQI5LxRFs1WJz0MeB+BqK1IX5W6VteI7Y3FmsyjLxHP4d652NxgYPNYT0kelh2pQsW5VwSy1UuJCAwIxUpm+UZ4qpdPwcGi5uolQE7jmmykDrwtMVyGyeeagupsBmYjFZ81hcmt2V7+58uJsZJPGFHJJ6Ae/auq8M6OdLsP3oBup/3kvseyj6DiqHhjRnlkXULxCFHNvGw5z/AHz/AErqguQGyTgYwa1hHqzhr1OZ8sdiEgAkflTZDnAPWptoKkZzjpiq7tg5rU5hgXcuDx6VXlBBweasZ54NRSEl1zQgPlD9qDj4hWf/AGDY/wD0ZLRS/tRf8lDtP+wdH/6Mloq0Id+y2cfES8/7Bsn/AKMir6yjyQVJ9hXyZ+y2cfES7P8A1DZP/RkVfWcBy2cdKT3AmUbV25oC/vGbOSaRMFtwBx2xU0agHJ6Uhki+nYU88IcjI9KZGpwQTk9SafuAVi/3QKSBj944CZxipmAWMdfSqsDM6hu/8qtN93n8qAF/hBHp0qCWxtp+ZLeNmPfGDUxOAMCnE8jtSduo07bEUOlWMR3Lbx56884q8oBUBQMelQgGRSM1MrAemKaSBtvca644pF+7z1qSTGBTPagByDLHnign5+elLGeD7UxTlqYiQ88etNfKjg07Izx2pJchGI6igQIO5601ucjFMjfOSTzS7ssQOMUDEccZxyRSwIUjAJycd6eewPOe1Bb5sdgKAD+HIpF+Z9xGDTjjimM2HyDQBL1/KmAcU1HwDnuaVgcDBoAbjeSO1c7qmksjvLaLlM8xjqPpXRZKg460x+U/2u9TKKktS4TcHdHCytglXGD3DDBqrMOoHArvJbeGePE0aSY/vCq76TYbgfssfPtWLovozrji7bo4NVkkYRwI0sh/hQZ//VW9o3h4JIJ9SCySg5WEHKp7n1NdJFDFHHiNFRRzhRikHJzxginCklqzGriJT02Ixw3IqORADx065qZxhx6GopmzIAOgrZHOQgqDjPJ5qGZAyspPXmrDKD8x4NQSjr6+tAyONcJz1FQyMVOT1H61YJ/dcdcVXOHBJ60hHyl+1E274iWhxj/iWx/+jJaKT9qEbfiHaD/qHR/+jJaK0Qg/ZfYL8RLoEZDadIP/ACJHX1cpXaSBj2r5S/Ze/wCSh3n/AGDZP/RkVfVQIIOTjHeuOtdS3NI7FmEfNgHgDpU4YLnGQcetVoTyDjrxUyAnk1mptIq2pJEzAAF2yfepSxwRk1Xz+9HHQVIp4G3g1HtZWtcdkSRytHFgEfiKmindwASv5VUk4Aqa3GFzRGtO9rhyqxZMpDY+Un6UiSNkE4zSbeS2BnFNJHHrVOpUTvcXKiczlQWVAO/WnrIZIshevXmoA4xtYZBGMVKiiNc57VUas776A4oniYhApXOByc04ygdjgVXicsxBp3ABBNaKs2tCeVE+9QOAeaajdCQfypuckZ54pfXB61TqsOUVXUHJyPwp7upQgHkioSecU5h+7U46DmpVZ6hyhGyqajZljIJIwT1pInLORzilckY28jPNEa91cOUl3qXY5HAxSqylclhmm7vXrTJcbenFP21lcXKSpIDxuBApCw9Rn61Fg9h15pxUAjihV32DlJMgYOR70O2MYIpjKAM8YNOUDHQVSq62sHKBOQM4yacccFsZAqvKv7wAKMY9OaicADgDFS69ug+UtMBg9KQkHIqvDht2QKY6qshKjrR7fS9g5SZsJxUZwcAVEGWQH5RxSFFx0Gc9qPbJ9A5bDpJBng8iqzNhxk8018Bj8q4+lMYAHlQRSdddg5R7OFPPTNQzMCQRgduaSUA54GKjUIyEYXIo9um7WDlGgn5l5HcGoVOSSOOcEUjBM8Ac1WuCqkccUvrCSux8h8w/tRnPxEtP+wbH/wCjJaKi/aZ/5H6z466dGf8AyJJRXVB80UzNqzF/Zjz/AMLAu/fTpP8A0ZHX1MjA4FfK37NDbfH93/2DpP8A0ZHX1AkgAznNcWJdpmsFoaMbnjHK+1SxynzMHp2qlbk4HNWshScH5qw5m1cu2tixvJbjqaljBZgP1qJABHknB61LCeT60krvURJKgPT6U9G2oFHrTM45qTBLD0Ap295yQX0Jc4fB6UrsAn6UmNx6mnoFAwB19a2Sb2JuMAyNxPQ4p8md/A4HSk9j3NSr93JqFHSw7hBwCfWhmw3AzTEYjgdKcv0ourWQWJRntSr6+tBOCQKVVxyDzWtxDc/vtvPTNSZBzmqtyWXaQcHpUkLF0Gc9KxjUXM49RtaXEJzOqBcA96VOHx2JqVRlAR95aRhuGehJFVytaivcRjlhtGe30pjk7l9OtT57YHA5pq+/NNq/UARWJLdsd6apLN1HvU0pxDx1NQouHBPpzVyXK0kJPqK4xH7ilQkD5uKJX2rnFQ7t6kj16UpSSkCFlPO4VGpG07ulIxJXjqKYQQ4BFYttu5ViQDauV4z3NMflD3pHJZQOwoUARtWl+iAgGUYjsaVm/dgj6U6QZ+lRliCQR2wPpUL3dGNkYwHUZ4PBokUI2M8ioyx4B6560pOWyeuMVUGrWE9yBmZSVP51X3YzinSsfMPNQb8E+9ZXs7FEbsME5wR0qvJJvUFu9Omf5T/KqbvhcZ9TUp9B2Pmr9pZt3j2z9tOjH/kSSiov2jznx3aH/qHx/wDoySivVpawRzy3K/7P2p2Gk+Nbm41S9trOA2LoJLiQRqW3xnGT34P5V9Ep438Kqh/4qPR89v8ATI/8a+KaKipQVR3bHGbifbcHjvwqCD/wkmjjHreR/wCNWY/HfhMn5vE2ij/t9j/xr4borNYSO1x+0Z93R+P/AAiSM+J9FA976L/4qnp8QPCAZifFGiYz/wA/0f8A8VXwdRV/V13Fzn3mfiB4QZh/xVOiAf8AX9F/jU6/ELwf38U6Hx/0/Rf/ABVfAtFL6sr3uP2h9+f8LD8HKePFOhn/ALfov/iqlX4i+DSuT4q0MH0+3Rf/ABVfn9RVKgl1Fzn6An4g+Dcr/wAVZoWP+v8Ai/8AiqcfiL4NHTxXoX/gfF/8VX5+UUewXcOc/QQfELwZt/5GzQvb/T4v/iqfH8Q/BYI3eK9B/wDA+L/4qvz4opLDxQc5+gx+Ingvd/yNmhY6f8f8X/xVSj4jeCx/zNmg4/6/4v8A4qvz0opqgl1DnP0Hn+IPguVVx4t0EEf9P8X/AMVUq/EXwUFwPFmg8f8AT/F/8VX550Ulh4qTkHO9j9DB8R/BYf8A5GzQcf8AX/F/8VTF+I/g3ofFmhYz/wA/8XH/AI9X57UVXsfMXMfoaPiL4Kwf+Kt0DJ/6f4v/AIqm/wDCxvBY6eLNB5/6f4v/AIqvz0oo9ig5j9C/+Fj+C26+LNBx0x9vi/8AiqQfEbwZ0Pi3QevX7fF/8VX560UexXcfOfoTJ8RPBbDH/CWaD/4Hxf8AxVMT4heC1Jz4s0Hn0v4v/iq/PmipeHi3cOdn6DS/EPwWWJXxZoP/AIHxf/FU0fETwZt/5GrQs4/5/wCL/wCKr8+6KfsFe9w52ffb/EHwftx/wlehnn/n/i/+KoT4ieEAMHxTomP+v6L/AOKr4EoqFhkne4+c++X+IXg8njxToeB/0/Rf41HJ8QPCBbA8U6Jj1+3R/wCNfBVFN4ZPqLnZ93t4+8I5x/wlGiY9r6P/ABqvL498KE4/4SfRSPa+j/xr4YopPCq24/aM+4W8d+FMg/8ACS6Mf+32P/Go5PHPhQk/8VJo2P8Ar9j/AMa+IqKFhYrqHtGfaMnjnwuWOPEOk/8AgZH/AI1TuPG3hobceIdK/C7jP9a+OqKj6lHuP2r7HpHx31Ox1XxjbT6ZeW93AtkiGSCQOoYO5xkd+R+dFeb0V1xjyqxm3d3P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The&nbsp;cavovarus&nbsp;deformity is characterized by an elevated longitudinal arch (cavus). An inverted heel (varus) then results from the muscle imbalance between the posterior tibialis and the peroneal muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Drs. Vineeta Swaroop and Luciano Dias.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29636=[""].join("\n");
var outline_f28_60_29636=null;
var title_f28_60_29637="Ambrisentan: Drug information";
var content_f28_60_29637=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ambrisentan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/29/5589?source=see_link\">",
"    see \"Ambrisentan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14627079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Canadian Labeling Adds New Contraindication in Patients with Idiopathic Pulmonary Fibrosis (IPF)",
"     </span>",
"     <span class=\"collapsible-date\">",
"      July 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       GlaxoSmithKline, Inc, in conjunction with Health Canada, is informing healthcare professionals that patients with idiopathic pulmonary fibrosis (IPF) should not receive ambrisentan (Volibris&reg;). Ambrisentan is not indicated for this condition, and was found to be ineffective in a randomized clinical trial evaluating efficacy for IPF. Furthermore, higher rates of pulmonary compromise, respiratory hospitalizations, and death were reported with ambrisentan (90 events, 27%) compared to placebo (28 events, 17%). Ambrisentan should be discontinued in any patients receiving treatment for IPF.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Additional information can be found at  file://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/volibris_hpc-cps-eng.php",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5032853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Letairis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6772884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Volibris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5032857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Endothelin Antagonist;",
"     </li>",
"     <li>",
"      Vasodilator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5032893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pulmonary arterial hypertension:",
"     </b>",
"     Oral: Initial: 5 mg once daily; if tolerated, may increase to maximum 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Coadministration with cyclosporine:",
"     </b>",
"     Oral: Ambrisentan dose should not exceed 5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5032894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5032895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate renal impairment: No dosage adjustments are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe renal impairment: There is no data available for use in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5032896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild hepatic impairment: There is no data available for use in mild hepatic impairment; exposure may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate-to-severe hepatic impairment: Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5032903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Letairis&reg;: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5032855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11216920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Ambrisentan (Letairis&reg;) is only available through Letairis Education and Access Program (LEAP). Only prescribers and pharmacies registered with LEAP may prescribe and dispense ambrisentan. Further information may be obtained from the manufacturer, Gilead Sciences, Inc (1-866-664-5327).",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7885303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088617.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088617.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5032899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Swallow tablet whole. Do not split, crush, or chew tablets. May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5032860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary artery hypertension (PAH) World Health Organization (WHO) Group I to improve exercise ability and decrease the rate of clinical deterioration",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5032870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (15%)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Palpitation (5%), flushing (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (4%), abdominal pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hemoglobin decreased (7% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (6%), dyspnea (4%), nasopharyngitis (3%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Anemia, angioedema, dizziness, fatigue, fluid retention, heart failure, hypersensitivity, liver enzymes increased, nausea, rash, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5032865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Idiopathic pulmonary fibrosis (IPF) (with or without pulmonary hypertension [WHO Group 3]); pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to ambrisentan or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5032866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluid retention/peripheral edema: Development of peripheral edema due to treatment and/or disease state (pulmonary arterial hypertension) may occur; a higher incidence is seen in elderly patients. There have also been postmarketing reports of fluid retention requiring treatment (eg, diuretics, fluid management, hospitalization). Further evaluation may be necessary to determine cause and appropriate treatment or discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hematologic changes: A reduction in hematocrit/hemoglobin may be observed within the first few weeks of therapy with subsequent stabilization of levels. Hemoglobin reductions &gt;15% have been observed in some patients. Measure hemoglobin prior to initiating therapy, at 1 month, and periodically thereafter. Significant decreases in hemoglobin in the absence of other causes may warrant the discontinuation of therapy. Use not recommended in patients with clinically significant anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic effects: Increases in serum liver aminotransferases have been reported during postmarketing use; however, in the majority of the cases, alternative causes of hepatotoxicity could be identified. Perform liver enzyme testing only when clinically indicated. Discontinue therapy if signs/symptoms of hepatic injury appear, if serum liver aminotransferases &gt;5 times ULN are observed, or if aminotransferases are increased in the presence of bilirubin &gt;2 times ULN.  Hepatotoxicity has been reported with other endothelin receptor antagonists (eg, bosentan); however, ambrisentan may be tried in patients that have experienced asymptomatic increases in liver enzymes caused by another endothelin receptor antagonist after the liver enzymes have returned to normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Spermatogenesis: Sperm count may be reduced in men during treatment (as observed with bosentan). No changes in sperm function or hormone levels have been noted. Fertility issues may require discussion with patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use caution in patients with mild hepatic impairment; ambrisentan exposure may be increased. Use not recommended in patients with moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pulmonary veno-occlusive disease (PVOD): Discontinue in any patient with pulmonary edema suggestive of PVOD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull;	Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Use in pregnancy is contraindicated; may cause birth defects.",
"     </b>",
"     Exclude pregnancy prior to initiating therapy and monthly thereafter during therapy. Two reliable methods of contraception must be used in women of childbearing potential during therapy and for one month after stopping treatment except in patients with tubal ligation or an implanted IUD (Copper T 380A or LNg 20). No other contraceptive measures are required for these patients. A missed menses should be reported to healthcare provider and prompt immediate pregnancy testing. Women should also be educated on the appropriate use of emergency contraception if failure of contraceptive is known or suspected or in the event of unprotected sex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Letairis Education and Access Program (LEAP):",
"     <b>",
"      [U.S. Boxed Warning]: Because of the high likelihood of teratogenic effects, ambrisentan is only available through the LEAP restricted distribution program.",
"     </b>",
"     Patients, prescribers, and pharmacies must be registered with and meet conditions of LEAP. Call 1-866-664-5327 for more information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5032876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP3A4 (minor), P-glycoprotein, UGT1A3, UGT1A9, UGT2B7;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5032875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Ambrisentan. Management: Limit ambrisentan dose to 5 mg/day and monitor for ambrisentan adverse reactions in patients receiving systemic cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5032879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit/grapefruit juice may increase levels/effects of ambrisentan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John&rsquo;s wort (concurrent use may decrease levels/effects of ambrisentan).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5032861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5032862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Use in pregnancy is contraindicated.",
"     </b>",
"     Based on animal studies, ambrisentan is likely to produce major birth defects if used by pregnant women. Pregnancy must be excluded prior to initiation of therapy and follow-up pregnancy tests should be obtained monthly. Two reliable methods of contraception must be used throughout treatment and for one month after stopping treatment unless the patient has undergone a tubal ligation or the insertion of an intrauterine device (Copper T 380A or LNg 20). No other contraceptive measures are required for these patients.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5032864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5032898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Avoid grapefruit and grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Letairis Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $7738.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $7738.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5032901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for significant peripheral edema and evaluate etiology if it occurs; liver enzyme testing when clinically appropriate",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A woman of childbearing potential must have a negative pregnancy test prior to the initiation of therapy and monthly thereafter. Hemoglobin and hematocrit should be measured at baseline, at 1 month, and periodically thereafter (generally stabilizes after the first few weeks of treatment).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Volibris (AT, AU, BE, CH, CL, CO, CZ, DE, DK, EE, FR, GB, GR, HN, IE, IL, IT, MY, NO, NZ, PL, PT, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5032882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks endothelin receptor subtypes ET",
"     <sub>",
"      A",
"     </sub>",
"     and ET",
"     <sub>",
"      B",
"     </sub>",
"     on vascular endothelium and smooth muscle. Stimulation of ET",
"     <sub>",
"      A",
"     </sub>",
"     receptors, located primarily in pulmonary vascular smooth muscle cells is associated with vasoconstriction and cellular proliferation. Stimulation of ET",
"     <sub>",
"      B",
"     </sub>",
"     receptors, located in both pulmonary vascular endothelial cells and smooth muscle cells is associated with vasodilation,  antiproliferative effects, and endothelin clearance. Although ambrisentan blocks both ET",
"     <sub>",
"      A",
"     </sub>",
"     and ET",
"     <sub>",
"      B",
"     </sub>",
"     receptors, the affinity is greater for the ET",
"     <sub>",
"      A",
"     </sub>",
"     receptor (&gt;4000 fold higher affinity).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5032884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via CYP3A4, CYP2C19, and uridine 5'-diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S, and 1A3S;",
"     <i>",
"      in vitro",
"     </i>",
"     studies also suggest it is a substrate of organic anion transporting polypeptides (OATP) 1B1 and 1B3 and P-glycoprotein (P-gp)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Primarily nonrenal",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2007, 131(6):1917-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/60/29637/abstract-text/17565025/pubmed\" id=\"17565025\" target=\"_blank\">",
"        17565025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galie N, Badesch D, Oudiz R, et al, &ldquo;Ambrisentan Therapy for Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       J Am Col Cardiol",
"      </i>",
"      , 2005, 46(3):529-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/60/29637/abstract-text/16053970/pubmed\" id=\"16053970\" target=\"_blank\">",
"        16053970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langleben D, &ldquo;Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension,&rdquo;",
"      <i>",
"       Clin Chest Med",
"      </i>",
"      , 2007, 28(1):117-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/60/29637/abstract-text/17338931/pubmed\" id=\"17338931\" target=\"_blank\">",
"        17338931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(11):1573-619.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/60/29637/abstract-text/19389575/pubmed\" id=\"19389575\" target=\"_blank\">",
"        19389575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vatter H and Seifert V, &ldquo;Ambrisentan, a Non-peptide Endothelin Receptor Antagonist,&rdquo;",
"      <i>",
"       Cardiovasc Drug Rev",
"      </i>",
"      , 2006, 24(1):63-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/60/29637/abstract-text/16939634/pubmed\" id=\"16939634\" target=\"_blank\">",
"        16939634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8653 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29637=[""].join("\n");
var outline_f28_60_29637=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14627079\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708620\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032853\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6772884\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032857\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032893\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032894\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032895\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032896\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032903\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032855\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11216920\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885303\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032899\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032860\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032870\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032865\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032866\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032876\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032875\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032879\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032861\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032862\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032864\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032898\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324139\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032901\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875347\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032882\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5032884\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/29/5589?source=related_link\">",
"      Ambrisentan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_60_29638="Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus";
var content_f28_60_29638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29638/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29638/contributors\">",
"     Philip E Cryer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29638/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29638/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29638/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29638/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/60/29638/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brain relies almost exclusively on glucose as a fuel, but cannot synthesize or store it. As a result, adequate uptake of glucose from the plasma is essential for normal brain function and survival. Given the survival value of maintenance of the plasma glucose concentration, it is not surprising that very effective physiological and behavioral mechanisms that normally prevent or rapidly correct hypoglycemia have evolved. As a result, hypoglycemia is an uncommon clinical event except in patients who use drugs that lower glucose levels, particularly those with diabetes who use insulin, a sulfonylurea, or a glinide. In addition to being at increased risk for hypoglycemia, diabetic patients treated with insulin often have impaired neurohumoral responses to and few early symptoms of low blood glucose concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic card will review glucose metabolism and the response to hypoglycemia in normal subjects and in patients with diabetes. The therapeutic approach to hypoglycemia in diabetic patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REGULATION OF GLUCOSE HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, the extracellular supply of glucose is carefully regulated primarily by insulin and glucagon (",
"    <a class=\"graphic graphic_figure graphicRef67404 \" href=\"UTD.htm?12/25/12695\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As plasma glucose concentrations rise after a meal, glucose enters the pancreatic beta-cells. In the cells, the enzyme glucokinase, which phosphorylates glucose to glucose-6-phosphate, may act as the glucose sensor, initiating a sequence of events leading to entry of calcium and insulin release. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41702?source=see_link\">",
"     \"Insulin secretion and pancreatic beta-cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin acts to restore normoglycemia primarily through the following two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It decreases hepatic glucose production by diminishing both glycogenolysis and gluconeogenesis. It does so directly and indirectly by diminishing delivery of the gluconeogenic precursors, lactate and alanine, among other amino acids, and glycerol to the liver via its antiglycolytic, antiproteolytic, and antilipolytic actions.",
"     </li>",
"     <li>",
"      It increases glucose uptake by skeletal muscle and adipose tissue by translocating glucose transporters from an intracellular pool to the cell surface.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insulin also inhibits glucagon secretion by direct inhibition of the glucagon gene in the pancreatic alpha-cells, which further diminishes hepatic glucose production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=see_link&amp;anchor=H4#H4\">",
"     \"Insulin action\", section on 'Insulin and glucose metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect of these responses is inhibition of hepatic glucose production and increased peripheral utilization of the glucose load that is not taken up by the liver. As a result, plasma glucose concentrations normally return to baseline values within several hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESPONSE TO HYPOGLYCEMIA IN NORMAL SUBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the fasting state, when glucose cannot be obtained from the intestinal absorption of food, glucose counterregulatory mechanisms prevent or rapidly correct falling plasma glucose concentrations (",
"    <a class=\"graphic graphic_figure graphicRef67404 \" href=\"UTD.htm?12/25/12695\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75618 \" href=\"UTD.htm?40/50/41771\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. There is a hierarchy among the defense mechanisms, and in non-diabetic individuals the glycemic thresholds for activation of these defenses are reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/4\">",
"     4",
"    </a>",
"    ]. The counterregulatory hormonal responses begin well before the onset of symptoms of hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Counterregulatory hormones",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first defense is a decrease in insulin secretion as plasma glucose concentrations decline within the physiological range (starting at an arterialized venous plasma glucose threshold of 80 to 85",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.4 to 4.7",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      The second defense is an increase in glucagon secretion. Glucagon acts only on the liver, increasing glucose production by stimulating both glycogenolysis and gluconeogenesis from alanine, among other amino acids, and glycerol. A normally functioning liver is necessary for an adequate response to glucagon. The glycemic threshold for glucagon is 65 to 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.6 to 3.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      The third defense is an increase in epinephrine secretion. Acting via beta-2-adrenergic receptors, epinephrine has similar hepatic effects as glucagon. It also increases the delivery of gluconeogenic substrates from the periphery, inhibits glucose utilization by several tissues and, via alpha-2-receptors, inhibits insulin secretion. As with glucagon, a normally functioning liver is necessary for an adequate response. The glycemic threshold for epinephrine secretion is also 65 to 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.6 to 3.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Cortisol and growth hormone contribute only if the hypoglycemia persists for several hours. These hormones limit glucose utilization and enhance hepatic glucose production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Relation between insulin and glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the earliest stages (within minutes) of a hypoglycemic episode, decreased insulin is the most important regulatory hormone response and increased glucagon is the most important counterregulatory hormone response. The secretion of glucagon and insulin are closely coupled, both anatomically and physiologically.",
"   </p>",
"   <p>",
"    Insulin, perhaps among other beta-cell secretory products, normally restrains glucagon secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/5\">",
"     5",
"    </a>",
"    ], an effect that is lost in insulin deficient diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41702?source=see_link\">",
"     \"Insulin secretion and pancreatic beta-cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Behavioral defenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial symptoms of sweating, anxiety, palpitations, hunger, and tremor occur as the plasma glucose concentration falls below 55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These symptoms trigger the important behavioral defense, ie, the ingestion of food. They are signaled largely by increased sympathetic neural activity.",
"   </p>",
"   <p>",
"    Hypoglycemia can also cause cognitive dysfunction, which occurs in normal subjects at plasma glucose concentrations below 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Cognitive dysfunction can impair behavioral defenses. More severe neurologic symptoms, including obtundation, seizures, and coma, occur with progressive hypoglycemia. Profound and prolonged hypoglycemia can cause brain death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RESPONSE TO HYPOGLYCEMIA IN DIABETES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Impairment of behavioral and counterregulatory responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia in insulin or insulin secretagogue treated patients with diabetes is typically the result of the interplay of absolute or relative therapeutic insulin excess and compromised physiological and behavioral defenses against falling plasma glucose concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protective response to hypoglycemia is impaired in many diabetic patients (",
"    <a class=\"graphic graphic_table graphicRef75618 \" href=\"UTD.htm?40/50/41771\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1-3,6\">",
"     1-3,6",
"    </a>",
"    ]. The first defense, the ability to suppress insulin release, cannot occur in patients with absolute beta-cell failure, ie, those with type 1 diabetes and long-standing type 2 diabetes. Therefore, inhibition of hepatic glucose production continues. Thus, the main defense against hypoglycemia is increased release of counterregulatory hormones (glucagon and epinephrine), which raise plasma glucose concentrations by stimulating glucose production and by antagonizing the insulin-induced increase in glucose utilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucagon response to hypoglycemia, although normal at the onset of diabetes, is lost in parallel with that of insulin in type 1 diabetes and more slowly in type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1-3,6-8\">",
"     1-3,6-8",
"    </a>",
"    ]. This may be the result of beta-cell failure and subsequent loss of the hypoglycemia-induced decline in intraislet insulin that normally signals increased glucagon secretion during hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. Such patients still have some glucagon responses to other stimuli such as amino acids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of absent insulin and glucagon responses, patients are dependent upon epinephrine to protect against hypoglycemia. However, the epinephrine response to hypoglycemia also becomes attenuated in many patients, at least in part because of recent antecedent hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1,2,7,11\">",
"     1,2,7,11",
"    </a>",
"    ]. An attenuated epinephrine response causes defective glucose counterregulation, which is associated with a 25-fold or greater increased risk of severe hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. An attenuated sympathoadrenal (largely sympathetic neural) response causes hypoglycemia unawareness, which is associated with a six-fold increased risk of severe hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypoglycemia-associated autonomic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of hypoglycemia-associated autonomic failure (HAAF) in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/7\">",
"     7",
"    </a>",
"    ] and long-standing (absolute endogenous insulin deficient) type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/8\">",
"     8",
"    </a>",
"    ] posits that recent antecedent iatrogenic hypoglycemia causes both defective glucose counterregulation and hypoglycemia unawareness and thus a vicious cycle of recurrent hypoglycemia (",
"    <a class=\"graphic graphic_algorithm graphicRef51847 \" href=\"UTD.htm?30/39/31358\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It does so by shifting the glycemic threshold for the sympathoadrenal response to subsequent hypoglycemia to a lower plasma glucose concentration. This shift causes defective glucose counterregulation by reducing epinephrine responses in the setting of absent insulin and glucagon responses at a given level of hypoglycemia. It also causes hypoglycemia unawareness by reducing neurogenic symptom responses. Sleep and prior exercise can cause a similar phenomenon&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise mechanism(s) of the key feature of HAAF, the attenuated sympathoadrenal response to falling plasma glucose concentrations, is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One hypothesis is that hypoglycemic episodes lead to upregulation of glucose transport in the brain, resulting in the maintenance of glucose uptake and therefore the prevention of warning symptoms of hypoglycemia. Another is that an increase in cortisol during hypoglycemia causes a reduced sympathoadrenal response to subsequent hypoglycemia. A third is that hypoglycemia-induced alterations in hypothalamic functions, or even a cerebral network, reduce the sympathoadrenal response to subsequent hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HAAF is a functional disorder distinct from classical diabetic autonomic neuropathy, the result of nerve fiber loss. Nonetheless, sympathoadrenal responses to a given level of hypoglycemia are reduced further in patients with autonomic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Type 1 versus type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it was originally developed in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/7\">",
"     7",
"    </a>",
"    ], the concept of HAAF also applies to type 2 diabetic patients treated with intensive",
"    <span class=\"nowrap\">",
"     (basal/bolus)",
"    </span>",
"    insulin regimens (",
"    <a class=\"graphic graphic_table graphicRef75618 \" href=\"UTD.htm?40/50/41771\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/8\">",
"     8",
"    </a>",
"    ]. Insulin secretion decreases progressively over time in type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/18\">",
"     18",
"    </a>",
"    ]. As patients with type 2 diabetes develop absolute insulin deficiency and are treated with exogenous insulin, insulin secretion does not decrease and glucagon secretion does not increase when plasma glucose concentrations fall. Furthermore, antecedent hypoglycemia reduces the sympathoadrenal responses to subsequent falling glucose levels in type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/7\">",
"     7",
"    </a>",
"    ], the features of HAAF develop later in the natural history of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. This different temporal pattern of the pathophysiology of glucose counterregulation likely explains why iatrogenic hypoglycemia is relatively uncommon early in the course of type 2 diabetes (even during treatment with insulin), when the glucoregulatory defenses are intact, but occurs more frequently as patients approach the insulin deficient end of the spectrum of type 2 diabetes, when the defenses become compromised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nocturnal hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of severe hypoglycemia occur during sleep. Nocturnal hypoglycemia is frequent even with the use of continuous subcutaneous insulin infusion (CSII) or a basal-bolus regimen with insulin analogues [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/19\">",
"     19",
"    </a>",
"    ]. Overnight is typically the longest interprandial period and time between self monitoring of blood glucose (SMBG) and the time of maximal sensitivity to insulin. Furthermore, sympathoadrenal responses to hypoglycemia are reduced during sleep and, therefore, people with diabetes are less likely to be awakened by symptoms of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As discussed earlier, even asymptomatic nocturnal hypoglycemia impairs defenses against subsequent hypoglycemia.",
"   </p>",
"   <p>",
"    The notion that nocturnal hypoglycemia causes hyperglycemia the following morning (the Somogyi hypothesis) has been discredited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The opposite is typically found, namely, a direct relation between the overnight blood glucose nadir and the following morning blood glucose value, ie, patients with morning hyperglycemia typically have high, not low, blood glucose concentrations at night. The most common causes of morning hyperglycemia are nocturnal growth hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/24\">",
"     24",
"    </a>",
"    ] and hypoinsulinemia.",
"   </p>",
"   <p>",
"    Strategies to prevent nocturnal hypoglycemia and the best solution for morning hyperglycemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise increases glucose utilization by muscle and, therefore, can cause hypoglycemia in patients with insulin deficient diabetes who have near normal or moderately elevated plasma glucose levels at the start of exercise. In addition, as noted earlier, exercise, like hypoglycemia, can cause HAAF hours later (",
"    <a class=\"graphic graphic_algorithm graphicRef51847 \" href=\"UTD.htm?30/39/31358\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29638/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Hypoglycemia can be prevented by frequent SMBG and, when indicated, reduced insulin doses, carbohydrate ingestion, or both prior to exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     \"Effects of exercise in diabetes mellitus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoglycemia is an uncommon clinical event except in patients who use drugs that lower plasma glucose concentrations.",
"     </li>",
"     <li>",
"      Behavioral defenses and glucose counterregulatory mechanisms normally prevent or rapidly correct hypoglycemia (",
"      <a class=\"graphic graphic_figure graphicRef67404 \" href=\"UTD.htm?12/25/12695\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75618 \" href=\"UTD.htm?40/50/41771\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Response to hypoglycemia in normal subjects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The protective response to hypoglycemia is impaired in most patients with type 1 diabetes and in many patients with long-standing (absolute endogenous insulin deficient) type 2 diabetes (",
"      <a class=\"graphic graphic_table graphicRef75618 \" href=\"UTD.htm?40/50/41771\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Response to hypoglycemia in diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia, even if asymptomatic, causes a vicious cycle of recurrent hypoglycemia by causing hypoglycemia-associated autonomic failure, the clinical syndromes of defective glucose counterregulation and hypoglycemia unawareness (",
"      <a class=\"graphic graphic_algorithm graphicRef51847 \" href=\"UTD.htm?30/39/31358\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypoglycemia-associated autonomic failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia is the limiting factor in the glycemic management of diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"       \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Cryer PE. Hypoglycemia in Diabetes: Pathophysiology, Prevalence and Prevention, American Diabetes Association, Alexandria, VA 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/2\">",
"      Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/3\">",
"      Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     Cryer PE. The prevention and correction of hypoglycemia. In: Handbook of Physiology: The Endocrine Pancreas and Regulation of Metabolism, Jefferson LS, Cherrington AD (Eds), Oxford University Press, New York 2001. Vol II, p.1057.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/5\">",
"      Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes 2010; 59:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/6\">",
"      Cryer PE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest 2006; 116:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/7\">",
"      Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/8\">",
"      Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/9\">",
"      Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes 2005; 54:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/10\">",
"      Gosmanov NR, Szoke E, Israelian Z, et al. Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 2005; 28:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/11\">",
"      Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991; 40:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/12\">",
"      White NH, Skor DA, Cryer PE, et al. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983; 308:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/13\">",
"      Bolli GB, De Feo P, De Cosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. Diabetes 1984; 33:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/14\">",
"      Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008; 25:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/15\">",
"      Arbelaez AM, Powers WJ, Videen TO, et al. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 2008; 57:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/16\">",
"      Bottini P, Boschetti E, Pampanelli S, et al. Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: evidence for a nonselective defect. Diabetes 1997; 46:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/17\">",
"      Meyer C, Grossmann R, Mitrakou A, et al. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 1998; 21:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/18\">",
"      U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/19\">",
"      Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab 2006; 91:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/20\">",
"      Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/21\">",
"      Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes 2003; 52:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/22\">",
"      Tordjman KM, Havlin CE, Levandoski LA, et al. Failure of nocturnal hypoglycemia to cause fasting hyperglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1987; 317:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/23\">",
"      Hirsch IB, Smith LJ, Havlin CE, et al. Failure of nocturnal hypoglycemia to cause daytime hyperglycemia in patients with IDDM. Diabetes Care 1990; 13:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29638/abstract/24\">",
"      Campbell PJ, Bolli GB, Cryer PE, Gerich JE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 1985; 312:1473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1808 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29638=[""].join("\n");
var outline_f28_60_29638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REGULATION OF GLUCOSE HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESPONSE TO HYPOGLYCEMIA IN NORMAL SUBJECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Counterregulatory hormones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Relation between insulin and glucagon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Behavioral defenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RESPONSE TO HYPOGLYCEMIA IN DIABETES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Impairment of behavioral and counterregulatory responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Glucagon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypoglycemia-associated autonomic failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Type 1 versus type 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nocturnal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1808|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/39/31358\" title=\"algorithm 1\">",
"      HAAF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1808|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/25/12695\" title=\"figure 1\">",
"      Response to hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/50/41771\" title=\"table 1\">",
"      Counterregulatory response hypoglycemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25511?source=related_link\">",
"      Insulin action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41702?source=related_link\">",
"      Insulin secretion and pancreatic beta-cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_60_29639="Ventricular escape tutorial";
var content_f28_60_29639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1097px;\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Complete heart block: sinus rhythm with slow junctional or idioventricular escape rhythym",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 97px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple successive QRS complexes appear that are of ventricular origin and occur at a rate which is slower than the underlying sinus rhythm. The presence of P waves that occur independent of the QRS complexes is evidence of atrioventricular dissociation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29639=[""].join("\n");
var outline_f28_60_29639=null;
var title_f28_60_29640="Milk allergy: Clinical features and diagnosis";
var content_f28_60_29640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Milk allergy: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29640/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29640/contributors\">",
"     Kirsi M Jarvinen-Seppo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29640/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29640/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29640/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/60/29640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk allergy (CMA) is the most common food allergy in young children, but is uncommon in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/1\">",
"     1",
"    </a>",
"    ]. This food allergy presents with a wide range of clinical syndromes due to immunologic responses to cow's milk proteins that can be immunoglobulin (Ig)E-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-IgE-mediated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] CMA does not include other adverse reactions to milk, such as lactose intolerance, which are non-immune mediated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, and diagnosis of CMA will be presented in this topic review. Cross-reactivity of cow's milk with other mammalian milks and management of milk allergy are discussed separately. General discussions of food allergy are presented separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=see_link\">",
"     \"Milk allergy: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk allergy (CMA) is the most common food allergy in young children, affecting about two percent of children under four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/1\">",
"     1",
"    </a>",
"    ]. CMA is even more prevalent in infants. Two studies published in the 1990s reported a CMA prevalence of 2.2 and 2.8 percent at one year in general population birth cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], consistent with the rate found in another cohort of over 6000 newborns followed for 18 to 34 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, a lower rate of 0.6 percent in three-year-old children was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of CMA in adults is not as well reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of CMA by patient report in a multinational survey of 17,280 adults (aged 20 to 44 years) from 15 countries that questioned participants about foods that \"nearly always\" caused \"illness\" or \"trouble\" was 4.3 percent. However, a much lower proportion of adults have confirmed CMA, ranging from 0.1 to 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/1,9,11,12\">",
"     1,9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two small series, over 80 percent of adults with CMA were female [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In contrast, childhood CMA is more prevalent in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Referral populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk is among the most common foods responsible for food-induced anaphylactic reactions, seen both in the field and in emergency departments, especially in children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. CMA was reported in about 40 percent of patients seen in a university-based pediatric allergy outpatient clinic focusing on food allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/17\">",
"     17",
"    </a>",
"    ]. Thirty-seven percent of children with atopic dermatitis referred to a university-based dermatology clinic had clinically significant IgE-mediated food hypersensitivity; of them, 17 percent had CMA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute allergic responses to milk are due to IgE directed against various allergens in milk. All milk proteins are potential allergens and polysensitization to several proteins occurs in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cow's milk contains casein (alphaS1-, alphaS2-, beta-, and kappa-caseins) and whey (alpha-lactalbumin, ALA; beta-lactoglobulin, BLG; bovine lactoferrin; bovine serum albumin, BSA; and bovine immunoglobulins) proteins that account for approximately 80 and 20 percent of total protein, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/20\">",
"     20",
"    </a>",
"    ]. Most patients with CMA are sensitized to several milk proteins, including BLG, casein, ALA, BSA, bovine lactoferrin, and bovine immunoglobulins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/20\">",
"     20",
"    </a>",
"    ]. Casein, BLG, and ALA are the major milk allergens and co-sensitization to these three allergens is common [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However, sensitization to milk proteins present in very low concentrations, such as bovine lactoferrin, BSA, and bovine immunoglobulins, is also seen in up to half of patients with CMA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/20,22,23\">",
"     20,22,23",
"    </a>",
"    ]. Some patients are sensitized exclusively to these minor allergens. As an example, sensitization to BSA is independent of sensitization to the other milk allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/20\">",
"     20",
"    </a>",
"    ]. The clinical relevance of sensitization to different milk proteins is largely unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cooking diminishes the allergenicity of whey proteins, particularly beta-lactoglobulin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], presumably by denaturation of heat-labile proteins that results in loss of conformational epitopes. This may explain why extensively heated milk (eg, milk in baked goods) is better tolerated by many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/26\">",
"     26",
"    </a>",
"    ]. Similarly, yogurt cultures, which ferment and acidify milk, diminish the amount of intact whey protein in milk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/25\">",
"     25",
"    </a>",
"    ] and may result in tolerance of yogurt-based dairy products by individuals with CMA exclusively sensitized to whey proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23433?source=see_link\">",
"     \"Molecular features of food allergens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of non-IgE-mediated milk allergy, and milk allergy due to mixed IgE and non-IgE mediated processes, is less well-understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings of cow's milk allergy (CMA) frequently appear during the first few months of life, often within days or weeks after the introduction of a cow's milk-based formula into the diet, although symptoms may also occur with exclusive breastfeeding if the mother ingests cow's milk. Patients with CMA present with a wide range of IgE- and non-IgE-mediated clinical syndromes (",
"    <a class=\"graphic graphic_table graphicRef50085 \" href=\"UTD.htm?14/11/14523\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/2-4,27\">",
"     2-4,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated food-triggered reactions generally occur immediately, within minutes to two hours after ingestion. These reactions can present with skin, oropharyngeal, upper and lower respiratory tract, gastrointestinal tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"UTD.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64957 \" href=\"UTD.htm?35/20/36172\">",
"     table 3",
"    </a>",
"    ). Reactions can vary from mild to life-threatening anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cow's milk is the third most common food, after peanut and tree nuts, responsible for food-induced anaphylaxis in pediatric and mixed age populations (10 to 19 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/17,18,28\">",
"     17,18,28",
"    </a>",
"    ]. Milk is also the third most common food responsible for fatal or near-fatal food-induced anaphylactic reactions (8 to 15 percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/16,29-31\">",
"     16,29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occupational and household exposures involving inhalation of cooking or processing vapors containing milk droplets may cause respiratory symptoms. Casual contact by touching can cause localized urticaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=see_link\">",
"     \"Respiratory manifestations of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mixed IgE and non-IgE mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mixed reactions may have either humoral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cell-mediated mechanisms and may present with acute and or chronic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Atopic dermatitis (eczema)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food allergy plays a pathogenic role in a subset of patients, primarily infants and children, with atopic dermatitis. Milk is second most common allergy (egg allergy is the most common) reported in infants and young children with moderate to severe atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The role of food allergy in atopic dermatitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Allergic eosinophilic gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk is also among the major allergens identified in allergic eosinophilic esophagitis, a disorder characterized by eosinophilic inflammation of the esophagus. Patients with this disorder have symptoms suggestive of gastroesophageal reflux, but are unresponsive to conventional reflux therapies. Other presenting symptoms include feeding disorders, vomiting, abdominal pain, dysphagia, and food impaction. Patients with allergic eosinophilic gastroenteritis (eosinophilic gastroenteropathy of the stomach and intestines) may have symptoms of abdominal pain, nausea, vomiting, diarrhea, or weight loss. The role of food allergy in eosinophilic gastroenteritis is less clear than in eosinophilic esophagitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Non-IgE mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-IgE-mediated reactions usually have a delayed onset beyond two hours of ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Food protein-induced enterocolitis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food protein-induced enterocolitis syndrome (FPIES) can present in one of two ways. The typical presentation is that of severe vomiting and diarrhea within two to four hours after ingestion of the offending allergen, causing profound dehydration, lethargy, and sometimes shock. The acute phase can be the first manifestation of FPIES or can occur when the allergen is removed from the diet and then reintroduced. Chronic exposure to the offending allergen may present with vomiting and diarrhea, failure to thrive, and hypoalbuminemia. Cow's milk is among the major offending allergens. FPIES in children is presented in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Protein-induced proctitis/proctocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein-induced",
"    <span class=\"nowrap\">",
"     proctitis/proctocolitis",
"    </span>",
"    usually presents by six months of life with bloody-streaked, mucousy, loose stools and occasionally diarrhea in breastfed or standard formula-fed infants who are otherwise well-appearing. Cow's milk and soy are the major causative foods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms in gastroesophageal reflux (GER) may be associated with cow's milk allergy. Underlying causes of GER, such as eosinophilic esophagitis and dietary protein-induced gastroenteropathy, should be ruled out in patients with GER symptoms and suspected milk allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=see_link\">",
"     \"Gastroesophageal reflux in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Infantile colic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of diet in infantile colic is still controversial. Studies have shown an improvement in colic symptoms after a change to a soy-based or hydrolyzed cow's milk-based formula or elimination of cow's milk from the diet and worsening of symptoms upon rechallenge in some infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and etiology of colic\", section on 'Cow's milk protein'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cow's milk",
"    <span class=\"nowrap\">",
"     allergy/intolerance",
"    </span>",
"    has been suggested as a cause of constipation in infants and children, especially in those with refractory chronic constipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Heiner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heiner syndrome (food-induced pulmonary hemosiderosis) is a pulmonary disease that is caused by food hypersensitivity, primarily to cow's milk. This disorder mainly affects infants. Symptoms include cough, recurrent fever, wheezing, nasal congestion, recurrent otitis media, hemoptysis, failure to thrive, dyspnea, colic, anorexia, vomiting, diarrhea, and hematochezia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients have precipitating antibodies (IgG) to cow's milk proteins and may also have milk-specific IgE. Radiologic evidence of pulmonary infiltrates was a universal finding in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations of food allergy: An overview\", section on 'Pulmonary manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Natural course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tolerance is achieved by the majority of children with CMA. Non-IgE mediated CMA tends to resolve more quickly than IgE-mediated CMA. An early report indicated that most children with IgE-mediated CMA become tolerant by three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/6\">",
"     6",
"    </a>",
"    ]. However, a more recent study suggested that IgE-mediated CMA is more persistent, with children outgrowing this allergy in later childhood and adolescence (64 percent by 12 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/37\">",
"     37",
"    </a>",
"    ]. Whether these differing results are due to population differences or a change in the natural history of milk allergy is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several prognostic indicators for the development of tolerance to milk have been identified in patients with IgE-mediated CMA. These include lower initial level of milk-specific IgE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/37\">",
"     37",
"    </a>",
"    ], faster rate of decline of milk-specific IgE level over time [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/38\">",
"     38",
"    </a>",
"    ], and absence of concomitant allergic rhinitis or asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/37,39\">",
"     37,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general discussion of the diagnosis food allergy is presented elsewhere. A summary of this information, with a focus on those aspects that are most relevant to the diagnosis of cow's milk allergy (CMA), is provided below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of CMA is based upon the history and laboratory testing, when available (diagnostic tests for non-IgE-mediated manifestations of CMA are limited) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The gold-standard for diagnosis is a clinician-supervised double-blind, placebo controlled oral food challenge, although an open challenge will often suffice. Measurement of cow's milk-specific IgE can aid in the diagnosis of IgE-mediated CMA and may eliminate the need for oral food challenges. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of in vitro immunoassays for specific IgE (which are still commonly referred to as IgE RAST tests), other diagnostic allergy procedures, including skin testing and food challenges, should be performed by allergy specialists with training in the management of serious allergic reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of an immediate reaction consisting of typical allergic symptoms, supported by positive tests for specific IgE antibodies, is sufficient to establish a presumptive diagnosis for suspected IgE-mediated reactions. Either skin prick tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in vitro tests for IgE are usually performed initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher concentrations of cow's milk-specific IgE and larger skin test wheals correlate with an increased likelihood of a reaction upon ingestion, although these findings are based upon few clinical studies. Unfortunately, these values are not predictive of the nature or severity of reaction to milk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cow's milk-specific IgE level of 15",
"      <span class=\"nowrap\">",
"       kIU/L",
"      </span>",
"      using the ImmunoCAP assay (ThermoFisher Scientific, Portage, Michigan) is 95 percent predictive of a clinical reaction to ingested milk [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/42\">",
"       42",
"      </a>",
"      ]. A level of 5",
"      <span class=\"nowrap\">",
"       kIU/L",
"      </span>",
"      in children less than two years of age is similarly predictive of a reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/43\">",
"       43",
"      </a>",
"      ]. However, the predictive values for clinical reactivity associated with food-specific IgE levels determined by the ImmunoCAP assay should not be applied to results from other assays [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar analyses have been performed for skin testing using a commercial cow's milk extract; a wheal diameter of 8 mm in children over two and 6 mm in children two years of age and under is 95 percent predictive of a clinical reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic procedure may include elimination of the suspected food, challenge, and re-elimination. In breastfed infants, this includes a maternal exclusion diet avoiding cow's milk protein, and in formula-fed infants, use of either extensively hydrolyzed or amino acid-based infant formulae (",
"    <a class=\"graphic graphic_table graphicRef79377 \" href=\"UTD.htm?9/53/10075\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29640/abstract/47\">",
"     47",
"    </a>",
"    ]. If minimal to no improvement is noted on a milk avoidance diet, the food in question is not responsible for symptoms, the diet has not been restricted enough, or the patient may have multiple food allergies and additional foods may be considered suspicious. Oral food challenges and food allergen avoidance are covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of suspected occupational asthma due to IgE-mediated CMA, involves skin prick testing, pulmonary function testing, and possible bronchoprovocation challenge. Occupational asthma is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Non-IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE tests are expected to be negative if the symptoms do not suggest an IgE-mediated reaction, such as delayed gastrointestinal reactions and some cases of atopic dermatitis. Atopy patch testing may provide additional information in these cases. There are currently no standardized reagents, application methods, or guidelines for interpretation for atopy patch testing. Thus, this type of testing cannot be recommended outside of research settings. This method is discussed in greater detail separately, as is diagnosis of CMA in these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link&amp;anchor=H12#H12\">",
"     \"Future diagnostic tools for food allergy\", section on 'Atopy patch testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=see_link\">",
"     \"Future diagnostic tools for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnostic pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digestion, various processing methods (heating, cooking), and fermentation may influence the amount of relevant allergen in the final product. Thus, tolerance of milk in processed foods may not exclude allergy to milk in forms such as liquid milk or ice cream. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Cow's milk may be initially missed as a potential allergen, due to the ubiquitous nature of milk proteins (",
"    <a class=\"graphic graphic_table graphicRef63271 \" href=\"UTD.htm?37/5/37980\">",
"     table 5",
"    </a>",
"    ). It should also be considered as a possible contaminant in infants reacting to mixed jarred baby foods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis of milk allergy includes other food allergies, especially egg allergy, since egg proteins are commonly present in the same foods (eg, pancakes, cakes, cookies, macaroni and cheese). Gastroesophageal reflux disease, colic, and fussiness are common in early infancy, but are unlikely to be isolated or sole manifestations of cow's milk allergy. Chronic exposure to milk protein in food protein-induced enterocolitis may present with subtle symptoms of regurgitation, diarrhea, and failure to thrive in early infancy.",
"   </p>",
"   <p>",
"    Other differential diagnoses include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic",
"      <span class=\"nowrap\">",
"       urticaria/anaphylaxis",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"       \"Idiopathic anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hereditary or acquired angioedema (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"       \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lactose intolerance (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toddler's diarrhea (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of the causes of chronic diarrhea in children\", section on 'Functional diarrhea'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cow's milk allergy is the most common food allergy in young children affecting about 2.5 percent of infants. Milk is a less common allergen in adults, affecting about 0.2 percent of the adult population. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tolerance is achieved by the majority of children with CMA. Non-IgE mediated CMA tends to resolve by early childhood, whereas IgE-mediated CMA may persist into adolescence and beyond. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Natural course'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"       \"The natural history of childhood food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Casein and whey proteins are the milk proteins responsible for the majority of IgE-mediated milk allergies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of milk allergy include IgE mediated reactions, such as",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      and anaphylaxis, mixed IgE and non-IgE mediated reactions such as atopic dermatitis (eczema) and eosinophilic esophagitis, and non-IgE mediated forms of allergy that present with delayed gastrointestinal manifestations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of IgE-mediated milk allergy is based upon careful history supported by skin prick tests and in vitro tests for specific IgE. An oral food challenge is warranted if the diagnosis of milk allergy is uncertain. Diagnostic testing for non-IgE mediated manifestations is limited. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/1\">",
"      Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007; 120:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/2\">",
"      H&oslash;st A. Cow's milk protein allergy and intolerance in infancy. Some clinical, epidemiological and immunological aspects. Pediatr Allergy Immunol 1994; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/3\">",
"      Heine RG, Elsayed S, Hosking CS, Hill DJ. Cow's milk allergy in infancy. Curr Opin Allergy Clin Immunol 2002; 2:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/4\">",
"      J&auml;rvinen KM, Chatchatee P. Mammalian milk allergy: clinical suspicion, cross-reactivities and diagnosis. Curr Opin Allergy Clin Immunol 2009; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/5\">",
"      Bahna SL. Cow's milk allergy versus cow milk intolerance. Ann Allergy Asthma Immunol 2002; 89:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/6\">",
"      H&oslash;st A, Halken S. A prospective study of cow milk allergy in Danish infants during the first 3 years of life. Clinical course in relation to clinical and immunological type of hypersensitivity reaction. Allergy 1990; 45:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/7\">",
"      Schrander JJ, van den Bogart JP, Forget PP, et al. Cow's milk protein intolerance in infants under 1 year of age: a prospective epidemiological study. Eur J Pediatr 1993; 152:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/8\">",
"      Saarinen KM, Juntunen-Backman K, J&auml;rvenp&auml;&auml; AL, et al. Supplementary feeding in maternity hospitals and the risk of cow's milk allergy: A prospective study of 6209 infants. J Allergy Clin Immunol 1999; 104:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/9\">",
"      Osterballe M, Hansen TK, Mortz CG, et al. The prevalence of food hypersensitivity in an unselected population of children and adults. Pediatr Allergy Immunol 2005; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/10\">",
"      Woods RK, Abramson M, Bailey M, Walters EH. International prevalences of reported food allergies and intolerances. Comparisons arising from the European Community Respiratory Health Survey (ECRHS) 1991-1994. Eur J Clin Nutr 2001; 55:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/11\">",
"      Osterballe M, Mortz CG, Hansen TK, et al. The prevalence of food hypersensitivity in young adults. Pediatr Allergy Immunol 2009; 20:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/12\">",
"      Jansen JJ, Kardinaal AF, Huijbers G, et al. Prevalence of food allergy and intolerance in the adult Dutch population. J Allergy Clin Immunol 1994; 93:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/13\">",
"      St&ouml;ger P, W&uuml;thrich B. Type I allergy to cow milk proteins in adults. A retrospective study of 34 adult milk- and cheese-allergic patients. Int Arch Allergy Immunol 1993; 102:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/14\">",
"      Lam HY, van Hoffen E, Michelsen A, et al. Cow's milk allergy in adults is rare but severe: both casein and whey proteins are involved. Clin Exp Allergy 2008; 38:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/15\">",
"      Ngamphaiboon J, Chatchatee P, Thongkaew T. Cow's milk allergy in Thai children. Asian Pac J Allergy Immunol 2008; 26:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/16\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/17\">",
"      J&auml;rvinen KM, Sicherer SH, Sampson HA, Nowak-Wegrzyn A. Use of multiple doses of epinephrine in food-induced anaphylaxis in children. J Allergy Clin Immunol 2008; 122:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/18\">",
"      Colver AF, Nevantaus H, Macdougall CF, Cant AJ. Severe food-allergic reactions in children across the UK and Ireland, 1998-2000. Acta Paediatr 2005; 94:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/19\">",
"      Eigenmann PA, Sicherer SH, Borkowski TA, et al. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998; 101:E8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/20\">",
"      Wal JM. Bovine milk allergenicity. Ann Allergy Asthma Immunol 2004; 93:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/21\">",
"      Docena GH, Fernandez R, Chirdo FG, Fossati CA. Identification of casein as the major allergenic and antigenic protein of cow's milk. Allergy 1996; 51:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/22\">",
"      Natale M, Bisson C, Monti G, et al. Cow's milk allergens identification by two-dimensional immunoblotting and mass spectrometry. Mol Nutr Food Res 2004; 48:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/23\">",
"      Gaudin JC, Rabesona H, Choiset Y, et al. Assessment of the immunoglobulin E-mediated immune response to milk-specific proteins in allergic patients using microarrays. Clin Exp Allergy 2008; 38:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/24\">",
"      Chen WL, Hwang MT, Liau CY, et al. Beta-lactoglobulin is a thermal marker in processed milk as studied by electrophoresis and circular dichroic spectra. J Dairy Sci 2005; 88:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/25\">",
"      Ehn BM, Ekstrand B, Bengtsson U, Ahlstedt S. Modification of IgE binding during heat processing of the cow's milk allergen beta-lactoglobulin. J Agric Food Chem 2004; 52:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/26\">",
"      Nowak-Wegrzyn A, Bloom KA, Sicherer SH, et al. Tolerance to extensively heated milk in children with cow's milk allergy. J Allergy Clin Immunol 2008; 122:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/27\">",
"      Fiocchi A, Sch&uuml;nemann HJ, Brozek J, et al. Diagnosis and Rationale for Action Against Cow's Milk Allergy (DRACMA): a summary report. J Allergy Clin Immunol 2010; 126:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/28\">",
"      Uguz A, Lack G, Pumphrey R, et al. Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign. Clin Exp Allergy 2005; 35:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/29\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/30\">",
"      Pumphrey RS. Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 2004; 257:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/31\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/32\">",
"      Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999; 104:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/33\">",
"      Ellman LK, Chatchatee P, Sicherer SH, Sampson HA. Food hypersensitivity in two groups of children and young adults with atopic dermatitis evaluated a decade apart. Pediatr Allergy Immunol 2002; 13:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/34\">",
"      Niggemann B, Sielaff B, Beyer K, et al. Outcome of double-blind, placebo-controlled food challenge tests in 107 children with atopic dermatitis. Clin Exp Allergy 1999; 29:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/35\">",
"      Sicherer SH, Teuber S, Adverse Reactions to Foods Committee. Current approach to the diagnosis and management of adverse reactions to foods. J Allergy Clin Immunol 2004; 114:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/36\">",
"      Moissidis I, Chaidaroon D, Vichyanond P, Bahna SL. Milk-induced pulmonary disease in infants (Heiner syndrome). Pediatr Allergy Immunol 2005; 16:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/37\">",
"      Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow's milk allergy. J Allergy Clin Immunol 2007; 120:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/38\">",
"      Shek LP, Soderstrom L, Ahlstedt S, et al. Determination of food specific IgE levels over time can predict the development of tolerance in cow's milk and hen's egg allergy. J Allergy Clin Immunol 2004; 114:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/39\">",
"      Levy Y, Segal N, Garty B, Danon YL. Lessons from the clinical course of IgE-mediated cow milk allergy in Israel. Pediatr Allergy Immunol 2007; 18:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/40\">",
"      Fiocchi A, Brozek J, Sch&uuml;nemann H, et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines. Pediatr Allergy Immunol 2010; 21 Suppl 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/41\">",
"      NIAID-Sponsored Expert Panel, Boyce JA, Assa'ad A, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol 2010; 126:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/42\">",
"      Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001; 107:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/43\">",
"      Garc&iacute;a-Ara C, Boyano-Mart&iacute;nez T, D&iacute;az-Pena JM, et al. Specific IgE levels in the diagnosis of immediate hypersensitivity to cows' milk protein in the infant. J Allergy Clin Immunol 2001; 107:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/44\">",
"      Wang J, Godbold JH, Sampson HA. Correlation of serum allergy (IgE) tests performed by different assay systems. J Allergy Clin Immunol 2008; 121:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/45\">",
"      Perry TT, Matsui EC, Kay Conover-Walker M, Wood RA. The relationship of allergen-specific IgE levels and oral food challenge outcome. J Allergy Clin Immunol 2004; 114:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/46\">",
"      Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol 2004; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29640/abstract/47\">",
"      Vandenplas Y, Koletzko S, Isolauri E, et al. Guidelines for the diagnosis and management of cow's milk protein allergy in infants. Arch Dis Child 2007; 92:902.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2386 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29640=[""].join("\n");
var outline_f28_60_29640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Referral populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mixed IgE and non-IgE mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Allergic eosinophilic gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Non-IgE mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Food protein-induced enterocolitis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Protein-induced proctitis/proctocolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Infantile colic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Constipation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Heiner syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Natural course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Non-IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnostic pitfalls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2386|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/11/14523\" title=\"table 1\">",
"      Milk allergy presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/20/36172\" title=\"table 3\">",
"      Symptoms and signs of anaphylaxis in infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/53/10075\" title=\"table 4\">",
"      Infant hypoallergenic formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/5/37980\" title=\"table 5\">",
"      Ingredient label terms for milk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10680?source=related_link\">",
"      Clinical features and etiology of colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30441?source=related_link\">",
"      Gastroesophageal reflux in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40087?source=related_link\">",
"      Milk allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23433?source=related_link\">",
"      Molecular features of food allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/55/38776?source=related_link\">",
"      Respiratory manifestations of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_60_29641="Blood glucose self-monitoring in management of adults with diabetes mellitus";
var content_f28_60_29641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blood glucose self-monitoring in management of adults with diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29641/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29641/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29641/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/60/29641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with diabetes mellitus who use insulin and some patients who take other glucose lowering medications that can cause hypoglycemia should measure their blood glucose concentrations to help maintain safe, target-driven glucose control. The effectiveness of self-monitoring in patients with type 2 diabetes who do not use hypoglycemic agents is less certain.",
"   </p>",
"   <p>",
"    Self-monitoring of blood glucose (SMBG) usually requires intermittent capillary blood sampling and the use of a glucose meter, with different frequencies of testing indicated for type 1 and type 2 diabetes. Devices to sample the glucose continuously from subcutaneous fluid are also available, with ongoing development in progress.",
"   </p>",
"   <p>",
"    In addition to self-monitoring of blood glucose, periodic measurement of glycated hemoglobin (A1C) estimates chronic glycemic control. Several practical points about blood glucose monitoring will be reviewed here, including the accuracy of glucose meters and glucose test strips, the accuracy of the operator, and how to use the glucose information that is obtained. The use of A1C measurements to estimate mean blood glucose is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"     \"Estimation of blood glucose control in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the results of randomized trials (described below), we suggest SMBG in patients who take medications that can cause hypoglycemia and that need to be adjusted based on ambient glucose levels. For example, in order to avoid hypoglycemia and achieve target glucose levels, patients with type 1 diabetes who take mealtime insulins should usually test before meals to adjust doses, based on meal size and content, anticipated activity levels, and glucose levels. Similar guidelines apply to insulin-treated type 2 diabetes, although their glucose levels are characteristically more stable, and they may require less frequent monitoring.",
"   </p>",
"   <p>",
"    Patients treated with sulfonylureas or meglitinides, which can also cause hypoglycemia, should be tested once to twice per day during titration of their doses, but after a stable dose and target glycemic targets are achieved, may only need to test several times per week, usually in the morning or before dinner. All insulin and sulfonylurea patients need to test more frequently before and during long car rides, during sick days, and when there are changes in diet and exercise patterns.",
"   </p>",
"   <p>",
"    Self-monitoring of glucose may not be necessary at all, or only in unusual circumstances, for patients with type 2 diabetes who are diet-treated or who are treated with oral agents not associated with hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of the Diabetes Control and Complications Trial (DCCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/1\">",
"     1",
"    </a>",
"    ] and a follow-up study to that trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/2\">",
"     2",
"    </a>",
"    ] demonstrate that intensive insulin therapy is appropriate for most patients with type 1 diabetes to decrease the risk of both micro- and macrovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .) SMBG is an integral part of intensive therapy in type 1 diabetes, which is widely accepted as recommended therapy owing to its benefits. Self-monitoring allows adjustments of doses and timing of insulin and of timing and content of meals and snacks based on immediate feedback of glucose results and allows timely intervention for low or decreasing glucose levels to avert serious hypoglycemic events. Self-monitoring of blood glucose is also important for patients with type 1 diabetes who are not managed with intensive insulin, although they may require somewhat less frequent testing.",
"   </p>",
"   <p>",
"    The American Diabetes Association (ADA) recommends that patients with type 1 diabetes on multiple-dose insulin or insulin pump therapy monitor blood glucose at least prior to meals and snacks, occasionally postprandially, at bedtime, prior to exercise, when they suspect low blood glucose, after treating low blood glucose (until glucoses are normal), and prior to critical tasks such as driving [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/3\">",
"     3",
"    </a>",
"    ]. For most patients with type 1 diabetes, testing blood glucose levels this frequently is necessary to safely achieve A1C targets without frequent or severe hypoglycemia. Testing blood glucose levels before and at intervals after meals; before, during, and after exercise; and occasionally during the night will provide useful information for adjusting insulin and carbohydrate intake. In addition, patients with hypoglycemia unawareness may need to test more frequently, particularly prior to driving or operating any machinery, watching small children, and other activities where compromise of cognitive function may be dangerous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of SMBG in terms of improving glycemic control in patients with type 2 diabetes (especially those not receiving insulin) is less clear than for type 1 diabetes. Multiple observational studies have evaluated SMBG in type 2 diabetes, with some showing benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and others not [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Meta-analyses of randomized trials report conflicting results, with one reporting no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/10\">",
"     10",
"    </a>",
"    ] and subsequent analyses, limited to trials evaluating SMBG in patients not treated with insulin (ie, only diet or oral agents), reporting a modest decrease in A1C in the SMBG group compared with no SMBG (pooled mean difference -0.2 to -0.3 percent at six months of follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. This small change is of uncertain clinical significance. In one meta-analysis that included patients with type 2 diabetes treated with oral agents or once daily long-acting insulin, there was a larger reduction in A1C (-0.5 percent) with SMBG compared with no SMBG, particularly when SMBG was combined with patient education and feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/15\">",
"     15",
"    </a>",
"    ]. There is no evidence that SMBG affects quality of life or long-term clinically important outcomes (eg, diabetes complications).",
"   </p>",
"   <p>",
"    In one of the larger trials included in the meta-analyses, 610 patients with type 2 diabetes who were treated with oral agents were randomly assigned to SMBG or non-SMBG groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/16\">",
"     16",
"    </a>",
"    ]. After 27 weeks, A1C decreased in both groups. However, there was a significantly greater reduction in A1C in the SMBG group (between group difference 0.25 percent). In contrast, other randomized trials have not shown a significant reduction in A1C with self monitoring of glucose versus no monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and in one study of newly diagnosed patients, SMBG was associated with higher scores on a depression scale [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of SMBG have several potential biases. Patients who adhere to self-monitoring may have better lifestyle compliance as well, or may have worse glucose control and therefore are more motivated. Patients who are less motivated may not be willing to participate in randomized studies, so even randomized trials may represent only a selected patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring blood glucose is a tool, not a therapeutic intervention. It provides important information with which motivated insulin-treated patients can modify their behavior and improve their A1C values safely by reducing hypoglycemia risk. As an example, SMBG may also be useful for some type 2 diabetic patients who would take action to modify eating patterns or exercise, as well as be willing to intensify pharmacotherapy, based on SMBG results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/20\">",
"     20",
"    </a>",
"    ]. However, SMBG is expensive. In an economic analysis of self-monitoring of blood glucose (SMBG) using data from a UK trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/17\">",
"     17",
"    </a>",
"    ], SMBG with or without training in patient-initiated management of SMBG feedback was considered unlikely to be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, self-monitoring of glucose may not be necessary at all, or only in unusual circumstances, for patients with type 2 diabetes who are diet-treated or who are treated with oral agents not associated with hypoglycemia. In addition, it may be unnecessarily burdensome in frail elderly individuals with cognitive impairment or difficulty with fine motor skills from neurological or musculoskeletal conditions. In such patients, the target for glycated hemoglobin (A1C) should be somewhat higher (&le;8 percent) than for younger and more fit elderly patients and, therefore, there is little role for regular self-monitoring of blood glucose, unless the patient is taking insulin. Glycemic targets are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link\">",
"     \"Treatment of type 2 diabetes mellitus in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SOURCES OF ERROR IN SMBG",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Operator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Errors in SMBG are most frequently attributed to operator-error [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/22\">",
"     22",
"    </a>",
"    ]. Problems arise from failure to use test strips appropriate to the meters, calibrate the meter correctly, dirty meters, inadequate hand washing, or improper storage of the test strips.",
"   </p>",
"   <p>",
"    Patients who are motivated and test often usually get much more reliable results than those who are less interested or who test less often (such as non-expert clinicians) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We also recommend the following steps to increase the accuracy of glucose monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The glucose meter and strips should be brought in for clinic visits. The patient's method of testing should be observed periodically and any technical mistakes corrected. Patients should be queried regarding storage of strips.",
"     </li>",
"     <li>",
"      If SMBG results do not seem consistent with expectations, we recommend that the patient bring the glucose meter in to be checked against meters of known accuracy or with a simultaneous lab value.",
"     </li>",
"     <li>",
"      Most meters can be downloaded so that the actual measurements (rather than reliance on patients&rsquo; self-report of frequency of testing and specific results) can be reviewed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blood glucose meters",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of SMBG systems available. Most glucose meters are reasonably accurate",
"    <span class=\"nowrap\">",
"     (+/-10",
"    </span>",
"    percent) and require only a very small drop of blood. In an evaluation of the accuracy of 27 monitoring systems, 16 fulfilled minimum accuracy requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/24\">",
"     24",
"    </a>",
"    ]. However, accuracy during episodes of hypoglycemia and in patients with poor peripheral tissue perfusion may be less than optimal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In a separate analysis of seven commonly used meters, the imprecision ranged from 1.1 to 4.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, glucose meters reported whole blood glucose values, which made it difficult to compare finger stick results with results from a laboratory, which are always plasma. However, the majority of available glucose meters now provide plasma equivalent values rather than whole blood glucose values. Thus, results from most available glucose meters and commercial laboratories should now be comparable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucose strips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some glucose strips have considerable batch to batch variation and require recalibration to a meter every time a new batch is used. Many strips are packaged in groups (10, 25, 50, or 100) inside a canister containing a desiccant to control humidity. Common errors include leaving the lid off for periods of time, with exposure to heat, moisture, and humidity, and mixing lots of strips into one can for convenience. Patients may forget to match the code on the strip bottle to the meter code, with uncompensated batch variation causing erroneous glucose value readings. Fortunately, most meters now have eliminated the need to code each bottle of strips. Many newer meters overcome this problem by automatically recognizing codes for strips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Site of testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several blood glucose meters are now available that use sites other than the finger to obtain blood samples in an effort to reduce the discomfort involved with fingersticks. A study of one device that can be used to obtain samples from the arm found that it provided accurate results and was less painful than fingerstick testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring from alternate sites, such as the skin of the forearm, may give slightly lower results than those taken at the fingertips, since they may sample venous blood rather than capillary blood. While this should not be a problem if the patient uses one or the other site exclusively, the between-test variability will increase if numerous sites (such as fingertips and forearm sites) are used. In addition, during times when the blood glucose concentration is either rising rapidly (such as immediately after food ingestion) or falling rapidly (in response to rapidly acting insulin or exercise), blood glucose results from alternate sites may give significantly delayed results compared with fingerstick readings (",
"    <a class=\"graphic graphic_figure graphicRef54372 \" href=\"UTD.htm?27/5/27741\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other sugars",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA issued a safety alert in February 2006 that some glucose monitors (those using the enzyme glucose dehydrogenase pyrroloquinoline quinone or GDH-PQQ) will give falsely elevated readings in patients who have received treatments containing other sugars, including xylose as part of a d-xylose absorption test, maltose or galactose in IV solutions (IV immune globulin is formulated with maltose), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    in peritoneal dialysis fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/32\">",
"     32",
"    </a>",
"    ]. Most glucose meters do not use this enzyme and the test method used is identified in the package insert for the glucose strips. Several patient deaths were attributed to inappropriate insulin treatment for falsely elevated glucose strip readings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/33\">",
"     33",
"    </a>",
"    ]. New test strips have been designed to minimize interference with non-glucose sugars [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3347321\">",
"    <span class=\"h1\">",
"     USING THE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with type 1 diabetes, self-monitoring of blood sugar levels before and at intervals after meals; before, during, and after exercise; and occasionally during the night will provide useful information for adjusting insulin regimens and other behaviors that influence glycemic control. At a minimum, monitoring should be used to avoid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    help treat potentially dangerous hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H6#H6\">",
"     \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Morning hyperglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, this regimen will be effective only if the patient is able to use the information to make appropriate dietary or therapeutic adjustments. As an example, patterns of glycemic control can be most easily identified if the blood glucose values are entered in columns, corresponding to times of the day, and the relation to both food intake and exercise noted.",
"   </p>",
"   <p>",
"    Many glucose meters provide data management features that can be downloaded onto a computer, allowing graphic representation of glycemic variation by time of day or over a period of weeks, allowing calculation of means, and visualization of trends and variances. Unless results are reviewed on a frequent basis to detect and address blood glucose patterns, self-monitoring will not fulfill its purpose. Relying on the automatic data storage of the meters, without regularly reviewing the results, may detract from the clinical utility of monitoring.",
"   </p>",
"   <p>",
"    Optimal use of the data obtained is best done in two stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pattern identification &mdash; Patterns, as opposed to intermittent problems, are best identified if there are a relatively large number of measurements. Thus, blood glucose values should be recorded four to seven times daily for several days and evaluated for patterns of variation, which allow adjustment of doses or types of insulin at different times of the day.",
"     </li>",
"     <li>",
"      Insulin algorithms &mdash; Once a basic regimen of eating, exercise, and insulin dosing has been established, there will still be a day-to-day variability in blood glucose values due, among other factors, to the vagaries of insulin and food absorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"       \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"      </a>",
"      .) This can be effectively treated by an insulin algorithm in which the before-meal dose of short-acting insulin is adjusted according to the blood glucose value and, for patients who use carbohydrate counting, anticipated carbohydrate content of the meal. Changes in exercise can also be included in this calculation. The adjustments should be small in patients who are very sensitive to insulin or who are taking low doses of insulin (as with a subcutaneous continuous insulin infusion via a pump). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H8#H8\">",
"       \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Insulin algorithm'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H12#H12\">",
"       \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Late afternoon hypoglycemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=see_link&amp;anchor=H14#H14\">",
"       \"Cases illustrating problems with intensive insulin therapy for diabetes mellitus\", section on 'Late morning hyperglycemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of SMBG in patients with type 2 diabetes, while most often less than for patients with type 1 diabetes, is dependent on the glycemic targets set and the treatments used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11332?source=see_link\">",
"     \"Case illustrating blood glucose monitoring in type 2 diabetes\"",
"    </a>",
"    .) If SMBG is initiated to improve glycemic control, patient education strategies are necessary to ensure successful management of SMBG feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/15\">",
"     15",
"    </a>",
"    ]. In one small longitudinal study of patient views on SMBG, the frequency of testing decreased over time, often because patients did not know how to respond to high readings, and patients perceived that providers were more interested in A1C values than glucose logs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study, use of SMBG was successful in reducing A1C values when accompanied by training of patients and clinicians to collect and interpret SMBG profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With a well-educated and motivated patient, therapeutic advice can often be given over the telephone or even via fax or e-mail. It is important not to recommend many changes at the same time. Having made a change, it is usually best to wait several days until the effect of that change can be assessed from further blood glucose measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTINUOUS GLUCOSE MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Real-time continuous glucose monitoring (CGM) has the potential to improve glycemic control while decreasing the incidence of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, the improvement in glycemic control compared with SMBG is variable, CGM is expensive, and because of reliability issues and the need to calibrate the CGM, CGM does not eliminate the need for fingersticks. CGM has the greatest potential value in patients with hypoglycemic unawareness who are at risk for or have severe hypoglycemia, including pregnant women; unfortunately, currently available meters are most inaccurate in the low range of glucose.",
"   </p>",
"   <p>",
"    Continuous blood glucose monitoring systems that are available or in development measure the glucose content of interstitial fluid (which correlates well with plasma glucose) using an electrochemical enzymatic sensor. Interstitial fluid is accessed by a needle sensor inserted subcutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In an animal model, the timing of glucose excursions in the interstitial fluid from subcutaneous adipose tissue and muscle reflected the alterations of glucose in the brain; however, the magnitude of the glucose excursion was lower in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With some devices (sometimes referred to as &ldquo;professional CGM&rdquo;), the patient receives no information while wearing the device. Results can be determined in a clinician's office and graphed, providing useful information about the extent of within-day and between-day variations in blood glucose and the frequency of unrecognized hypoglycemia (",
"    <a class=\"graphic graphic_figure graphicRef62355 \" href=\"UTD.htm?22/21/22879\">",
"     figure 2",
"    </a>",
"    ). Most devices (often referred to as &ldquo;personal CGM&rdquo;) now provide the patient with real time results of glucose values on a continuous basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent and reliable use of a continuous glucose monitoring (CGM) system can modestly improve glycemic control in adults with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/39,42-45\">",
"     39,42-45",
"    </a>",
"    ]. Studies to date have demonstrated variable outcomes with regard to improving hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/19,42,44-46\">",
"     19,42,44-46",
"    </a>",
"    ]. In a meta-analysis of individual patient data from six trials (892 patients) comparing CGM to self-monitoring of blood glucose (SMBG) in patients with type 1 diabetes, the overall mean difference in A1C was 0.3 percent, favoring CGM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/47\">",
"     47",
"    </a>",
"    ]. Although there was a small reduction in the incidence of hypoglycemia with CGM, the interpretation of the data was limited by the overall low frequency of hypoglycemia and significant heterogeneity among the trials. Other meta-analyses of trials comparing CGM with SMBG in patients with type 1 diabetes also found a significant reduction in mean A1C (weighted mean difference [WMD] -0.2 to -0.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. In one meta-analysis, there was also a significant reduction in A1C with use of CGM versus SMBG in adults with type 2 diabetes (WMD -0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest trials in the meta-analyses was a 26-week multicenter trial comparing CGM with SMBG in 322 motivated adults and children with type 1 diabetes already receiving intensive insulin therapy (insulin pump or multiple daily injections) and performing self blood glucose monitoring on average six to seven times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/42\">",
"     42",
"    </a>",
"    ]. There was a small but significant between group difference in A1C levels (-0.5 percent) favoring CGM, but only in patients who were &ge;25 years of age. In contrast, there was no between group difference in A1C levels in those 15 to 24 or 8 to 14 years of age. The rate of severe hypoglycemia was low and did not differ between the two study groups. However, one patient (&ge;25 years of age) randomly assigned to CGM had six episodes of severe hypoglycemia. In a subsequent analysis of the data, more frequent CGM use (at least six",
"    <span class=\"nowrap\">",
"     days/week",
"    </span>",
"    compared with less often) was associated with improvement in A1C in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another trial included in the meta-analyses, 156 children and adults with poorly-controlled type 1 diabetes were randomly assigned to CGM continuously, CGM intermittently, or SMBG (five times daily) for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/43\">",
"     43",
"    </a>",
"    ]. There was a significant 1 percent reduction in A1C in the continuous CGM group compared with intermittent CGM or SMBG. There was not a significant A1C reduction in the intermittent CGM group. These data suggest that more frequent use of CGM is necessary to obtain glycemic benefits.",
"   </p>",
"   <p>",
"    Continuous glucose monitoring devices can be used with multiple injections or insulin pump therapy. Studies are evaluating the efficacy of a fully automated closed loop system of insulin delivery based upon continuous glucose sensing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H12#H12\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Continuous subcutaneous insulin infusion (insulin pump)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reliability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interstitial fluid glucose sensor yields lower glucose values compared with venous plasma glucose when blood glucose concentrations are rapidly rising (",
"    <a class=\"graphic graphic_figure graphicRef62355 \" href=\"UTD.htm?22/21/22879\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/40\">",
"     40",
"    </a>",
"    ]. The accuracy of CGM is improving. In an evaluation of over 60,000 paired sensor and glucose meter values from 72 patients with type 1 diabetes, the overall percentage of sensor readings within",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    20 and",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    30 percent agreement with reference glucose readings was 75.6 and 86.6 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/53\">",
"     53",
"    </a>",
"    ]. The highest rate of agreement occurred in the 240 to 400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.3 to 22.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    range. In another study evaluating paired sensor and venous blood glucose values from subjects with type 1 diabetes, the overall percentage of sensor readings with large errors (&ge;25 percent above or below the reference values) was 17.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/54\">",
"     54",
"    </a>",
"    ]. Very large errors (&ge;50 percent from reference glucose) occurred in 2.6 percent.",
"   </p>",
"   <p>",
"    CGM tends to be less accurate in the lower glucose range (&lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 3.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and may be inadequate for reliably detecting hypoglycemia. In one study comparing a CGM (second generation sensor) to plasma glucose collected approximately every 15 minutes, the mean absolute relative difference of the sensor glucose compared with the laboratory reference value for levels &lt;80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    was 21.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies emphasize that continuous glucose sensing devices should not be relied upon exclusively to give patients information about their blood glucose concentrations. Patients must continue to do at a minimum several fingersticks daily to calibrate the currently available devices and to verify that the sensor readings are accurate.",
"   </p>",
"   <p>",
"    There are few studies comparing CGM devices worn simultaneously by the same patient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In a study comparing three continuous glucose monitors under closed-loop blood glucose control, the clinical accuracy and reliability varied among the three devices [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/57\">",
"     57",
"    </a>",
"    ]. Paired sensor and venous plasma glucose values from six patients with type 1 diabetes were compared every 15 minutes for 48 hours. For blood glucose values ranging from 36 to 563",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2 to 31",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the mean absolute relative difference of the sensor glucose compared with venous plasma glucose was 11.8, 16.5, and 20.3 percent for the Navigator, Seven Plus, and Guardian systems, respectively. Reliability (ratio of the number of glucose values reported over the 48-hour period relative to the total number possible for that period) ranged from 76 (Seven Plus) to nearly 100 percent (Navigator and Guardian), indicating more missing data for the Seven Plus. These data suggest that in a closed-loop system, the Navigator (no longer available in North America) might perform the best. The continuing development and improvement of new generations of CGM devices requires close attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently available CGM instruments are relatively expensive. Initial costs are approximately 1000 to 2000 dollars for devices that directly sample subcutaneous fluid, with additional costs for supplies ranging between 350 to 450 dollars per month. Insurance companies have improved reimbursement over the past five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8183014\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient selection is a key factor for the successful use of CGM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/3\">",
"     3",
"    </a>",
"    ]. For maximum benefit of CGM, patients must understand the technology and use CGM on a near daily basis. In a study of 20 adults with type 1 diabetes evaluating patients who did and did not have an improvement in A1C or a reduction in hypoglycemia with CGM, good coping skills, the ability to retrospectively analyze data, and adequate spousal or significant other involvement were important factors for the effective use of CGM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients with type 1 diabetes most likely to benefit from CGM include those who already understand and are highly motivated to use intensive insulin therapy, continue frequent home glucose monitoring using fingersticks, and use the trending information from CGM to make insulin adjustments (eg, a mealtime insulin dose could be reduced if the trend on the CGM device shows a brisk downward trend) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/38\">",
"     38",
"    </a>",
"    ]. These patient selection criteria are largely consistent with guidelines from the American Diabetes Association and the Endocrine Society [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/3,59\">",
"     3,59",
"    </a>",
"    ]. In particular, the Endocrine Society Guidelines recommend CGM in adults with type 1 diabetes mellitus with A1C levels &le;7 and who have demonstrated that they can use these devices on a nearly daily basis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/59\">",
"     59",
"    </a>",
"    ]. CGM is not recommended for the inpatient or critical care setting.",
"   </p>",
"   <p>",
"    Intermittent use of CGM may be valuable for the detection of nocturnal hypoglycemia or patterns of hypoglycemia, particularly in patients with hypoglycemia unawareness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent episodes of hypoglycemia. It also may be appropriate for select patients with type 2 diabetes treated with multiple daily insulin injections, particularly in patients with frequent hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497369\">",
"    <span class=\"h1\">",
"     PATIENTS WITH SPECIAL NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visually impaired patients may have difficulty using glucose meters; with help, this problem can be overcome with \"talking meters\" or large-screen meters. Patients or providers may contact:",
"   </p>",
"   <p>",
"    &nbsp;American Association of Diabetes Educators (AADE)",
"   </p>",
"   <p>",
"    &nbsp;200 W. Madison Street, Suite 800",
"   </p>",
"   <p>",
"    &nbsp;Chicago, IL 60606",
"   </p>",
"   <p>",
"    &nbsp;Tel: 1-800-338-3633",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4883080\">",
"    <span class=\"h1\">",
"     URINE TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although measuring urine glucose is less painful and may arguably be easier than measuring blood glucose, it has significant errors that limit its accuracy as a reflection of glycemic control and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4883087\">",
"    <span class=\"h2\">",
"     Testing for ketonuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of urinary ketones is less subject to error because any positive value suggests the presence of ketonemia. In patients with type 1 diabetes, the urine should be tested for ketones if the blood glucose concentration is above 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for unexplained reasons, especially if the person feels generally unwell at the time. Testing for ketonuria should also be performed during periods of illness or stress, or if there are symptoms compatible with ketoacidosis such as nausea, vomiting, and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29641/abstract/20,61\">",
"     20,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of ketones in the urine does not always mean that the person has impending ketoacidosis. Ketonuria indicates that the person is in a catabolic state and is breaking down fat, and can occur in anyone who has a negative caloric balance while dieting. However, in the absence of a person purposely trying to restrict calories, the presence of urine ketones along with hyperglycemia is more serious than hyperglycemia alone. Under these circumstances, the person should be advised to retest every two to three hours, take measures to keep well-hydrated, and take extra insulin if indicated. Treatment of diabetic ketoacidosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/42/35490?source=see_link\">",
"       \"Patient information: Counting carbs if you do not use insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=see_link\">",
"       \"Patient information: My child has diabetes: How will we manage? (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"       \"Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=see_link\">",
"       \"Patient information: Managing diabetes in school (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=see_link\">",
"       \"Patient information: Giving your child insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=see_link\">",
"       \"Patient information: Checking your child&rsquo;s blood sugar level (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-monitoring of blood glucose (SMBG) is an integral component of the intensive insulin regimen recommended for most patients with type 1 diabetes. Patients with type 1 diabetes will usually require testing before meals; before, during, and after exercise; and occasionally during the night to adjust insulin doses for meals and avoid hypoglycemic events. Similar guidelines apply to insulin-treated type 2 diabetes, although their glucose levels are characteristically more stable and they may require less frequent monitoring. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Type 1 diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with type 2 diabetes treated with sulfonylureas or meglitinides, which can also cause hypoglycemia, should be tested once to twice per day during titration of their doses, but after a stable dose and target glycemic targets are achieved, may only need to test several times per week, usually in the morning or before dinner. All insulin and sulfonylurea patients need to test more frequently before and during long car rides, during sick days, and when there are changes in diet and exercise patterns. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Type 2 diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SMBG may not be necessary or less frequent SMBG may be appropriate for patients with type 2 diabetes who are not taking medications associated with hypoglycemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Type 2 diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Errors in SMBG may result from poor technique, lower test sensitivity in measuring low blood glucose levels, improper storage of test strips, or interfering substances. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sources of error in SMBG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood is usually sampled from the fingertips. Monitoring from alternate sites, such as the skin of the forearm, may give slightly lower results than those taken at the fingertips, since they may sample venous blood rather than capillary blood. While this should not be a problem if the patient uses one or the other site exclusively, the between-test variability will increase if numerous sites (such as fingertips and forearm sites) are used. Alternative sites may also give less reliable results when there are rapid fluctuations in blood sugar. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Site of testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With continuous glucose monitoring (CGM), blood glucose levels are reported to the patient in real time. Consistent and reliable use of a continuous glucose monitoring (CGM) system can modestly improve glycemic control in adults with type 1 diabetes. Some studies have shown fewer periods of hypoglycemia with CGM, but there are concerns with reproducibility of glucose results, particularly in the lower glucose range, with currently available CGM. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Continuous glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with type 1 diabetes most likely to benefit from CGM include those who already understand and are highly motivated to use intensive insulin therapy, continue frequent home glucose monitoring using fingersticks, and use the trending information from CGM to make insulin adjustments. CGM is not recommended for the inpatient or critical care setting. (See",
"      <a class=\"local\" href=\"#H8183014\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies are currently evaluating the efficacy of a fully automated closed loop system of insulin delivery based upon continuous glucose sensing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H12#H12\">",
"       \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Continuous subcutaneous insulin infusion (insulin pump)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/2\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/3\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/4\">",
"      Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001; 111:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/5\">",
"      Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/6\">",
"      Faas A, Schellevis FG, Van Eijk JT. The efficacy of self-monitoring of blood glucose in NIDDM subjects. A criteria-based literature review. Diabetes Care 1997; 20:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/7\">",
"      Harris MI, National Health and Nutrition Examination Survey (NHANES III). Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/8\">",
"      Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006; 29:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/9\">",
"      Franciosi M, Pellegrini F, De Berardis G, et al. Self-monitoring of blood glucose in non-insulin-treated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabet Med 2005; 22:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/10\">",
"      Coster S, Gulliford MC, Seed PT, et al. Self-monitoring in Type 2 diabetes mellitus: a meta-analysis. Diabet Med 2000; 17:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/11\">",
"      Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005; 28:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/12\">",
"      Poolsup N, Suksomboon N, Rattanasookchit S. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technol Ther 2009; 11:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/13\">",
"      Malanda UL, Welschen LM, Riphagen II, et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012; 1:CD005060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/14\">",
"      Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ 2012; 344:e486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/15\">",
"      Clar C, Barnard K, Cummins E, et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/16\">",
"      Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008; 10:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/17\">",
"      Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/18\">",
"      O'Kane MJ, Bunting B, Copeland M, et al. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/19\">",
"      Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006; 295:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/20\">",
"      Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 2004; 27:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/21\">",
"      Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008; 336:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/22\">",
"      Lewandrowski K, Cheek R, Nathan DM, et al. Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing. Am J Med 1992; 93:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/23\">",
"      Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/24\">",
"      Freckmann G, Baumstark A, Jendrike N, et al. System accuracy evaluation of 27 blood glucose monitoring systems according to DIN EN ISO 15197. Diabetes Technol Ther 2010; 12:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/25\">",
"      Trajanoski Z, Brunner GA, Gfrerer RJ, et al. Accuracy of home blood glucose meters during hypoglycemia. Diabetes Care 1996; 19:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/26\">",
"      Brunner GA, Ellmerer M, Sendlhofer G, et al. Validation of home blood glucose meters with respect to clinical and analytical approaches. Diabetes Care 1998; 21:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/27\">",
"      Desachy A, Vuagnat AC, Ghazali AD, et al. Accuracy of bedside glucometry in critically ill patients: influence of clinical characteristics and perfusion index. Mayo Clin Proc 2008; 83:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/28\">",
"      Kuo CY, Hsu CT, Ho CS, et al. Accuracy and precision evaluation of seven self-monitoring blood glucose systems. Diabetes Technol Ther 2011; 13:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/29\">",
"      Fineberg SE, Bergenstal RM, Bernstein RM, et al. Use of an automated device for alternative site blood glucose monitoring. Diabetes Care 2001; 24:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/30\">",
"      Ellison JM, Stegmann JM, Colner SL, et al. Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites. Diabetes Care 2002; 25:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/31\">",
"      Jungheim K, Koschinsky T. Glucose monitoring at the arm: risky delays of hypoglycemia and hyperglycemia detection. Diabetes Care 2002; 25:956.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Parenteral maltose/parenteral galactose/oral xylose-containing products. file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150453.htm (Accessed on September 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/33\">",
"      Frias JP, Lim CG, Ellison JM, Montandon CM. Review of adverse events associated with false glucose readings measured by GDH-PQQ-based glucose test strips in the presence of interfering sugars. Diabetes Care 2010; 33:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/34\">",
"      Lock JP, Brazg R, Bernstein RM, et al. Performance of a new test strip for freestyle blood glucose monitoring systems. Diabetes Technol Ther 2011; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/35\">",
"      Peel E, Douglas M, Lawton J. Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients' perspectives. BMJ 2007; 335:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/36\">",
"      Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care 2011; 34:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/37\">",
"      Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005; 28:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/38\">",
"      Hirsch IB. Clinical review: Realistic expectations and practical use of continuous glucose monitoring for the endocrinologist. J Clin Endocrinol Metab 2009; 94:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/39\">",
"      Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006; 29:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/40\">",
"      Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002; 25:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/41\">",
"      Nielsen JK, Djurhuus CB, Gravholt CH, et al. Continuous glucose monitoring in interstitial subcutaneous adipose tissue and skeletal muscle reflects excursions in cerebral cortex. Diabetes 2005; 54:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/42\">",
"      Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/43\">",
"      Deiss D, Bolinder J, Riveline JP, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care 2006; 29:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/44\">",
"      Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Hirsch IB, et al. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009; 32:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/45\">",
"      Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011; 34:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/46\">",
"      Tanenberg R, Bode B, Lane W, et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc 2004; 79:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/47\">",
"      Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 343:d3805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/48\">",
"      Gandhi GY, Kovalaske M, Kudva Y, et al. Efficacy of continuous glucose monitoring in improving glycemic control and reducing hypoglycemia: a systematic review and meta-analysis of randomized trials. J Diabetes Sci Technol 2011; 5:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/49\">",
"      Langendam M, Luijf YM, Hooft L, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev 2012; 1:CD008101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/50\">",
"      Szypowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials. Eur J Endocrinol 2012; 166:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/51\">",
"      Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012; 157:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/52\">",
"      Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Buckingham B, et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009; 32:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/53\">",
"      Mastrototaro J, Shin J, Marcus A, et al. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther 2008; 10:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/54\">",
"      Castle JR, Pitts A, Hanavan K, et al. The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes. Diabetes Care 2012; 35:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/55\">",
"      Garg SK, Smith J, Beatson C, et al. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther 2009; 11:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/56\">",
"      Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care 2008; 31:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/57\">",
"      Damiano ER, El-Khatib FH, Zheng H, et al. A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 2013; 36:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/58\">",
"      Ritholz MD, Atakov-Castillo A, Beste M, et al. Psychosocial factors associated with use of continuous glucose monitoring. Diabet Med 2010; 27:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/59\">",
"      Klonoff DC, Buckingham B, Christiansen JS, et al. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/60\">",
"      American Diabetes Association. Urine glucose and ketone determinations. Diabetes Care 1995; 18 Suppl 1:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29641/abstract/61\">",
"      Weber C, Kocher S, Neeser K, Joshi SR. Prevention of diabetic ketoacidosis and self-monitoring of ketone bodies: an overview. Curr Med Res Opin 2009; 25:1197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1781 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29641=[""].join("\n");
var outline_f28_60_29641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SOURCES OF ERROR IN SMBG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Operator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blood glucose meters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucose strips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Site of testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other sugars",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3347321\">",
"      USING THE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTINUOUS GLUCOSE MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reliability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8183014\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497369\">",
"      PATIENTS WITH SPECIAL NEEDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4883080\">",
"      URINE TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4883087\">",
"      Testing for ketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1781|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/5/27741\" title=\"figure 1\">",
"      Change in blood glucose forearm and fingerstick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/21/22879\" title=\"figure 2\">",
"      CGMS output",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11332?source=related_link\">",
"      Case illustrating blood glucose monitoring in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4232?source=related_link\">",
"      Cases illustrating problems with intensive insulin therapy for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/42/35490?source=related_link\">",
"      Patient information: Counting carbs if you do not use insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/11/38066?source=related_link\">",
"      Patient information: Managing diabetes in school (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/48/18179?source=related_link\">",
"      Patient information: My child has diabetes: How will we manage? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=related_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_60_29642="Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications";
var content_f28_60_29642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Jerome O Klein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Stephen Pelton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/60/29642/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/60/29642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute otitis media (AOM) is defined by the presence of fluid in the middle ear accompanied by acute signs of illness and signs or symptoms of middle ear inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Acute otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology and microbiology of AOM have been influenced by several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000",
"     </li>",
"     <li>",
"      Publication of guidelines by the American Academy of Pediatrics and the American Academy of Family Physicians (AAFP) in 2004, which provided diagnostic criteria for AOM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The educational campaign of the Centers for Disease Control and Prevention (CDC) and other authoritative groups to influence parents and clinicians to avoid inappropriate usage of antimicrobial agents for uncertain diagnoses of acute otitis media [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk factors, microbiology, clinical features, and complications of AOM will be reviewed here. Related topics are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"       Acute otitis media in children: Diagnosis",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"       Acute otitis media in children: Treatment",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link\">",
"       Acute otitis media in children: Prevention of recurrence",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link\">",
"       Otitis media with effusion (serous otitis media) in children",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"       External otitis: Pathogenesis, clinical features, and diagnosis",
"      </a>",
"      &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"       Acute otitis media in adults (suppurative and serous)",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=see_link\">",
"       Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428761755\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute otitis media (AOM) is defined by the presence of fluid in the middle ear accompanied by acute signs of illness and signs or symptoms of middle ear inflammation. Bulging of the tympanic membrane (TM) (",
"    <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"     picture 1",
"    </a>",
"    ) is considered the quintessential sign that distinguishes AOM from otitis media with effusion and a normal TM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Acute otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute otitis media (AOM) is the most frequent diagnosis in sick children visiting clinicians&rsquo; offices and the most common reason for administration of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. AOM occurs at all ages but is most prevalent in infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 60 and 80 percent of children have at least one episode of AOM by one year of age, and 80 to 90 percent by two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. AOM is slightly more common in boys than girls.",
"   </p>",
"   <p>",
"    Children who have had little or no experience with AOM by the age of three years are unlikely to have subsequent severe or recurrent disease. AOM is infrequent in school-age children, adolescents, and adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute otitis media in adults (suppurative and serous)\", section on 'Epidemiology of AOM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Universal immunization of infants with the 7-valent pneumococcal conjugate vaccine (PCV7) has decreased the incidence of AOM. In clinical trials, PCV7 reduced the overall incidence of AOM by 6 to 7 percent (although there was a 34 percent decrease in pneumococcal AOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Postmarketing studies using medical claims from two states found that office visits for otitis media decreased by 12 and 43 percent after the introduction of PCV7 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/15\">",
"     15",
"    </a>",
"    ]. These studies used prevaccine and postvacccine claims data and are not able to distinguish the effect of vaccine from secular changes, such as changes in diagnostic criteria. The 13-valent pneumococcal vaccine has replaced PCV7, but its impact on the incidence of AOM has not yet been studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H4#H4\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on '13-valent vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for AOM have been established, the most of important of which is age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age",
"      </strong>",
"      &ndash; The age-specific attack rate for AOM peaks between 6 and 18 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/16\">",
"       16",
"      </a>",
"      ]. After that, the incidence declines with age, although there is a small increase between five to six years (the time of school entry). AOM is infrequent in school-age children, adolescents, and adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link&amp;anchor=H8#H8\">",
"       \"Acute otitis media in adults (suppurative and serous)\", section on 'Epidemiology of AOM'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The occurrence of disease early in life is probably a result of a number of factors, including immature anatomy, physiology, and immunologic naivet&eacute;. Some of these factors are identifiable (eg, the change in skull configuration and vectors of the eustachian tube, development of antibodies following exposure to bacterial pathogens), but others remain to be defined.",
"     </li>",
"     <li>",
"      <strong>",
"       Family history",
"      </strong>",
"      &ndash; Pooled analysis of three studies (1240 children) found that the risk of AOM was increased if any other member of the family had history of AOM (relative risk 2.63, 95% CI 1.86-3.72) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The role of genetic factors in the development of AOM is suggested by a two-year prospective study of same-sex twins and triplets [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/18\">",
"       18",
"      </a>",
"      ]. The estimate of discordance for an episode of AOM was greater among dizygotic than monozygotic twins (0.49 versus 0.04 percent). Potential pathogenetic mechanisms for the heritability of AOM include anatomic, physiologic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunologic features. Proinflammatory cytokine gene polymorphisms that increase susceptibility to otitis media and recurrent AOM have been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Day care",
"      </strong>",
"      &ndash; The spread of bacterial and viral pathogens is common in day care centers. Multiple observational studies indicate that children attending day care centers, especially with four or more other children, have a higher incidence of AOM than children who receive care at home [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/12,22-24\">",
"       12,22-24",
"      </a>",
"      ]. In pooled analysis of six studies (1972 children), the relative risk (RR) of AOM for children who attended day care outside the home compared with children who received care at home was 2.45 (95% CI 1.51-3.98) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"       17",
"      </a>",
"      ]. In pooled analysis of four studies (1030 children), the RR of AOM for children who attended family day care versus home care was 1.59 (95% CI, 1.19-2.13) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Lack of breastfeeding",
"      </strong>",
"      &ndash; Lack of or limited breastfeeding is associated with an increased risk of AOM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/12,17,25\">",
"       12,17,25",
"      </a>",
"      ]. In pooled analysis of six studies (2548 children), the risk of AOM was decreased among children who were breastfed for at least three months (relative risk 0.87, 95% CI 0.79-0.95) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Breastfeeding diminishes colonization of the nasopharynx by bacterial pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17,25\">",
"       17,25",
"      </a>",
"      ]. Additional reasons for the lower incidence of AOM among breastfed infants are uncertain but may be related to immunologic or nonimmune protective factors in breast milk, the facial musculature associated with breastfeeding, or the position maintained during feeding from the breast contrasted with bottle feeding [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H4#H4\">",
"       \"Infant benefits of breastfeeding\", section on 'Anti-microbial components'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tobacco smoke and air pollution",
"      </strong>",
"      &ndash; Exposure to tobacco smoke and ambient air pollution increases the risk of AOM. In pooled analysis of three studies (1784 children), the relative risk of AOM was 1.66 (95% CI 1.33-2.06) among children whose parents smoked [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"       17",
"      </a>",
"      ]. In another pooled analysis, the odds ratio for recurrent AOM was 1.48 (95% CI 1.08-2.04) if either parent smoked [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/28\">",
"       28",
"      </a>",
"      ]. The mechanism for this association is not entirely clear but may be related to increased nasopharyngeal and oropharyngeal carriage of Streptococcus pneumoniae [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link&amp;anchor=H13#H13\">",
"       \"Secondhand smoke exposure: Effects in children\", section on 'Middle ear disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Data are lacking regarding an association between ambient air pollution and middle ear disease in children. Several observational studies have noted modest associations between some air pollutants and otitis media in children, but the findings are inconsistent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/31-34\">",
"       31-34",
"      </a>",
"      ]. Community-wide surveillance in a large city identified an association between levels of sulfur dioxide (a marker for air pollution) and higher ragweed pollen counts and invasive pneumococcal infections in children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pacifier use",
"      </strong>",
"      &ndash; In pooled analysis of two studies (4110 children), children who used a pacifier had a slightly higher incidence of AOM than children who did not (relative risk 1.24, 95% CI 1.06-1.46) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Race and ethnicity",
"      </strong>",
"      &ndash; Native Americans, Alaskan and Canadian Eskimos, and indigenous Australian children have a higher incidence of severe and recurrent AOM than do children of Caucasian descent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/36\">",
"       36",
"      </a>",
"      ]. In indigenous populations, 40 percent of the children may have chronic perforation of the tympanic membrane by 18 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'TM perforation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Developing areas",
"      </strong>",
"      &ndash; Lack of access to medical care and local environmental factors lead to severe suppurative episodes of otitis media in children living in developing areas [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Other risk factors",
"      </strong>",
"      &ndash; Other important risk factors in the development of single and recurrent episodes of AOM include [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/16\">",
"       16",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Social and economic conditions (poverty and household crowding increase the risk)",
"     </li>",
"     <li>",
"      Season (increased incidence during the fall and winter months)",
"     </li>",
"     <li>",
"      Altered host defenses and underlying disease (eg, cleft palate, Down syndrome, allergic rhinitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The middle ear is a narrow box that is part of an aerated system that includes the nares, the eustachian tube, and the mastoid air cells (",
"    <a class=\"graphic graphic_figure graphicRef62666 \" href=\"UTD.htm?40/35/41523\">",
"     figure 1",
"    </a>",
"    ). The system is lined with respiratory mucosa; events affecting one part of the system are usually reflected in similar changes throughout the system. Extension of the suppurative process to adjacent structures may lead to complications such as mastoiditis, labyrinthitis, petrositis, meningitis, and lateral sinus thrombosis. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Complications and sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pathogenesis of acute otitis media (AOM) generally involves the following sequence of events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has an antecedent event (usually a viral upper respiratory tract infection) while colonized with an otopathogen(s). Some evidence suggests that co-colonization with bacterial pathogens may be sufficient to trigger the cascade of events [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/41,43,44\">",
"       41,43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The event results in inflammatory edema of the respiratory mucosa of the nose, nasopharynx, and eustachian tube.",
"     </li>",
"     <li>",
"      Inflammatory edema obstructs the narrowest portion of the eustachian tube, the isthmus.",
"     </li>",
"     <li>",
"      Obstruction of the isthmus causes negative pressure followed by accumulation of secretions produced by the middle ear mucosa.",
"     </li>",
"     <li>",
"      The secretions have no egress and accumulate in the middle ear space.",
"     </li>",
"     <li>",
"      Viruses and bacteria that colonize the upper respiratory tract enter the middle ear via aspiration, reflux, or insufflation.",
"     </li>",
"     <li>",
"      Microbial growth in the middle ear secretions may result in suppuration with clinical signs of AOM.",
"     </li>",
"     <li>",
"      The middle ear effusion may persist for weeks to months following sterilization of the middle ear infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute otitis media in children: Treatment\", section on 'Clinical course'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104578784\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiology of acute otitis media (AOM) has been documented by cultures of middle ear effusion obtained by needle aspiration (",
"    <a class=\"graphic graphic_figure graphicRef61937 \" href=\"UTD.htm?32/11/32959\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/45\">",
"     45",
"    </a>",
"    ]. Similar studies have been performed to identify viral etiologies of AOM.",
"   </p>",
"   <p>",
"    Bacterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    viral respiratory tract pathogens can be isolated from most middle ear aspirates from children with AOM when a variety of microbiologic methods are used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In one series, bacteria (with or without viruses) were detected in 92 percent, viruses (with or without bacteria) in 70 percent, and both bacteria and viruses in 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of combined bacterial and viral infections in two-thirds of cases has important clinical implications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/48\">",
"     48",
"    </a>",
"    ]. Mixed viral and bacterial infections may respond differently to antibiotic therapy than purely bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The presence of viruses may increase middle ear inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], decrease neutrophil function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/53\">",
"     53",
"    </a>",
"    ], and reduce antibiotic penetration into the middle ear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three species of bacteria account for most of the bacterial isolates from middle ear fluid:",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    , nontypeable",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    , and",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef61937 \" href=\"UTD.htm?32/11/32959\">",
"     figure 2",
"    </a>",
"    ). This continues to be true even after the introduction of the conjugate pneumococcal vaccines to the routine childhood immunization schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/8,47,55-57\">",
"     8,47,55-57",
"    </a>",
"    ]. However, the relative importance of the species is changing.",
"   </p>",
"   <p>",
"    In prelicensure clinical trials, the 7-valent pneumococcal conjugate vaccine (PCV7) reduced the incidence of pneumococcal AOM by 34 percent, although the overall incidence of AOM declined by only 6 to 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In the years immediately following introduction of PCV7, two prospective studies, both in community-based pediatric practices, noted significant declines in the proportion of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    isolates from middle ear fluid (from approximately 45 to 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/55,58\">",
"     55,58",
"    </a>",
"    ]. During the same time frames, the proportion of nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    isolates increased from approximately 40 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/55,58\">",
"     55,58",
"    </a>",
"    ]. However, more recently, the proportion of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    isolates is reported to be nearly equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have examined the microbiology and clinical features of bilateral versus unilateral AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Children with bilateral AOM were more likely to have bacteria isolated from middle ear aspirate than children with unilateral AOM.",
"    <em>",
"     H. influenzae",
"    </em>",
"    was isolated more often in children with bilateral than unilateral AOM, whereas",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    was isolated with equal frequency in children with bilateral and unilateral AOM.",
"   </p>",
"   <p>",
"    <strong>",
"     S. pneumoniae",
"    </strong>",
"    &ndash;",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    accounts for approximately 50 percent of bacterial isolates from the middle ear fluid of young children with severe, persistent, or refractory AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/57\">",
"     57",
"    </a>",
"    ]. The proportion of pneumococcal isolates resistant to penicillin varies worldwide, but resistance is more likely to be found in children with recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/39,57\">",
"     39,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Widespread use of the 7-valent pneumococcal conjugate vaccine (PCV7) appears to have changed the",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    serotypes responsible for AOM. Before the introduction of PCV7 (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ), serotypes included in the vaccine comprised 60 to 70 percent of AOM isolates in the 6- to 59-month age group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/61\">",
"     61",
"    </a>",
"    ]. Following universal immunization of infants with PCV7, most isolates recovered from the nasopharynx of asymptomatic children and the middle ear of children with AOM are nonvaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/57,58,62-64\">",
"     57,58,62-64",
"    </a>",
"    ]. Specifically, serotype 19A emerged as an important cause of both respiratory tract infection and invasive disease. Of specific concern, multi-drug-resistant 19A pneumococcus has been reported as the cause of recalcitrant AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/62,64,65\">",
"     62,64,65",
"    </a>",
"    ] and coalescent mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/66\">",
"     66",
"    </a>",
"    ]. The 13-valent pneumococcal conjugate vaccine, which was licensed in 2010, includes serotype 19A (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=see_link\">",
"     \"Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     H. influenzae",
"    </strong>",
"    &ndash;",
"    <em>",
"     H. influenzae",
"    </em>",
"    accounts for approximately 45 percent of bacterial isolates from the middle ear fluid of young children with severe, persistent, or refractory AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/8,57,64\">",
"     8,57,64",
"    </a>",
"    ].",
"    <em>",
"     H. influenzae",
"    </em>",
"    AOM is more often bilateral than unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/59,60,67\">",
"     59,60,67",
"    </a>",
"    ]. Most",
"    <em>",
"     H. influenzae",
"    </em>",
"    isolates from the middle ear are nontypeable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/57\">",
"     57",
"    </a>",
"    ]. Approximately one-third to one-half of strains of",
"    <em>",
"     H. influenzae",
"    </em>",
"    recovered from middle ear fluids produce beta-lactamase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/39,56,68\">",
"     39,56,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=see_link&amp;anchor=H9#H9\">",
"     \"Microbiology, epidemiology and treatment of Haemophilus influenzae\", section on 'Nontypeable H. influenzae'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Universal immunization of infants with the conjugate",
"    <em>",
"     H. influenzae",
"    </em>",
"    type b vaccine has had little effect on Haemophilus AOM because more than 90 percent of",
"    <em>",
"     Haemophilus",
"    </em>",
"    AOM is caused by nontypeable strains. However, studies of the microbiology of AOM after the introduction of the pneumococcal conjugate vaccine suggest the proportion of cases due to",
"    <em>",
"     H. influenzae",
"    </em>",
"    AOM is increasing in frequency. However, it is unclear if the number of cases is also increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/8,57,58,69\">",
"     8,57,58,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     M. catarrhalis",
"    </strong>",
"    &ndash;",
"    <em>",
"     M. catarrhalis",
"    </em>",
"    accounts for approximately 10 percent of bacterial middle ear isolates in children with AOM in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/68\">",
"     68",
"    </a>",
"    ], a percentage that has been little affected by universal immunization of infants with pneumococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/8,58\">",
"     8,58",
"    </a>",
"    ]. More than 90 percent of strains produce beta-lactamase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/58,68\">",
"     58,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Group A streptococcus",
"    </strong>",
"    &ndash; Group A",
"    <em>",
"     streptococcus",
"    </em>",
"    occasionally causes AOM (2 to 10 percent of isolates) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/8\">",
"     8",
"    </a>",
"    ]. Group A streptococcal AOM tends to occur in older children and to be more frequently associated with local complications (eg, tympanic membrane perforation, mastoiditis) and less frequently associated with fever and systemic or respiratory symptoms than AOM caused by other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Staphylococcus aureus",
"    </strong>",
"    &ndash;",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    is an uncommon cause of AOM, but its prevalence appears to have increased after licensure of the 7-valent pneumococcal conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/8,69,72,73\">",
"     8,69,72,73",
"    </a>",
"    ]. It is found often as a cause of acute otorrhea in children with tympanostomy tubes in place.",
"   </p>",
"   <p>",
"    <strong>",
"     Other bacteria",
"    </strong>",
"    &ndash; Anaerobic bacteria infrequently cause AOM. Enteric gram-negative bacilli such as",
"    <em>",
"     Escherichia coli",
"    </em>",
"    may cause AOM in the first months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    has a special role in chronic suppurative otitis media. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32503?source=see_link&amp;anchor=H12#H12\">",
"     \"Other Pseudomonas aeruginosa infections\", section on 'Ear infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microbiologic and epidemiologic data suggest that viral infection is frequently associated with AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/46,76-79\">",
"     46,76-79",
"    </a>",
"    ]. With advances in microbiologic techniques, including reverse transcriptase PCR, viruses are increasingly detected in the middle ear fluid of children with AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/46,78\">",
"     46,78",
"    </a>",
"    ]. The most frequently isolated viruses are respiratory syncytial virus, picornaviruses (eg, rhinovirus, enterovirus), coronaviruses, influenza viruses, adenoviruses, and human metapneumovirus. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Mycoplasma pneumoniae",
"    </em>",
"    rarely has been isolated from middle ear fluids of children with AOM.",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    has been associated with otitis media in infants younger than six months of age.",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    has been isolated from some patients with acute and chronic otitis media [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=see_link\">",
"     \"Chlamydia trachomatis infections in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H5#H5\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164880855\">",
"    <span class=\"h2\">",
"     In young infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiology of AOM in infants younger than 2 months has been evaluated in several observational studies, the most recent of which is from the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/74,75,80-86\">",
"     74,75,80-86",
"    </a>",
"    ]. Bacterial pathogens isolated from the middle ear aspirates of young infants with AOM most commonly are similar to those identified in older children (eg,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     H. influenzae",
"    </em>",
"    ). In infants younger than 2 weeks, pathogens that cause neonatal sepsis (group B streptococcus, enteric gram-negative bacilli, and",
"    <em>",
"     S. aureus",
"    </em>",
"    ) also may be found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164315075\">",
"    <span class=\"h2\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developing countries the most common bacterial causes of AOM are the same as in developed countries. In addition, otitis media may be caused by",
"    <em>",
"     Mycobacteria tuberculosis",
"    </em>",
"    ,",
"    <em>",
"     Corynebacterium diphtheriae",
"    </em>",
"    , and",
"    <em>",
"     Clostridium tetani",
"    </em>",
"    . Parasitic (",
"    <em>",
"     Ascaris lumbricoides",
"    </em>",
"    ) and fungal (",
"    <em>",
"     Blastomyces dermatitidis",
"    </em>",
"    ,",
"    <em>",
"     Candida",
"    </em>",
"    and",
"    <em>",
"     Aspergillus",
"    </em>",
"    species) middle ear infections may occur but are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute otitis media (AOM), particularly infants, may present with nonspecific symptoms and signs, including fever, irritability, headache, apathy, anorexia, vomiting, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/88-91\">",
"     88-91",
"    </a>",
"    ]. Fever occurs in one- to two-thirds of children with AOM, though temperature &gt;40&deg;C (104&deg;F) is unusual unless accompanied by bacteremia or other focus of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/92\">",
"     92",
"    </a>",
"    ]. The lack of specificity of symptoms of AOM in young children, particularly in infants, makes the diagnosis challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ear pain (otalgia) is the most common complaint in children with AOM and the best predictor of AOM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/88,89,91\">",
"     88,89,91",
"    </a>",
"    ]. However, ear pain and other ear-related symptoms (eg, ear rubbing) are not always present [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/88,89,93\">",
"     88,89,93",
"    </a>",
"    ]. In a prospective study of 335 consecutive episodes of AOM, otalgia was severe in 42 percent, mild to moderate in 40 percent, and absent in 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/93\">",
"     93",
"    </a>",
"    ]. Children older than two years complained of ear pain more often than children younger than two years (25 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/93\">",
"     93",
"    </a>",
"    ]. Other causes of ear pain in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13050?source=see_link\">",
"     \"Evaluation of earache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important sign for distinguishing AOM from otitis media with effusion and normal is the presence of bulging of the tympanic membrane (",
"    <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Other signs and symptoms of AOM include otorrhea and hearing loss. Findings that may be associated with complications of AOM include vertigo, nystagmus, tinnitus, swelling about the ear, and facial paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Complications and sequelae'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical syndromes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Otitis-conjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptom complex of otitis media and purulent conjunctivitis is called otitis-conjunctivitis (conjunctivitis-otitis) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. In a series of 124 patients with otitis-conjunctivitis, 50 percent were younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/96\">",
"     96",
"    </a>",
"    ]. The ear pain typically began on the same day as, or within three days after, the ophthalmologic symptoms. Otitis-conjunctivitis is usually caused by nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    , although it can be caused by other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Bullous myringitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous myringitis is inflammation of the tympanic membrane that occurs in association with AOM in which bullae are present on the tympanic membrane (",
"    <a class=\"graphic graphic_picture graphicRef86980 \" href=\"UTD.htm?12/26/12706\">",
"     picture 2",
"    </a>",
"    ). Bullous myringitis occurs in approximately 5 percent of cases of AOM in children younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/99\">",
"     99",
"    </a>",
"    ]. Children with bullous myringitis usually have more pain at the time of diagnosis than children without bullous myringitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/61\">",
"     61",
"    </a>",
"    ]. The distribution of viral and bacterial pathogens in cases of bullous myringitis is similar to that in cases of AOM without bullae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/100-105\">",
"     100-105",
"    </a>",
"    ]. The treatment and prognosis for bullous myringitis are the same as for AOM without bullae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of acute otitis media (AOM) requires all of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of an acute history (eg, fever, irritability)",
"     </li>",
"     <li>",
"      Signs and symptoms of middle ear inflammation (eg, bulging of the tympanic membrane, distinct erythema of the tympanic membrane or otalgia, fever)",
"     </li>",
"     <li>",
"      Middle ear effusion (eg, tympanic membrane opacity, decreased or absent tympanic membrane mobility, presence of an air-fluid level, or otorrhea) (",
"      <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef67928 \" href=\"UTD.htm?21/56/22415\">",
"       movie 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of acute otitis media is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"     \"Acute otitis media in children: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188478064\">",
"    <span class=\"h2\">",
"     Clues to etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of specificity of most ear-related findings in the diagnosis of AOM, some clinical features correlate with particular organisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eye findings, particularly conjunctivitis, are more common with",
"      <em>",
"       H. influenzae",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/106\">",
"       106",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Otitis-conjunctivitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      <em>",
"       H. influenzae",
"      </em>",
"      is isolated more often from children with bilateral than unilateral AOM, whereas",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is isolated with equal frequency in bilateral and unilateral AOM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Although spontaneous tympanic membrane perforation can occur in all types of bacterial AOM, AOM caused by group A streptococci (GAS) is associated with higher rates of tympanic membrane perforation than AOM caused by other pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SEQUELAE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111860507\">",
"    <span class=\"h2\">",
"     Intratemporal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intratemporal (extracranial) complications of acute otitis media (AOM) include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hearing loss (secondary to middle ear fluid, ossicular fixation or disruption, or involvement of the eighth cranial nerve)",
"     </li>",
"     <li>",
"      Balance and motor problems",
"     </li>",
"     <li>",
"      Tympanic membrane perforation, tympanosclerosis (asymptomatic whitish plaques) (",
"      <a class=\"graphic graphic_picture graphicRef58460 \" href=\"UTD.htm?33/59/34751\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Middle ear atelectasis (retraction or collapse of the tympanic membrane due to chronic or recurrent decreased pressure in the middle ear) (",
"      <a class=\"graphic graphic_picture graphicRef78843 \" href=\"UTD.htm?4/0/4098\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cholesteatoma (",
"      <a class=\"graphic graphic_picture graphicRef76079 \" href=\"UTD.htm?6/8/6272\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ossicular fixation or discontinuity secondary to proliferation of fibrous tissue in the mucous membranes (&ldquo;adhesive otitis media&rdquo;)",
"     </li>",
"     <li>",
"      Extension of the suppurative process to adjacent structures (mastoiditis, petrositis, labyrinthitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22228262\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with middle ear effusion have persistent or fluctuating conductive hearing loss. Fluid filling the middle ear space prevents the tympanic membrane from vibrating adequately, thereby diminishing movement of the ossicular chain. The hearing loss remains as long as fluid fills the middle ear space. The median loss is 25 dB, which is equivalent to putting plugs in the child's ears. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology of hearing impairment in children\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite treatment with appropriate antimicrobial agents, middle ear fluid may persist for weeks to months after the onset of signs of AOM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute otitis media in children: Treatment\", section on 'Clinical course'",
"    </a>",
"    .) Some studies have noted that children with prolonged time spent with middle ear effusion have lower scores on tests of speech, language, and cognitive abilities than children without prolonged middle ear effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/109-112\">",
"     109-112",
"    </a>",
"    ]. Other studies found no significant differences in developmental outcome between children with and without prolonged middle ear effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/113-117\">",
"     113-117",
"    </a>",
"    ]. Systematic reviews and meta-analyses have found either inconclusive evidence or small to no negative effects of prolonged middle ear effusion on speech and language development [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/118-120\">",
"     118-120",
"    </a>",
"    ]. However, the findings may not be generalizable to children at increased risk of speech and language delay (eg, those with craniofacial anomalies, preexisting developmental delays, persistent bilateral otitis media, etc).",
"   </p>",
"   <p>",
"    Sensorineural hearing loss is an uncommon consequence of AOM but may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104578870\">",
"    <span class=\"h3\">",
"     Balance and motor problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute otitis media may have balance, motor, or vestibular problems related to vestibular dysfunction or labyrinthitis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/108,121-124\">",
"     108,121-124",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\", section on 'Otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     TM perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased pressure in the middle ear can result in central ischemia, necrosis, and spontaneous perforation of the tympanic membrane, usually accompanied by otorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/107\">",
"     107",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The frequency of spontaneous perforation is increased in Native Americans, Australian Aborigines, and in children in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/36\">",
"     36",
"    </a>",
"    ]. AOM caused by group A streptococci (GAS) is associated with higher rates of tympanic membrane perforation than AOM caused by other pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of tympanic membrane perforation associated with AOM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link&amp;anchor=H19#H19\">",
"     \"Acute otitis media in children: Treatment\", section on 'Tympanic membrane perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111861298\">",
"    <span class=\"h4\">",
"     Chronic suppurative otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unresolved or complicated AOM with perforation of the tympanic membrane may lead to chronic suppurative otitis media (CSOM) or chronic otomastoiditis, which is defined as the presence of perforation of the TM with chronic purulent drainage from the middle ear cleft for more than six weeks.",
"   </p>",
"   <p>",
"    Children with tympanic membrane perforation and suppurative discharge that persists despite oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical antibiotics should be referred to an infectious disease specialist or otolaryngologist as soon as possible. Children with perforation without drainage that persists for three months or longer should be referred to an otolaryngologist for further management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/107\">",
"     107",
"    </a>",
"    ]. Prevention of CSOM entails prompt and appropriate treatment of acute middle ear infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/36\">",
"     36",
"    </a>",
"    ]. Chemoprophylaxis is not warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24728?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of otorrhea (ear discharge) in children\", section on 'Chronic suppurative otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111859946\">",
"    <span class=\"h3\">",
"     Cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cholesteatoma is an abnormal growth of squamous epithelium in the middle ear and mastoid that may progressively enlarge to surround and destroy the ossicles. Recurrent acute otitis media, which may lead to retraction pockets in the tympanic membrane, is a risk factor for cholesteatoma.",
"   </p>",
"   <p>",
"    Clinical features suggestive of acquired cholesteatomas include deep retraction pockets, as in panel A (",
"    <a class=\"graphic graphic_picture graphicRef54514 \" href=\"UTD.htm?41/35/42550\">",
"     picture 6",
"    </a>",
"    ), a white mass behind the TM (",
"    <a class=\"graphic graphic_picture graphicRef76079 \" href=\"UTD.htm?6/8/6272\">",
"     picture 5",
"    </a>",
"    ), focal granulation at the periphery of the TM (",
"    <a class=\"graphic graphic_picture graphicRef72182 \" href=\"UTD.htm?35/19/36144\">",
"     picture 7",
"    </a>",
"    ), new-onset hearing loss, and ear drainage for more than two weeks despite treatment. The diagnosis and management of cholesteatoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link&amp;anchor=H9#H9\">",
"     \"Cholesteatoma in children\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link&amp;anchor=H16#H16\">",
"     \"Cholesteatoma in children\", section on 'Surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Mastoiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the mastoid air cells are connected to the distal end of the middle ear through a small canal or antrum (",
"    <a class=\"graphic graphic_figure graphicRef74487 \" href=\"UTD.htm?16/51/17204\">",
"     figure 3",
"    </a>",
"    ), most episodes of AOM are associated with some inflammation of the mastoid. In rare cases, resolution of the mastoid infection does not occur, and acute mastoiditis develops with pus filling the air cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H4#H4\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology of mastoiditis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111860927\">",
"    <span class=\"h3\">",
"     Other intratemporal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other intratemporal complications of AOM include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/108\">",
"     108",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Petrositis (extension of the infection into the petrous portion of the mastoid bone) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H10#H10\">",
"       \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Complications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Labyrinthitis (extension of infection into the cochlear and vestibular apparatus) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathophysiology, etiology, and differential diagnosis of vertigo\", section on 'Otitis media'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Facial paralysis (the facial nerve courses through the middle ear and mastoid); facial paralysis also may occur as a complication of acute mastoiditis or chronic suppurative otitis media (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=see_link&amp;anchor=H5#H5\">",
"       \"Facial nerve palsy in children\", section on 'Otitis media'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Intracranial complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial complications of AOM are uncommon in developed countries. However, they remain a concern in developing countries where access to medical care is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/60/29642/abstract/87,125\">",
"     87,125",
"    </a>",
"    ]. Intracranial complications of AOM include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epidural abscess (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=see_link&amp;anchor=H20#H20\">",
"       \"Epidural abscess\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Brain abscess (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lateral sinus thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=see_link&amp;anchor=H18#H18\">",
"       \"Septic dural sinus thrombosis\", section on 'Septic lateral sinus thrombosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cavernous sinus thrombosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=see_link&amp;anchor=H2#H2\">",
"       \"Septic dural sinus thrombosis\", section on 'Septic cavernous sinus thrombosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subdural empyema (collection of purulent material between the dura and the arachnoid membrane)",
"     </li>",
"     <li>",
"      Carotid artery thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       \"Patient information: Ear infections (otitis media) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=see_link\">",
"       \"Patient information: Ear infections (otitis media) in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute otitis media (AOM) is defined by the presence of fluid in the middle ear accompanied by acute signs of illness and signs or symptoms of middle ear inflammation, such as bulging (",
"      <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H428761755\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Viral upper respiratory infection is the most common predisposing factor for the development of AOM. The incidence of AOM in the United States is highest between 6 and 18 months of age. In addition to young age, other risk factors for AOM include family history, day care attendance, not having been breastfed, exposure to tobacco smoke, pacifier use, and ethnicity (Native Americans and Alaskan and Canadian Eskimos). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflammation of the upper respiratory tract predisposes to AOM via dysfunction of the eustachian tube, leading to negative pressure and accumulation of middle ear secretions and impairment in host defenses such as normal mucociliary action of the respiratory mucosa. Microbial growth in the middle ear secretions may result in suppuration and clinical signs of AOM. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      , nontypeable",
"      <em>",
"       Haemophilus influenzae",
"      </em>",
"      , and",
"      <em>",
"       Moraxella catarrhalis",
"      </em>",
"      account for most of the bacterial isolates from middle ear fluid. The most common viral pathogens include respiratory syncytial virus, rhinoviruses, influenza viruses, and adenoviruses. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with AOM, particularly infants, may present with nonspecific symptoms and signs (eg, fever, fussiness, headache, anorexia, vomiting, and diarrhea). Specific findings of AOM or",
"      <span class=\"nowrap\">",
"       complications/sequelae",
"      </span>",
"      of AOM include ear pain, otorrhea, bulging of the tympanic membrane (",
"      <a class=\"graphic graphic_picture graphicRef63268 \" href=\"UTD.htm?1/54/1891\">",
"       picture 1",
"      </a>",
"      ), hearing loss, vertigo, nystagmus, tinnitus, swelling about the ear, and facial paralysis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AOM may occur in conjunction with conjunctivitis; this symptom complex is usually caused by nontypeable",
"      <em>",
"       H. influenzae",
"      </em>",
"      . AOM also may occur with bullae on the tympanic membrane (bullous myringitis (",
"      <a class=\"graphic graphic_picture graphicRef86980 \" href=\"UTD.htm?12/26/12706\">",
"       picture 2",
"      </a>",
"      )); the distribution of viral and bacterial pathogens in cases of bullous myringitis is similar to that in cases of AOM without bullae. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Clinical syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of AOM requires evidence of acute onset, signs and symptoms of middle ear inflammation, AND the presence of middle ear effusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H19#H19\">",
"       \"Acute otitis media in children: Diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complications of AOM include mild conductive hearing loss; vestibular, balance, and motor dysfunctions; tympanic membrane perforation; inflammation of the mastoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mastoiditis; petrositis; and labyrinthitis. Intracranial complications are rare in developed countries; they include meningitis, epidural abscess, brain abscess, lateral sinus thrombosis, cavernous sinus thrombosis, subdural empyema, and carotid artery thrombosis. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Complications and sequelae'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/1\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 2004; 113:1451.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Get smart: Know when antibiotics work. Otitis media: Physician information sheet (pediatrics) file://www.cdc.gov/getsmart/campaign-materials/info-sheets/child-otitismedia.html (Accessed on February 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/3\">",
"      Hoover H, Roddey OF. The overlooked importance of tympanic membrane bulging. Pediatrics 2005; 115:513; author reply 513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/4\">",
"      Rothman R, Owens T, Simel DL. Does this child have acute otitis media? JAMA 2003; 290:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/5\">",
"      Shaikh N, Hoberman A, Kaleida PH, et al. Otoscopic signs of otitis media. Pediatr Infect Dis J 2011; 30:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/6\">",
"      Shaikh N, Hoberman A, Rockette HE, Kurs-Lasky M. Development of an algorithm for the diagnosis of otitis media. Acad Pediatr 2012; 12:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/7\">",
"      Nyquist AC, Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis. JAMA 1998; 279:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/8\">",
"      Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010; 304:2161.",
"     </a>",
"    </li>",
"    <li>",
"     Soni, A. Ear infections (otitis media) in children (0-17): use and expenditures, 2006. Statistical Brief No. 228. Agency for Healthcare Research and Quality Website. file://www.meps.ahrq.gov/mepsweb/data_files/publications/st228/stat228.pdf (Accessed on January 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/10\">",
"      Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/11\">",
"      Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/12\">",
"      Ladomenou F, Kafatos A, Tselentis Y, Galanakis E. Predisposing factors for acute otitis media in infancy. J Infect 2010; 61:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/13\">",
"      Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/14\">",
"      Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/15\">",
"      Poehling KA, Lafleur BJ, Szilagyi PG, et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 2004; 114:755.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Epidemiology. In: Otitis media in infants and children, 4th ed, BC Decker, Hamilton, ON 2007. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/17\">",
"      Uhari M, M&auml;ntysaari K, Niemel&auml; M. A meta-analytic review of the risk factors for acute otitis media. Clin Infect Dis 1996; 22:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/18\">",
"      Casselbrant ML, Mandel EM, Fall PA, et al. The heritability of otitis media: a twin and triplet study. JAMA 1999; 282:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/19\">",
"      Patel JA, Nair S, Revai K, et al. Association of proinflammatory cytokine gene polymorphisms with susceptibility to otitis media. Pediatrics 2006; 118:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/20\">",
"      Emonts M, Wiertsema SP, Veenhoven RH, et al. The 4G/4G plasminogen activator inhibitor-1 genotype is associated with frequent recurrence of acute otitis media. Pediatrics 2007; 120:e317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/21\">",
"      Emonts M, Veenhoven RH, Wiertsema SP, et al. Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media. Pediatrics 2007; 120:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/22\">",
"      Dewey C, Midgeley E, Maw R. The relationship between otitis media with effusion and contact with other children in a british cohort studied from 8 months to 3 1/2 years. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Int J Pediatr Otorhinolaryngol 2000; 55:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/23\">",
"      Rovers MM, Zielhuis GA, Ingels K, van der Wilt GJ. Day-care and otitis media in young children: a critical overview. Eur J Pediatr 1999; 158:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/24\">",
"      Wald ER, Dashefsky B, Byers C, et al. Frequency and severity of infections in day care. J Pediatr 1988; 112:540.",
"     </a>",
"    </li>",
"    <li>",
"     Ip S, Chung M, Raman G, et al. Breastfeeding and maternal and infant health outcomes in developed countries. Evidence Report/Technology Assessment No. 153. AHRQ Publication No. 07-E007. Agency for Healthcare Research and Quality, Rockville, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/26\">",
"      Paradise JL, Elster BA, Tan L. Evidence in infants with cleft palate that breast milk protects against otitis media. Pediatrics 1994; 94:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/27\">",
"      Sabirov A, Casey JR, Murphy TF, Pichichero ME. Breast-feeding is associated with a reduced frequency of acute otitis media and high serum antibody levels against NTHi and outer membrane protein vaccine antigen candidate P6. Pediatr Res 2009; 66:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/28\">",
"      Strachan DP, Cook DG. Health effects of passive smoking. 4. Parental smoking, middle ear disease and adenotonsillectomy in children. Thorax 1998; 53:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/29\">",
"      Greenberg D, Givon-Lavi N, Broides A, et al. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin Infect Dis 2006; 42:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/30\">",
"      Murphy TF. Otitis media, bacterial colonization, and the smoking parent. Clin Infect Dis 2006; 42:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/31\">",
"      MacIntyre EA, Karr CJ, Koehoorn M, et al. Residential air pollution and otitis media during the first two years of life. Epidemiology 2011; 22:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/32\">",
"      Zemek R, Szyszkowicz M, Rowe BH. Air pollution and emergency department visits for otitis media: a case-crossover study in Edmonton, Canada. Environ Health Perspect 2010; 118:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/33\">",
"      Brauer M, Gehring U, Brunekreef B, et al. Traffic-related air pollution and otitis media. Environ Health Perspect 2006; 114:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/34\">",
"      Heinrich J, Raghuyamshi VS. Air pollution and otitis media: a review of evidence from epidemiologic studies. Curr Allergy Asthma Rep 2004; 4:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/35\">",
"      Kim PE, Musher DM, Glezen WP, et al. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis 1996; 22:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/36\">",
"      Bluestone CD. Epidemiology and pathogenesis of chronic suppurative otitis media: implications for prevention and treatment. Int J Pediatr Otorhinolaryngol 1998; 42:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/37\">",
"      Morris PS, Leach AJ, Silberberg P, et al. Otitis media in young Aboriginal children from remote communities in Northern and Central Australia: a cross-sectional survey. BMC Pediatr 2005; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/38\">",
"      Minja BM, Machemba A. Prevalence of otitis media, hearing impairment and cerumen impaction among school children in rural and urban Dar es Salaam, Tanzania. Int J Pediatr Otorhinolaryngol 1996; 37:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/39\">",
"      Rovers MM, Schilder AG, Zielhuis GA, Rosenfeld RM. Otitis media. Lancet 2004; 363:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/40\">",
"      Winther B, Alper CM, Mandel EM, et al. Temporal relationships between colds, upper respiratory viruses detected by polymerase chain reaction, and otitis media in young children followed through a typical cold season. Pediatrics 2007; 119:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/41\">",
"      Revai K, Mamidi D, Chonmaitree T. Association of nasopharyngeal bacterial colonization during upper respiratory tract infection and the development of acute otitis media. Clin Infect Dis 2008; 46:e34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/42\">",
"      Alper CM, Winther B, Mandel EM, et al. Rate of concurrent otitis media in upper respiratory tract infections with specific viruses. Arch Otolaryngol Head Neck Surg 2009; 135:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/43\">",
"      Lysenko ES, Ratner AJ, Nelson AL, Weiser JN. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog 2005; 1:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/44\">",
"      Leach AJ, Boswell JB, Asche V, et al. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J 1994; 13:983.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Microbiology. In: Otitis Media in Infants and Children, 4th ed, BC Decker, Hamilton, ON 2007. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/46\">",
"      Ruohola A, Meurman O, Nikkari S, et al. Microbiology of acute otitis media in children with tympanostomy tubes: prevalences of bacteria and viruses. Clin Infect Dis 2006; 43:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/47\">",
"      Kaur R, Adlowitz DG, Casey JR, et al. Simultaneous assay for four bacterial species including Alloiococcus otitidis using multiplex-PCR in children with culture negative acute otitis media. Pediatr Infect Dis J 2010; 29:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/48\">",
"      Chonmaitree T. Acute otitis media is not a pure bacterial disease. Clin Infect Dis 2006; 43:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/49\">",
"      Chonmaitree T, Owen MJ, Patel JA, et al. Effect of viral respiratory tract infection on outcome of acute otitis media. J Pediatr 1992; 120:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/50\">",
"      Chonmaitree T, Owen MJ, Howie VM. Respiratory viruses interfere with bacteriologic response to antibiotic in children with acute otitis media. J Infect Dis 1990; 162:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/51\">",
"      Chonmaitree T, Patel JA, Lett-Brown MA, et al. Virus and bacteria enhance histamine production in middle ear fluids of children with acute otitis media. J Infect Dis 1994; 169:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/52\">",
"      Chonmaitree T, Patel JA, Sim T, et al. Role of leukotriene B4 and interleukin-8 in acute bacterial and viral otitis media. Ann Otol Rhinol Laryngol 1996; 105:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/53\">",
"      Abramson JS, Giebink GS, Quie PG. Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect Immun 1982; 36:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/54\">",
"      Canafax DM, Yuan Z, Chonmaitree T, et al. Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J 1998; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/55\">",
"      Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004; 23:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/56\">",
"      Pichichero ME, Casey JR, Hoberman A, Schwartz R. Pathogens causing recurrent and difficult-to-treat acute otitis media, 2003-2006. Clin Pediatr (Phila) 2008; 47:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/57\">",
"      Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010; 29:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/58\">",
"      Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/59\">",
"      McCormick DP, Chandler SM, Chonmaitree T. Laterality of acute otitis media: different clinical and microbiologic characteristics. Pediatr Infect Dis J 2007; 26:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/60\">",
"      Leibovitz E, Asher E, Piglansky L, et al. Is bilateral acute otitis media clinically different than unilateral acute otitis media? Pediatr Infect Dis J 2007; 26:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/61\">",
"      Hausdorff WP, Yothers G, Dagan R, et al. Multinational study of pneumococcal serotypes causing acute otitis media in children. Pediatr Infect Dis J 2002; 21:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/62\">",
"      Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/63\">",
"      McEllistrem MC, Adams JM, Patel K, et al. Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2005; 40:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/64\">",
"      Couloigner V, Levy C, Fran&ccedil;ois M, et al. Pathogens implicated in acute otitis media failures after 7-valent pneumococcal conjugate vaccine implementation in France: distribution, serotypes, and resistance levels. Pediatr Infect Dis J 2012; 31:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/65\">",
"      Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg Infect Dis 2009; 15:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/66\">",
"      Ongkasuwan J, Valdez TA, Hulten KG, et al. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 2008; 122:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/67\">",
"      Barkai G, Leibovitz E, Givon-Lavi N, Dagan R. Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009; 28:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/68\">",
"      Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992; 11:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/69\">",
"      Brook I, Gober AE. Bacteriology of spontaneously draining acute otitis media in children before and after the introduction of pneumococcal vaccination. Pediatr Infect Dis J 2009; 28:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/70\">",
"      Segal N, Givon-Lavi N, Leibovitz E, et al. Acute otitis media caused by Streptococcus pyogenes in children. Clin Infect Dis 2005; 41:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/71\">",
"      Leibovitz E, Serebro M, Givon-Lavi N, et al. Epidemiologic and microbiologic characteristics of culture-positive spontaneous otorrhea in children with acute otitis media. Pediatr Infect Dis J 2009; 28:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/72\">",
"      Klein J, Chan S. Methicillin-resistant Staphylococcus aureus in middle ear fluid of children. Clin Pediatr (Phila) 2010; 49:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/73\">",
"      Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet 2003; 361:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/74\">",
"      Turner D, Leibovitz E, Aran A, et al. Acute otitis media in infants younger than two months of age: microbiology, clinical presentation and therapeutic approach. Pediatr Infect Dis J 2002; 21:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/75\">",
"      Nozicka CA, Hanly JG, Beste DJ, et al. Otitis media in infants aged 0-8 weeks: frequency of associated serious bacterial disease. Pediatr Emerg Care 1999; 15:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/76\">",
"      Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999; 340:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/77\">",
"      Ruuskanen O, Arola M, Heikkinen T, Ziegler T. Viruses in acute otitis media: increasing evidence for clinical significance. Pediatr Infect Dis J 1991; 10:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/78\">",
"      Pitk&auml;ranta A, Virolainen A, Jero J, et al. Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 1998; 102:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/79\">",
"      Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. J Infect Dis 2004; 190:1369.",
"     </a>",
"    </li>",
"    <li>",
"     Barnett ED, Klein JO. Bacterial infections of the respiratory tract. In: Infectious Diseases of the Fetus and Newborn Infant, 7th, Remington JS, Klein JO, Wilson CB, et al.  (Eds), Elsevier Saunders, Philadelphia 2011. p.276.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/81\">",
"      Balkany TJ, Berman SA, Simmons MA, Jafek BW. Middle ear effusions in neonates. Laryngoscope 1978; 88:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/82\">",
"      Berman SA, Balkany TJ, Simmons MA. Otitis media in the neonatal intensive care unit. Pediatrics 1978; 62:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/83\">",
"      Bland RD. Otitis media in the first six weeks of life: diagnosis, bacteriology, and management. Pediatrics 1972; 49:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/84\">",
"      Tetzlaff TR, Ashworth C, Nelson JD. Otitis media in children less than 12 weeks of age. Pediatrics 1977; 59:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/85\">",
"      Shurin PA, Howie VM, Pelton SI, et al. Bacterial etiology of otitis media during the first six weeks of life. J Pediatr 1978; 92:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/86\">",
"      Karma PH, Pukander JS, Sipil&auml; MM, et al. Middle ear fluid bacteriology of acute otitis media in neonates and very young infants. Int J Pediatr Otorhinolaryngol 1987; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/87\">",
"      Berman S. Otitis media in developing countries. Pediatrics 1995; 96:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/88\">",
"      Niemela M, Uhari M, Jounio-Ervasti K, et al. Lack of specific symptomatology in children with acute otitis media. Pediatr Infect Dis J 1994; 13:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/89\">",
"      Kontiokari T, Koivunen P, Niemel&auml; M, et al. Symptoms of acute otitis media. Pediatr Infect Dis J 1998; 17:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/90\">",
"      Laine MK, T&auml;htinen PA, Ruuskanen O, et al. Symptoms or symptom-based scores cannot predict acute otitis media at otitis-prone age. Pediatrics 2010; 125:e1154.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Diagnosis. In: Otitis Media in Infants and Children, 4th ed, BC Decker, Hamilton, ON 2007. p.147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/92\">",
"      Schwartz RH, Rodriguez WJ, Brook I, Grundfast KM. The febrile response in acute otitis media. JAMA 1981; 245:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/93\">",
"      Hayden GF, Schwartz RH. Characteristics of earache among children with acute otitis media. Am J Dis Child 1985; 139:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/94\">",
"      Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J 2005; 24:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/95\">",
"      Block SL, Hedrick J, Tyler R, et al. Increasing bacterial resistance in pediatric acute conjunctivitis (1997-1998). Antimicrob Agents Chemother 2000; 44:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/96\">",
"      Bodor FF. Conjunctivitis-otitis syndrome. Pediatrics 1982; 69:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/97\">",
"      Bingen E, Cohen R, Jourenkova N, Gehanno P. Epidemiologic study of conjunctivitis-otitis syndrome. Pediatr Infect Dis J 2005; 24:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/98\">",
"      Murphy TF, Faden H, Bakaletz LO, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatr Infect Dis J 2009; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/99\">",
"      Kotikoski MJ, Palmu AA, Nokso-Koivisto J, Kleemola M. Evaluation of the role of respiratory viruses in acute myringitis in children less than two years of age. Pediatr Infect Dis J 2002; 21:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/100\">",
"      McCormick DP, Saeed KA, Pittman C, et al. Bullous myringitis: a case-control study. Pediatrics 2003; 112:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/101\">",
"      Kotikoski MJ, Kleemola M, Palmu AA. No evidence of Mycoplasma pneumoniae in acute myringitis. Pediatr Infect Dis J 2004; 23:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/102\">",
"      Merifield DO, Miller GS. The etiology and clinical course of bullous myringitis. Arch Otolaryngol 1966; 84:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/103\">",
"      Roberts DB. The etiology of bullous myringitis and the role of mycoplasmas in ear disease: a review. Pediatrics 1980; 65:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/104\">",
"      Hahn HB Jr, Riggs MW, Hutchinson LR. Myringitis bullosa. Clin Pediatr (Phila) 1998; 37:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/105\">",
"      Palmu AA, Kotikoski MJ, Kaijalainen TH, Puhakka HJ. Bacterial etiology of acute myringitis in children less than two years of age. Pediatr Infect Dis J 2001; 20:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/106\">",
"      Palmu AA, Herva E, Savolainen H, et al. Association of clinical signs and symptoms with bacterial findings in acute otitis media. Clin Infect Dis 2004; 38:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/107\">",
"      Bluestone CD. Clinical course, complications and sequelae of acute otitis media. Pediatr Infect Dis J 2000; 19:S37.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone CD, Klein JO. Complications and sequelae: Intratemporal. In: Otitis media in infants an children, 4th ed, BC Decker, Hamilton, ON 2007. p.327.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/109\">",
"      Teele DW, Klein JO, Chase C, et al. Otitis media in infancy and intellectual ability, school achievement, speech, and language at age 7 years. Greater Boston Otitis Media Study Group. J Infect Dis 1990; 162:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/110\">",
"      Klausen O, M&oslash;ller P, Holmefjord A, et al. Lasting effects of otitis media with effusion on language skills and listening performance. Acta Otolaryngol Suppl 2000; 543:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/111\">",
"      Petinou KC, Schwartz RG, Gravel JS, Raphael LJ. A preliminary account of phonological and morphophonological perception in young children with and without otitis media. Int J Lang Commun Disord 2001; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/112\">",
"      Bennett KE, Haggard MP, Silva PA, Stewart IA. Behaviour and developmental effects of otitis media with effusion into the teens. Arch Dis Child 2001; 85:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/113\">",
"      Paradise JL, Feldman HM, Campbell TF, et al. Effect of early or delayed insertion of tympanostomy tubes for persistent otitis media on developmental outcomes at the age of three years. N Engl J Med 2001; 344:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/114\">",
"      Paradise JL, Feldman HM, Campbell TF, et al. Early versus delayed insertion of tympanostomy tubes for persistent otitis media: developmental outcomes at the age of three years in relation to prerandomization illness patterns and hearing levels. Pediatr Infect Dis J 2003; 22:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/115\">",
"      Paradise JL, Dollaghan CA, Campbell TF, et al. Otitis media and tympanostomy tube insertion during the first three years of life: developmental outcomes at the age of four years. Pediatrics 2003; 112:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/116\">",
"      Paradise JL, Campbell TF, Dollaghan CA, et al. Developmental outcomes after early or delayed insertion of tympanostomy tubes. N Engl J Med 2005; 353:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/117\">",
"      Paradise JL, Feldman HM, Campbell TF, et al. Tympanostomy tubes and developmental outcomes at 9 to 11 years of age. N Engl J Med 2007; 356:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/118\">",
"      Roberts JE, Rosenfeld RM, Zeisel SA. Otitis media and speech and language: a meta-analysis of prospective studies. Pediatrics 2004; 113:e238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/119\">",
"      Casby MW. Otitis media and language development: a meta-analysis. Am J Speech Lang Pathol 2001; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     Shekelle P, Takata G, Chan L, et al. Diagnosis, natural history, and late effects of otitis media with effusion. Evidence Report/Technology Assessment No. 55. Agency for Healthcare Research and Quality 2003. file://archive.ahrq.gov/downloads/pub/evidence/pdf/otdiag/otdiag.pdf (Accessed on February 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/121\">",
"      Gawron W, Po��piech L, Orendorz-Fraczkowska K. An evaluation of postural stability and the effects of middle-ear drainage on vestibulo-spinal reflexes of children with chronic otitis media with effusion. Int J Pediatr Otorhinolaryngol 2004; 68:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/122\">",
"      Casselbrant ML, Furman JM, Rubenstein E, Mandel EM. Effect of otitis media on the vestibular system in children. Ann Otol Rhinol Laryngol 1995; 104:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/123\">",
"      Golz A, Westerman ST, Gilbert LM, et al. Effect of middle ear effusion on the vestibular labyrinth. J Laryngol Otol 1991; 105:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/124\">",
"      Golz A, Angel-Yeger B, Parush S. Evaluation of balance disturbances in children with middle ear effusion. Int J Pediatr Otorhinolaryngol 1998; 43:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/60/29642/abstract/125\">",
"      Penido Nde O, Borin A, Iha LC, et al. Intracranial complications of otitis media: 15 years of experience in 33 patients. Otolaryngol Head Neck Surg 2005; 132:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6021 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29642=[""].join("\n");
var outline_f28_60_29642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H428761755\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104578784\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164880855\">",
"      In young infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164315075\">",
"      Developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Otitis-conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Bullous myringitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H188478064\">",
"      Clues to etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COMPLICATIONS AND SEQUELAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111860507\">",
"      Intratemporal complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22228262\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104578870\">",
"      - Balance and motor problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - TM perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H111861298\">",
"      Chronic suppurative otitis media",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111859946\">",
"      - Cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111860927\">",
"      - Other intratemporal complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Intracranial complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6021\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6021|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/35/41523\" title=\"figure 1\">",
"      Middle ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/11/32959\" title=\"figure 2\">",
"      Otitis media bacterial isolates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/51/17204\" title=\"figure 3\">",
"      Mastoid anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6021|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/54/1891\" title=\"picture 1\">",
"      Acute otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/26/12706\" title=\"picture 2\">",
"      Bullous myringitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/59/34751\" title=\"picture 3\">",
"      Tympanosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/0/4098\" title=\"picture 4\">",
"      TM atelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/8/6272\" title=\"picture 5\">",
"      Cholesteatoma pars flaccida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/35/42550\" title=\"picture 6\">",
"      Rtxn pocket cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/19/36144\" title=\"picture 7\">",
"      Focal granulation TM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6021|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/56/22415\" title=\"movie 1\">",
"      Impaired TM mobility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6021|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=related_link\">",
"      Acute mastoiditis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27992?source=related_link\">",
"      Chlamydia trachomatis infections in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1450?source=related_link\">",
"      Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17033?source=related_link\">",
"      Epidural abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13050?source=related_link\">",
"      Evaluation of earache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24728?source=related_link\">",
"      Evaluation of otorrhea (ear discharge) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/601?source=related_link\">",
"      Impact of universal infant immunization with pneumococcal (Streptococcus pneumoniae) conjugate vaccines in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41608?source=related_link\">",
"      Microbiology, epidemiology and treatment of Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32503?source=related_link\">",
"      Other Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23145?source=related_link\">",
"      Septic dural sinus thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_60_29643="Chemical exposure antigen in HP";
var content_f28_60_29643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitides associated with plastic manufacturing, painting, electronics industry, and other chemicals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Environmental source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major causative antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Chemical HP",
"       </td>",
"       <td>",
"        Diphenylmethane diisocyanate (MDI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toluene diisocyanate (TDI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Detergent worker's lung (washing powder lung)",
"       </td>",
"       <td>",
"        Bacillus subtilis enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pauli's reagent alveolitis",
"       </td>",
"       <td>",
"        Sodium diazobenzene sulfate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vineyard sprayer's lung",
"       </td>",
"       <td>",
"        Copper sulfate (bordeaux mixture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyrethrum (pesticide)",
"       </td>",
"       <td>",
"        Pyrethrum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epoxy resin lung",
"       </td>",
"       <td>",
"        Phthalic anhydride (heated epoxy resin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bible printer's lung",
"       </td>",
"       <td>",
"        Moldy typesetting water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Machine operator's lung",
"       </td>",
"       <td>",
"        Pseudomonas fluorescens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosolized metal working fluid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29643=[""].join("\n");
var outline_f28_60_29643=null;
var title_f28_60_29644="Toxic ingredients inhalants";
var content_f28_60_29644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxic ingredients in abused inhalants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abused inhalant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxic ingredients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aerosol propellants",
"       </td>",
"       <td>",
"        Halogenated hydrocarbons, propane, isobutane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry-cleaning fluids, spot removers, furniture polish",
"       </td>",
"       <td>",
"        Chlorinated hydrocarbons, aliphatic (gasoline) hydrocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glues, cements, rubber patching",
"       </td>",
"       <td>",
"        Toluene, acetone, benzene, aliphatic acetates, n-hexane, cyclohexane, halocarbons, xylene, butyl alcohol, methylethylketone, methylethylisobutylketone, chloroform, ethanol, triorthocresyl phosphate, naphtha, isopropanol, glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lighter fluid",
"       </td>",
"       <td>",
"        Aliphatic and aromatic hydrocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fire-extinguishing agents",
"       </td>",
"       <td>",
"        Fluorocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fingernail polish remover",
"       </td>",
"       <td>",
"        Acetone, aliphatic acetates, benzene, alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bottle fuel gas",
"       </td>",
"       <td>",
"        Butane, propane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typewriter correction fluid",
"       </td>",
"       <td>",
"        Trichloroethane, trichloroethylene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural gas",
"       </td>",
"       <td>",
"        Methane, ethane, propane, butane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marker pens",
"       </td>",
"       <td>",
"        Toluene, xylene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paints, enamels, lacquers, lacquer and paint thinners",
"       </td>",
"       <td>",
"        Toluene, methylene chloride, aliphatic acetates, benzene, ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paint strippers",
"       </td>",
"       <td>",
"        Dichloromethane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Petroleum (gasoline, naphtha, benzene)",
"       </td>",
"       <td>",
"        Aliphatic and aromatic hydrocarbons, butane, hexane, pentane, benzene, toluene, xylene; tetraethyl lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whipped cream dispensers",
"       </td>",
"       <td>",
"        Nitrous oxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anesthetics",
"       </td>",
"       <td>",
"        Nitrous oxide, diethyl ether, halothane, chloroform, enflurane, isoflurane, trichloroethylene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Room odorizers",
"       </td>",
"       <td>",
"        Amyl, butyl, isobutyl nitrite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solvents",
"       </td>",
"       <td>",
"        Methylethylketone, carbon tetrachloride, chloroform, diethyl ether, n-hexane, methylisobutylketone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Dinwiddle, SH. Addiction 1994; 89:925; Brust, JC. Neurol Clin North Am 1998; 16:503; Caputo, RA. Int J Addict 1993; 28:1015.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29644=[""].join("\n");
var outline_f28_60_29644=null;
var title_f28_60_29645="Survival in asymptomatic LVD";
var content_f28_60_29645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Survival in HF and disease severity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Impact of severity of disease on mortality in patients with heart failure. Patients with symptomatic heart failure had a two-year survival rate of 50 percent in the Mayo study and 63 percent in the Framingham study. In contrast, asymptomatic patients had survival rates of 82 percent in the SAVE trial and 85 percent in the SOLVD trial.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. Mayo Clinic Proc 1993; 68:1143; Ho, KK, Anderson, KM, Kannel, WB, et al, Circulation 1993; 88:107; Pfeffer, MA, Braunwald, E, Moye, LA, et al, N Engl J Med 1992; 327:669; The SOLVD Investigators, N Engl J Med 1992; 327:685.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29645=[""].join("\n");
var outline_f28_60_29645=null;
var title_f28_60_29646="Typical DXA system";
var content_f28_60_29646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical dual-energy x-ray absorptiometry (DXA) system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29646=[""].join("\n");
var outline_f28_60_29646=null;
var title_f28_60_29647="Transcription fx myelopoiesis";
var content_f28_60_29647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transcription factors and myelopoiesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 565px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_60_29647=[""].join("\n");
var outline_f28_60_29647=null;
